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SUMMARY / ZUSAMMENFASSUNG 
 
 
 
CHAPTER 1 
Antibodies belong to the adapted immunity and in general recognize specifically a single 
antigen. They account for a high detection and clearing efficacy of microbial organisms. 
Antibodies have become an indispensable tool for biochemical and biophysical 
applications. However, antibodies or fragments of antibodies often feature unfavourable 
properties such as susceptibility to reducing agents and peptidases or low 
thermostability. These bottlenecks have been circumvented by employing other protein 
scaffolds that serve as alternatives to antibodies; an example – the ankyrin repeat 
protein – is presented in the first chapter. 
 
 
KAPITEL 1 
Antikörper gehören zur adaptiven Immunität und erkennen normalerweise spezifisch ein 
einzelnes Antigen. Sie sind verantwortlich für die Erkennung und Eliminierung von 
Mikroorganismen. Antikörper sind heutzutage unverzichtbare Werkzeuge für 
biochemische und biophysikalische Anwendungen. Leider haben Antikörper oder 
Fragmente von Antikörpern nachteilige Eigenschaften wie die Anfälligkeit der 
Strukturintegrität gegenüber reduzierenden Agenzien, Peptidasen oder hohen 
Temperaturen. Diesem Umstand versucht man mittels neuartigen Proteingerüsten 
gerecht zu werden, welche als Alternativen zu Antikörpern Anwendung finden; ein 
Beispiel – das Ankyrin Molekül – wird im ersten Kapitel präsentiert. 
 
* * * * * 
 
CHAPTER 2 
Macrophages, lymphocytes and specialized killer cells (leukocytes) are the innate cellular 
defence immune system and stimulate the release of signalling molecules upon detection 
of host danger signals. They release a cocktail of reactive oxygen and nitrogen species as 
well as peptidases to conquer foreign microorganisms. This cocktail acts non-specifically 
and is also harmful for the host. Diseases might develop and severe tissue damage can 
occur if persistent host danger signals cannot efficiently be removed and the peptidase 
action radius cannot be embanked by endogenous inhibitors. Human neutrophil elastase 
is such an antimicrobial peptidase that is known to be responsible for a number of lung 
diseases if not properly controlled. The second chapter provides insight into the 
development of a potent inhibitor against cathepsin G with a structural and inhibitory 
study of a redesigned sunflower trypsin inhibitor in complex with porcine pancreatic 
elastase, human neutrophil elastase and cathepsin G. 
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KAPITEL 2 
Makrophagen, Lymphozyten und spezialisierte Killerzellen (Leukozyten) bilden das 
zelluläre Immunabwehrsystem und stimulieren die Sezernierung von Botenstoffen nach 
der Erkennung von potenziell gefährlichen Signalen für den Wirt. Der sezernierte Cocktail 
aus reaktiven Sauerstoff- und Stickstoffspezies sowie Peptidasen bekämpft fremde 
Mikroorganismen. Dieser Mix agiert nicht spezifisch, er schädigt auch das Gewebe des 
Wirts und wirkt solange, bis die Mikroorganismen eliminiert sind. Geschieht dies nicht 
rasch genug, können sich durch die persistente Aktivität der Peptidasen pathogene 
Gewebeschäden bilden. Humane neutrophile Elastase ist solch eine antimikrobielle 
Peptidase, die für verschiedene Lungenkrankheiten verantwortlich ist. Das zweite Kapitel 
zeigt die Entwicklung eines potenten Inhibitors gegen Cathepsin G mit Resultaten einer 
strukturellen und enzymatisch-inhibitorischen Studie eines modifizierten Sonnenblumen-
Trypsin Inhibitors im Komplex mit Schweinepankreaselastase, humaner neutrophiler 
Elastase und Cathepsin G. 
 
* * * * * 
 
CHAPTER 3 
Chapter three presents the structural investigation of an amino-peptidase from 
Sphingosinicella xenopeptidilytica, named BapA. The peptidase exhibits unusual substrate 
specificities for beta-peptides. Structures of native BapA, its pro-form and BapA in 
complex with pefabloc SC, ampicillin and enzymatically hydrolyzed ampicillin provide 
informative insight into substrate binding. Moreover, a mechanism for the autoproteolytic 
activation and catalytic substrate hydrolysis is suggested. 
 
 
KAPITEL 3 
Im dritten Kapitel wird die strukturelle Untersuchung einer bakteriellen Aminopeptidase, 
genannt BapA, von Sphingosinicella xenopeptidilytica präsentiert. Die Peptidase hat ein 
ungewöhnliches Substratspektrum für beta-Peptide. Die Strukturen von nativem BapA, 
ihrer pro-Form und BapA im Komplex mit pefabloc SC, Ampicillin und enzymatisch 
hydrolysiertem Ampicillin geben einen profunden Einblick in die Substratbindung. Zudem 
zeigt ein postulierter Mechanismus die autoproteolytische Aktivierung und katalytische 
Hydrolyse von Substraten. 
 
* * * * * 
 
CHAPTER 4 
A small number of membrane-bound and intracellular multi-domain receptors (Toll, 
NLRP) that is part of the innate immune system, accounts for the detection of microbial 
derived structural components. Upon recognition, the receptors assemble into large 
supra-molecular complexes and provide an activation platform for enzymes of 
downstream signalling cascades. Death domains are essential domains that enable the 
PREFACE 
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formation of such protein complexes. The fourth chapter focuses on the functional 
investigation of a homotypic death domain interaction between the pyrin domain of 
NLRP1 and the adaptor protein ASC. 
 
 
KAPITEL 4 
Eine kleine Anzahl membranständiger und intrazellulärer Rezeptoren (Toll, NLRP) des 
angeborenen Immunsystems ist für die Erkennung mikrobieller Komponenten zuständig. 
Nach deren Erkennung bilden diese Rezeptoren supramolekulare Komplexe, die die 
Aktivierung von Enzymen weiterführender Signalkaskaden steuert. Todesdomänen bilden 
die wesentlichen Bausteine im Aufbau solcher Komplexe. Das vierte Kapitel widmet sich 
der funktionellen Untersuchung der homotypen Interaktion zwischen der Pyrin Domäne 
von NLRP1 und dem Adaptorprotein ASC. 
 
* * * * * 
 
APPENDIX 
The appendix section shows preliminary results obtained from ribosome display selection 
rounds of ankyrin repeat molecules against human caspases. 
 
 
ANHANG 
Im Anhang werden vorläufige Resultate der Selektion von Ankyrin Molekülen mittels 
Ribosomen Display gegen humane Caspasen gezeigt. 
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INTRODUCTION 
 
 
Antibodies belong to the adaptive immune system and represent anti-microbial 
membrane-bound or soluble receptors that are constantly subjected to sequence 
variability in order to adapt to new polypeptides from hostile invaders. Antibodies are the 
effector molecules of the humoral immunity. In their soluble form, they are able to bind 
specifically to foreign microorganisms and proteins, marking them for elimination. In 
their membrane bound form, they confer antigenic specificity onto B-cells leading to 
specific proliferation of B-cell clones through the interaction of membrane antibody and 
antigen. B-cells, upon stimulation, differentiate into long living memory B-cells, enabling 
a rapid response upon further antigen contact. Specificity, diversity, memory and self and 
not self recognition are characteristic for adaptive immune responses [1]. 
Antibodies are indispensable receptor molecules in the adaptive immune system. 
It seems that their beneficial aspects have also made them indispensable in diverse 
research fields. Specificity and high affinity towards target proteins are very important 
properties that allow the investigation of ligands, peptides and proteins and protein 
complexes. Recent biotechnical developments, however, employ repeat proteins as novel 
types of binding molecules. Similarly to antibodies, they display highly variable binding 
surfaces and possess all required features acting as antibody substituents often with 
improved biophysical properties. 
 
 
 
1. From antibodies to designed binding molecules 
Antibodies possess a common structure of four peptide chains: two identical polypeptidic 
light chains of about 25`000 molecular mass and two identical polypeptidic heavy chains 
of about 50`000 molecular mass (without glycosylations). The chains are covalently 
linked through disulfide bonds. Each antibody has two antigen binding sites 
(hypervariable regions). The in sequence variable loops are called complementarity 
determining regions and are responsible for the recognition of the antigen. 
Despite the versatility of antibodies, they frequently possess unfavourable 
biophysical properties, which limit their application range. A “perfect” antibody should be 
resistant to aggregation, precipitation and degradation by proteases, is usable in a 
variety of solvents including detergents and reducing agents, has a long half-life and is 
easily available and cheap. Antibodies are large and complex molecules that cannot be 
recombinantly expressed in bacteria due to the presence of disulfide bonds and functional 
glycosylations [2]. Furthermore, antibody production often requires time-consuming and 
costly immunizations of animals. 
To circumvent whole antibody productions, single polypeptide chain constructs 
comprising the variable domains (scFv, single chain Fragment variable) of the heavy and 
light chain of an antibody have been created. These artificial proteins mimic the function 
of antibodies. Because of their improved biophysical properties they are a popular 
“antibody format” [2], [3], [4]. 
FULL CONSENSUS DESIGNED ANKYRIN REPEAT PROTEIN 
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Although whole antibodies and scFv are frequently used in standardized protocols as high 
affinity detection tools, there has recently been a great progress in the development of 
other domains or scaffolds than immunoglobulins to serve as binding molecules. In 1992, 
Michaely and Bennett [5] report about ankyrin motifs. “Ankyrin” proteins are structural 
proteins involved in specific macromolecular recognition. These elongated proteins 
consist of stacked repeats and mimic in principle antibodies by forming a complementary 
protein surface well designed for their cognate interaction partner. Because this motif / 
repeat is found in proteins of the ankyrin family, it was termed ankyrin repeat1 (Figure 
1_1). 
Besides ankyrins, another class of repeat proteins is ubiquitously found in nature, 
the so called leucine rich repeat2 proteins. Numerous examples of LRR containing proteins 
are known that interact with various compounds (for reviews see [6], [7]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1_1) 
A) Schematic drawing of the secondary structure elements of a single ankyrin repeat; B) 
The tertiary structure of five stacked ankyrin repeats is shown as ribbon diagram. The 
figure shows a N3C ankyrin molecule with an amino-terminal N-cap and a carboxy-
terminal C-cap, flanking three internal repeats (ribbon diagram: adapted and modified 
from [8]). 
 
 
1.1 Repeat proteins in adaptive immunity? 
Few examples of repeat proteins involved in the adaptive immunity are known. Highly 
diverse LRR proteins, named variable lymphocyte receptors, have been identified in the 
jawless agnathan sea lamprey and hagfish, which, similarly to antibodies in jawed 
vertebrates, act in the adaptive immune system [9]. Somatic rearrangements of LRR 
cassettes within this locus generate unique variable lymphocyte receptor transcripts. 
                                                 
1
 Ankyrin repeat; AR 
2
 Leucine rich repeat; LRR 
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1.2 Repeat proteins as scaffolds for consensus design 
Repeat proteins such as ankyrin repeat proteins, tetratricopeptide repeat proteins or 
leucine rich repeat proteins provide a source of naturally occurring binding molecules that 
have evolved a successful binding strategy [10]. They have modular extended structures 
of repeated structural units that stack together to form a continuous target-binding 
surface. Furthermore, repeat proteins seem to have a high tolerance towards insertion 
and deletion at the level of entire repeats and insertions at the level of inter-repeat 
connections [11], [12]. 
Binding molecules that are based on other protein scaffolds such as the Z domain 
of staphylococcal protein A (affibodies) [13], anticalins [14] or green fluorescent protein 
[15] are well expressed and stable but limited by the size of their target-binding surface, 
reviewed in Skerra et al., 2007 [16]. 
 
 
1.3 Consensus designed ankyrin repeat proteins3 
The consensus design of ankyrin repeat proteins aims for the generation of combinatorial 
libraries of polypeptides with highly diversified binding specificities [17], [18]. 
Ankyrin repeat proteins have ideal folds for consensus design and protein 
engineering approaches. They are highly abundant in nature with a relatively small 
number of residues per repeat and a small number or residues per repeat that form the 
variable surface. This enables a statistical analysis of thousands of sequences. Extensive 
database searches and structural considerations are implemented into two different 
approaches for consensus designed ankyrin repeat proteins. Binz et al., 2003, combine a 
set of diverse repeats with flanking amino- and carboxy-terminal capping repeats from a 
desoxyribonucleic acid (DNA) binding AR protein GABPβ1 [19], which results in soluble 
expression [17]. These molecules are known as “NxC” AR proteins, where “N” and “C” 
refer to the N- and C-(amino- and carboxy) terminal capping repeats, and “x” to the 
number of internal ankyrin repeats. The consensus design by Mosavi et al., 2002, a 
design with identical repeats without caps, yields unfolded proteins in inclusion bodies 
that require refolding [20]. Structure based substitutions of hydrophobic against charged 
surface residues significantly improve the solubility of the redesigned ankyrins by Mosavi 
et al. [21]. These molecules are denoted “nANK”, where “n” and “ANK” indicate the 
number of ankyrin repeats, respectively [20], [21]. 
 
 
1.4 Structure of an ankyrin repeat 
The common scaffold of an ankyrin repeat contains 33 amino acids. The secondary 
structure elements of a single ankyrin module (Figure 1_1) comprise two antiparallel 
helices, which are connected by a short turn and a linker sequence at the carboxy-
terminus connecting the next repeat [22]. 
All design approaches are based on similar strategies. The lower the variance of 
an amino acid at a given position and given fold, the more likely it is to be key to fold 
                                                 
3
 Designed ankyrin repeat protein; DARPin 
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conservation [24]. This is a fundamental principle and a cornerstone for protein design 
strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2_1) 
Consensus sequence alignment with structural features of the ankyrin repeat proteins as 
published by Binz et al., 2003 [17], Mosavi et al., 2002 [20], Mosavi et al., 2003 [21] 
and Merz et al., 2008 [23]. Various leucines in the N-Cap (L8R, L20R and L21R) and in 
the C-Cap (L6R, L15R, L22R) have been replaced by arginines in the TALR sequence 
[21]. The randomized positions (X), coloured in red, in the consensus sequence designed 
by Binz et al., 2003 encode for every amino acid except cysteine, glycine and proline; Z 
within the same amino acid sequence encodes either for histidine asparagine or tyrosine. 
Pink highlighted amino acids are identical among all sequences. Lower panel: colour 
coded amino acid conservation throughout the repeat sequence and within the structure. 
 
 
The choice of amino acids for framework positions, which are necessary to conserve the 
fold, are chosen upon sequence statistics (relative occurrence) by Mosavi et al., 2002 
[20]. Sequence statistics, as well as extensive structural criteria, are taken into account 
to complement the ankyrin repeat design at less conserved positions with variable 
“consensus” residues by Binz et al., 2003 [17]. Unsurprisingly, both design strategies 
result in similar consensus sequences (Figure 2_1). Remaining with the antibody 
nomenclature, 26 residues constitute the constant part, which is responsible for 
CHAPTER 1 
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framework integrity and seven residues constitute the variable part, displaying the 
complementary variable surface. The positions of these randomized residues forming the 
complementary determining region are shown in Figure 3_1. Indispensable prerequisite 
for all consensus designs is a statistically significant number of available protein 
sequences. Such consensus designs of repeat proteins are reported for ankyrin repeat 
proteins [17], [20], [21], tetratricopeptide repeat proteins [25], [26] and leucine rich 
repeat proteins [27]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3_1) 
Surface representation of a designed N3C ankyrin molecule (Protein database code 
1MJO). The randomized residues pointing towards the concave side of the molecule are 
coloured in red. 
 
A number of DARPins in complex with their target molecule are known and have been 
structurally investigated [28], [29], [30]. This shows that in silico designed and in vitro 
selected repeat proteins can successfully serve as alternatives to antibodies. 
 
 
1.5 Consensus versus full consensus 
In consensus designed DARPins, variable and even framework positions can differ from 
one repeat to the next [17]. Since consensus designed DARPins are mostly generated 
through ribosome display and phage display selection techniques, it is primarily the 
selection pressure that determines the type of amino acid at a variable position besides 
additional variability introduced through various polymerase chain reaction (PCR) steps. 
Hence, one of the selected traits of consensus designed DARPins is their property to bind 
to target molecules with high specificity and affinity. Affinities in the nanomolar and 
picomolar range are reported [31], [32]. 
Full consensus designed DARPins, however, are designed in silico. They are not 
selected against a target protein and are mostly used for biophysical and structural 
investigations. In full consensus designed DARPins, all internal repeats consist of identical 
repeat sequences. The molecules are denoted NIxC, in contrast to consensus designed 
DARPins (denoted as NxC). Here, “N” and “C” also refer to the amino- and carboxy-
terminal capping repeats, “I” refers to the identical internal repeats, and “x” indicates the 
FULL CONSENSUS DESIGNED ANKYRIN REPEAT PROTEIN 
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number of identical internal repeats [23]. Structural considerations, molecular dynamics 
studies and statistics of relative occurrences from sequence alignments are used to 
determine the “variable” positions [33]. Such a full consensus designed DARPin is 
unlikely to have strong binding partner even though this cannot be excluded. 
 
 
1.6 Chemical and thermal stability 
Biochemical analyses show that several consensus and full consensus DARPins display a 
significantly higher thermostability and chemical stability (guanidinium chloride 
denaturation) compared to naturally occurring AR proteins [17], [20]. The increase in 
stability is probably due to the removal of unfavourable interactions (possibly present as 
a consequence of functional requirements), the removal of irregular insertions or 
deletions within the repeat and between the repeats, an optimized intra-repeat and inter-
repeat packing. Other reasons might be that nature simply has not evolved thus far and 
that the evolutionary pressure is not stringent enough to efficiently sort out stable from 
less stable ankyrin molecules. On the other hand, there might be no need to, because 
naturally occurring ankyrins, unlike the designed ones, have never been selected 
according to stabilities in systems that are beyond physiological conditions. 
The first published structures of designed N3C DARPins (E3_5 and OFF7, a binder 
against maltose binding protein) emphasize hydrogen bond networks within the β-turn 
and the conserved TPLH sequence motif (Figure 2_1, positions 6-9) as well as an 
undisturbed repeat stacking as the major stabilizing features compared to naturally 
occurring AR proteins [8], [28]. However, E3_19 and NI3C (a full consensus DARPin) also 
possess these hydrogen bond networks and identical repeat interfaces, but still show 
significantly different stabilities [34], [35]. Therefore, the composition of the six freely 
exchangeable surface exposed residues on the concave side of the consensus designed 
molecule (Figure 2_1) suggests strongest impact on the stability, because all other 
framework residues are identical. The thermal stability of a full consensus DARPin 
increases significantly when the variable residues are able to form salt bridge networks 
[23]. The presence of favourable and unfavourable charge interactions in DARPins was 
shown in several cases to be a discriminating feature for increased or decreased stability 
[23], [35]. 
 
 
 
2. Rationale and aim of the project 
The aim of this project is to solve the crystal structure of a full consensus NI3C DARPin 
and to explain its high thermal stability from a structural point of view. 
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Full-consensus designed ankyrin repeat proteins (DARPins), in which
randomized positions of the previously described DARPin library have
been fixed, are characterized. They show exceptionally high thermody-
namic stabilities, even when compared to members of consensus DARPin
libraries and even more so when compared to naturally occurring ankyrin
repeat proteins. We determined the crystal structure of a full-consensus
DARPin, containing an N-capping repeat, three identical internal repeats
and a C-capping repeat at 2.05 Å resolution, and compared its structure
with that of the related DARPin library members E3_5 and E3_19. This
structural comparison suggests that primarily salt bridges on the surface,
which arrange in a network with almost crystal-like regularity, increase
thermostability in the full-consensus NI3C DARPin to make it resistant to
boiling. In the crystal structure, three sulfate ions complement this network.
Thermal denaturation experiments in guanidine hydrochloride directly
indicate a contribution of sulfate binding to the stability, providing further
evidence for the stabilizing effect of surface-exposed electrostatic interac-
tions and regular charge networks. The charged residues at the place of
randomized residues in the DARPin libraries were selected based on
sequence statistics and suggested that the charge interaction network is a
hidden design feature of this protein family. Ankyrins can therefore use
design principles from proteins of thermophilic organisms and reach at least
similar stabilities.
© 2007 Elsevier Ltd. All rights reserved.
Edited by F. Schmid
Keywords: repeat protein; protein stability; salt bridge; thermodynamic
stability; X-ray crystallography
Introduction
Repeat proteins consist of repeating structural
units that stack together to form elongated non-
globular domains.1,2 In contrast to globular proteins,
they are not stabilized by interactions between resi-
dues that are very distant in sequence; instead, the
stabilizing and structure-determining interactions
are formed within a repeat and between neigh-
boring repeats. Repeat proteins can be extended in
size while still constituting a contiguous domain,
making them unique targets for protein engineering.
Repeat proteins constitute, next to immunoglobu-
lins, the most abundant natural protein classes
specialized in binding.
Because of their abundance and the multiple
occurrences of repeats within one protein sequence,
a statistical analysis of thousands of sequences can
be carried out to design consensus repeats. This
has been reported for ankyrin repeat (AR) pro-
teins, tetratricopeptide repeat proteins and leucine-
rich repeat proteins.3–6 The AR is one of the most
common protein sequence motifs. This 33-residue
motif consists of a β-turn, followed by two anti-
parallel α-helices and a loop reaching the turn of
the next repeat.7
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Two independent approaches used to apply con-
sensus design strategies to AR proteins have been
reported so far.3,4 Both employ a similar but not
identical consensus version of the 33-residue AR.7 In
one approach, large libraries of AR proteins,3 in
which only 26 of the 33 amino acids were specified
while 7 were allowed to vary in order to bind to
different target molecules, were made.8
The potential target interaction residues of a
single AR (2, 3, 5, 13, 14 and 33), henceforth
named randomized residues, are located on the
concave side of designed ankyrin repeat proteins
(DARPins).3 Highly specific binders for a number
of different target proteins have been selected using
the DARPin libraries8, and structures of ankyrin–
target protein complexes have been determined.9–12
In this approach, N- and C-capping repeats flanking
the randomized repeats that shield the hydro-
phobic core were employed. Recently, it was
shown experimentally that indeed the capping
repeats are required for soluble expression in
Escherichia coli13 and for shielding of the protein
against aggregation.
In another approach, a full consensus was derived
from sequence statistics.4 In these studies, no
capping repeats were employed, and the resulting
proteins were only soluble at acidic pH.4 The
introduction of positive charges in the C-terminal
consensus repeat then allowed the protein to be
soluble at neutral pH, but it still had to be produced
by in vitro refolding from inclusion bodies made
in E. coli.5 However, the gain in solubility was
accompanied by a significant loss in stability at
pH 4.
As described in detail elsewhere in this issue,14 a
full-consensus version of the DARPins, in which
randomized residues of the library have now been
defined such that every internal repeat has exactly
the same sequence, was designed. We denote these
proteins as NIxC, where “N” and “C” refer to the
N- and C-terminal capping repeats, respectively,
“I” refers to the internal full-consensus repeat and
the subscript x gives the number of identical
internal consensus repeats. The design of NIxC
proteins and their thermodynamic and kinetic
folding properties have been investigated.14 The
N- and C-terminal capping repeats were originally
taken3 from GABP β1 (guanine-adenine binding
protein β1) (PDB code 1AWC).15
Here we report the crystal structure of the full-
consensus DARPin NI3C at 2.05 Å resolution and
compare its features with the structures of two
related consensus DARPins E3_5 and E3_19 [Pro-
tein Data Bank (PDB) entries 1MJ0 and 2BKG,
respectively]. All three molecules were designed
using the same framework residues. In contrast
to NI3C, the internal repeats of E3_5
16 and E3_1917
do not have the same sequences because they
contain different residues at the randomized posi-
tions. From our structural analysis, we propose that
a highly regular array of salt bridges, the overall
charge distribution and the binding of sulfate ions
significantly contribute to the thermodynamic sta-
bility of NI3C. This study is intended to extend our
understanding of stabilizing charge effects in AR
proteins.
Results
Overall structure
The finalmodel of the full-consensusNI3CDARPin
structure at 2.05 Å resolution contains all amino acids
and side chains of the three identical internal repeats
and the flanking N- and C-terminal capping repeats.
The capping repeats expose a hydrophilic surface
and shield the hydrophobic core of the internal
repeats from the solvent to prevent aggregation. As
in all AR proteins, the repeats adopt an L-shaped
arrangement, which is caused by two almost
antiparallel α-helices and a β-turn forming the
interrepeat connection (Fig. 1a). Residues positioned
at the concave side of the DARPin library (rando-
mized positions) normally mediate specific interac-
tions with selected targets. Based on the statistics of
naturally occurring AR protein sequences, they were
designed to be highly charged in the full-consensus
version.14 As a consequence, three sulfate ions from
the crystallization buffer were found to bind to this
site (Fig. 1b).
E3_5/E3_19 consensus versus NI3C full
consensus
Sequence differences within repeats between the
full-consensus molecule NI3C and the unselected
librarymembers E3_5 and E3_19 occur at positions 2,
3, 5, 13, 14, 26 and 33 (for repeat numbering, see Fig.
2). Residues at these randomized positions depend
on the selection process and typically differ from one
repeat to the next. In contrast to E3_5 and E3_19, all
internal repeats in NI3C are identical (Fig. 2). As
discussed in detail elsewhere in this issue,14 amino
acid types were selected by sequence statistics and
structural considerations.
Briefly, at positions 2 and 3, lysine and aspartic
acid residues were introduced, respectively. While
lysine is the most prevalent amino acid at position 2,
aspartic acid is the second most abundant amino
acid at position 3 (after asparagine). A negatively
charged amino acid was selected for position 3 to
balance the positive charges that were introduced at
positions 2 and 33. For position 5, which is quite
variable, tyrosine was introduced as a spectroscopic
probe. In position 13, the second most abundant
arginine (after glutamine) was used to compensate
for negative charges, and the most abundant
glutamic acid was selected for position 14. Alanine
was inserted at position 26 because it is most
abundant at this position and possesses high helical
propensity. For position 33, the most abundant
lysine was selected. Figure 2 shows the correspon-
dence between the numbering within a single repeat
and the protein sequence.
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Structural comparison with other AR proteins
The overall structures of NI3C, E3_5 and E3_19 are
very similar. The RMSD values of the pairwise
comparisons of Cα atoms between NI3C/E3_5,
NI3C/E3_19 and E3_5/E3_19 are 0.62 Å, 0.50 Å
and 0.60 Å, respectively. Superpositions of the three
molecules NI3C, E3_5 and E3_19 revealed the largest
structural differences in the C-terminal capping
repeats, which move, in a first approximation, as
rigid bodies. This is illustrated by a significant re-
duction in the overall RMSD values when omitting
Fig. 2. Sequence alignment
and numbering of NI3C, E3_5
and E3_19. The N-terminal cap-
ping repeat includes a His6 tag
(MRGSHHHHHHGS; sequence
not shown). Identical residues are
shown against a black background,
whereas randomized residues at
positions 2, 3, 5, 13, 14, 26 and 33
in the first, second and third inter-
nal repeats are shown against a
white background. POSITION:
numbering within one repeat;
SEQUENCE: numbering through-
out the sequence.
Fig. 1. (a) Ribbon diagram of the NI3C structure. The terminal and internal repeats are in magenta and green,
respectively. (b) Stereo view of the interactions involving the three sulfate ions and the randomized residues. Dashed lines
in black denote HB between lysine and aspartate residues at positions 2 and 3, as well as HB between arginine and
glutamate residues at positions 13 and 14. Dashed lines in blue denote all interactions of the sulfate ions.
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the C-terminal repeats. The RMSD values for Cα
atoms of residues 1–139 for the pairs NI3C/E3_5,
NI3C/E3_19 and E3_5/E3_19 are 0.29 Å, 0.39 Å, and
0.36 Å, respectively. Shape complementarity (SC)
values were analyzed between internal repeats and
fragments thereof (see Materials and Methods).
They were, in most cases, higher between internal
consensus repeats than between the capping repeats
and the adjacent internal consensus repeats (Table
1). This also illustrates the success of consensus
design, as the internal repeats can apparently be
very well stacked.
Hydrogen bond network
The total numbers of intramolecular hydrogen
bonds (HB) in NI3C, E3_5 and E3_19 are 152, 149
and 152, respectively, excluding those involved in
binding sulfate ions. Interrepeat HB are least
frequent in NI3C, with 14 HB, compared to 16 and
17 HB in E3_5 and E3_19, respectively. Due to the
high sequence identity, the hydrogen-bonding pat-
tern is very similar in all three structures, as
indicated by 119 common HB. The main-chain
hydrogen-bonding pattern of the conserved TPLH
sequence motif (residues 6–9) at the beginning of the
first α-helix of every repeat is identical in NI3C, E3_5
and E3_19. Small structural differences between
different types of amino acids at the randomized
positions enable the formation of specific HB. In
NI3C, E3_5 and E3_19, there are 22, 17 and 19
specific HB, respectively.
A detailed analysis of the total number of HB at
the randomized positions reveals that 10 out of 34
HB in NI3C, 5 out of 30 HB in E3_5 and 6 out of 30
HB in E3_19 are formed by side chains, again
excluding those involved in binding sulfate ions. In
contrast, the majority of the randomized residues
contribute with their backbone atoms to the overall
hydrogen-bonding network.
The rather modest number of side-chain HB from
randomized residues in E3_5 and E3_19 shows that
these residues are more relevant to the binding of
the target molecules rather than to the formation of
extended hydrogen-bonding networks on the sur-
face of the molecules (Table 1). The side chains at
the previously randomized positions specified in
the full-consensus NI3C molecule are involved in
highly regular charge–charge interactions. This
charge network is extended by sulfate ions from
the crystallization buffer by bridging four arginine
and two tyrosines residues in the first two repeats
(Fig. 1b).
Charge network
Previous reports on DARPins3,4,16 emphasized the
highly regular hydrogen-bonding patterns between
“framework” parts (i.e., contributed by the constant
part of the sequence as important for stability). The
designed ankyrins displayed a significantly higher
thermodynamic stability compared to naturally
occurring AR proteins,3,4 which do not have such
regular hydrogen-bonding networks and show
greater variability.
The full-consensus AR NI3C possesses, in addi-
tion, a highly regular charge distribution, which
spans about half of the protein surface and causes an
even higher thermodynamic stability compared to
other library members. NI3C contains a regular
array of lysine and aspartic acid residues at posi-
tions 2 and 3 in the β-turns of internal repeats, as
well as arginine and glutamic acid residues at
positions 13 and 14 at the C-terminal ends of helices
in the concave binding region. Arg23 positioned in
the N-terminal capping repeat and Lys144 in the
β-turn of the C-terminal capping repeat extend the
charge network. The electron density of Arg23
suggests a double conformation. Both conforma-
tions allow the formation of salt bridges with a first
sulfate ion. In the concave binding region, three
equally spaced sulfate ions form salt bridges with
Arg56, Arg89 and Arg122 (corresponding to posi-
tion 13 of the internal repeat) and HBwith Tyr48 and
Tyr81 (position 5 in the internal repeat). In addition,
these arginine residues participate in salt bridges
with Glu57, Glu90 and Glu123 (corresponding to
position 14 of the internal repeats) (Fig. 1b).
Thermal denaturation measurements
The thermal denaturation of NI3C was monitored
at 222 nm using CD spectroscopy. Under physiolo-
gical conditions, NI3C, unlike E3_5 and E3_19,
3,17
did not show a transition in thermal denaturation
experiments.14 In order to denature the protein
Table 1. Summary of the structural analysis between NI3C, E3_5 and E3_19
Property Ankyrins NI3C E3_5 E3_19
Identity (%) NI3C 100 89 88
E3_5 88 100 88
E3_19 87 87 100
SC (shape complementary) NI3C 0.714 (SCN-1) 0.839 (SC1–2) 0.803 (SC2–3) 0.705 (SC3-C)
E3_5 0.722 (SCN-1) 0.762 (SC1–2) 0.805 (SC2–3) 0.798 (SC3-C)
E3_19 0.702 (SCN-1) 0.812 (SC1–2) 0.769 (SC2–3) 0.739 (SC3-C)
HB (overall) Total 152 149 152
Unique 22 17 19
Common 119
HB (randomized residues) Total 34 30 30
Side chain 10 5 6
Main chain 24 25 24
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completely and to reach the posttransition baseline,
thermal denaturation measurements were per-
formed in the presence of 4 M guanidinium
hydrochloride Gdn·HCl. Denaturation experiments
of NI3C in Gdn·HCl had revealed a complex
unfolding mechanism, which was interpreted as a
partial unfolding of the C-terminal capping repeat
prior to the main transition.13,14
A remarkable shift towards higher transition
temperatures in the thermal melting curves of
NI3C was found with increasing sulfate concentra-
tions (Fig. 3a and b). The increase in melting tem-
perature is much more modest with increasing
sodium chloride concentrations. The analysis of Tm
as a function of ionic strength revealed that Tm
increases linearly with ionic strength, which is in
agreement with previous studies,18 but the slope
of the regression line is significantly higher for
sulfate (0.0092 °C mM−1; R2=0.9884) than for
phosphate (0.0064 °C mM−1; R2=0.9767) or chlor-
ide (0.0021 °C mM−1; R2 =0.9268) ions (Fig. 3c). In
contrast, E3_19, which does not have specific
sulfate-binding sites and whose limited stability
has been proposed to be a consequence of local
repulsions,17 is also stabilized by sodium chloride
and sulfate (Fig. 3d). In this case, the melting point
depends only on ionic strength and is independent
of salt type.
Discussion
Thermal and chemical stabilities are highly rele-
vant to the biotechnological and biomedical applica-
tions of proteins and are thus an important design
goal. Consensus design exploits sequence statistics
and is based on the assumption that the most
frequently occurring residues in a first approxima-
tion are correlated with molecules of high thermal
stability.19 As most random mutations are destabi-
lizing, only those protein variants that have stabiliz-
ing residues elsewhere can tolerate them. The con-
sensus of all naturally occurring sequences would
be expected to reflect these favorable residue com-
binations. A structural inspection is still required
to avoid designing mutually exclusive residues.
Compared to naturally occurring ankyrin proteins
with similar numbers of repeats, consensus-
designed AR proteins showed higher thermody-
namic stabilities and increased stabilities towards
chemical denaturants.5,16
The previous consensus design of DARPins has
been limited to “framework” positions. The original
goal was to create a library with the potential to
recognize a wide range of target molecules. Conse-
quently, residues at the randomized positions were
allowed to vary and exerted attractive and repulsive
charge interactions. Nonetheless, key residues spe-
cifying intrarepeat and interrepeat HB were present
in every one of the internal DARPin repeats, but not
necessarily in natural AR proteins, thereby partially
explaining the greater stability of the designed
library molecules.3,16
Fig. 3. Thermal melting curves of NI3C in 20 mM
Hepes, 4MGdn·HCl (pH 7.4) and different salt conditions:
(a) sodium chloride: 30 mM (curve 1), 60 mM (curve 2),
300mM (curve 3), 600mM (curve 4) and 750mM (curve 5);
(b) sodium sulfate: 10 mM (curve 1), 20 mM (curve 2),
100mM (curve 3), 200mM (curve 4) and 250mM (curve 5).
(c) Melting points (Tm) of NI3C plotted as a function of
ionic strength for different sodium chloride (▴), sodium
sulfate (♦) and sodium phosphate (▪) concentrations. (d)Melting points of E3_19 as a function of ionic strengths in
the same buffers as for NI3C, but omitting Gdn·HCl. The
estimated errors on Tm are ±0.5 °C.
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In the present work, we investigated the structural
consequences of a full-consensus design where the
sequence variability of internal repeats has been
eliminated. In order to correlate structural features
with the increased thermal stability of the full-
consensus protein, we compared the crystal struc-
tures of the full-consensus ankyrin NI3C with the
previously published consensus ankyrins E3_516
and E3_1917 (PDB codes 1MJO and 2BKG, respec-
tively). A comparison of RMSD values (Table 1) and
visual inspection of Cα–Cα distance plots (data not
shown) indicate no major structural differences
between the molecules, except within the last repeat.
They have almost the same number of HB, and most
of them are common between all three molecules.
Contacts between repeat interfaces were measured
qualitatively by analyzing shape complemen-
tarities.20 Differences in SC values between internal
repeats of NI3C, E3_5 and E3_19 indicate that the
stackings of internal repeats differ due to minor
side-chain rearrangements. It is unlikely, however,
that these differences explain the higher stability of
NI3C.
Charges and charge networks
The major difference between NI3C, E3_5 and
E3_19 is observed in the surface charge distribution.
As explained above, the NI3C design was based on
sequence statistics, leading to a charge network that
must have been selected during the evolution of AR
proteins. One may speculate that residues involved
in stabilizing charge networks are most strongly
selected and thus dominate sequence statistics of
surface residues, whereas residues that are required
for target recognition cancel out in the alignments of
whole sequence families.
In the work of Mosavi et al.4, a different full-
consensus sequence had been derived. In their work,
positions 3 and 14 were chosen as uncharged (both
asparagine), and an additional charge was intro-
duced by an arginine at position 5 (tyrosine in this
work). Additionally, there were two charge reversals
in the framework of helix 2, which are lysine
at position 21 (here glutamic acid because of its
occurrence in GA-binding protein β1) and glutamic
acid at position 25 (here lysine because of the
negative charge at position 21). In the design of
Mosavi et al.4 (PDB entries 1N0Q and 1N0R), these
residues generated a cluster of positively charged
residues on the concave side of the molecule that
might be electrostatically unfavorable (Fig. 4a). In
contrast to this, the surface potential of the NI3C
molecule is more balanced in this area (Fig. 4b),
especially when considering the protein without the
sulfate ions.
Nature has used a multitude of strategies for the
adaptation of proteins to life at high temperatures.22
Surface charges were, for quite some time, consid-
ered as rather unimportant for protein stability. It
was argued that the high dielectric constant of the
solvent would decrease the strength of charge–
charge interactions.23 Recently, it was shown that
computational redesign of surface charges can
improve protein stability significantly,24 and struc-
tural genomics data on proteins from Thermotoga
maritima revealed a significant increase in the
density of salt bridges in proteins from this organ-
ism compared to their mesophilic counterparts.25 In
contrast, the importance of oligomerization order,
HB and secondary structure was found to be less
pronounced than previously assumed. Similar
results were found in another comprehensive struc-
tural bioinformatics study26 and in more specialized
studies on individual protein families.27–30 The
high number of salt bridges in hyperthermophilic
proteins was explained by the diminishing desolva-
tion penalty for salt bridges at increasing tempera-
tures.31 Therefore, the contribution of salt bridges to
protein stability becomes more important at higher
temperatures. NI3C has the smallest and most
balanced negative charge excess among all three
molecules studied here and, thus, essentially fewer
local repulsions. A higher charge imbalance on
E3_19 compared to E3_5 was proposed to be the
major cause of its decreased stability.17,32
Another possible explanation for the extraordina-
rily high temperature stability, even in the absence
of sulfate ions, is the flexibility of the salt bridge
network, giving it an entropic advantage. Although
the surface-exposed ion pair network looks rigid in
Fig. 4. Electrostatic surface potentials, calculated using
the Adaptive Poisson–Boltzmann Solver21 of (a) 4ANK
(PDB code 1N0R) and (b) NI3C. Both representations show
the concave binding site with the N- and C-termini on the
right and left sides, respectively. Bound sulfate ions in the
NI3C molecule are shown as spheres. Both surfaces were
in blue and red for positive and negative electrostatic
charge densities (same scale), respectively.
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the present NI3C structure, only modest side-chain
rearrangements would be necessary to swap
between intrarepeat and interrepeat salt bridges.
We suggest that the sum of all favorable charge
interactions (and the absence of unfavorable ones) of
the full-consensus ankyrin NI3C is responsible for its
significantly increased thermal stability. It is remark-
able that the sequence statistics, at least in part,
mirror these favorable properties.
Sulfates in the charge network
Three regularly arranged sulfate ions form the core
of the salt bridge network on the concave side of the
molecule. Thermal melting experiments in the
presence and in the absence of sulfate ions clearly
confirm the contribution of sulfate to the thermal
stability of the full-consensus NI3C ankyrin. It
should be noted that thermal stability is already
very high in the absence of sulfate. Even though the
surface potential is balanced (Fig. 4b), the protein can
bind three sulfate ions, which increase the total
negative charge excess of the molecule from 12 e− to
18 e−. Because of the alternating arrangement of
the charges, sulfate binding is energetically favored,
and the stabilizing effect may be rationalized by the
very short hydrogen-bonding distance of 2.4 Å
between the sulfate ions and tyrosine residues at
position 5 (Fig. 1b).
Summary and conclusion
The crystal structure and the thermal denatura-
tion studies of the designed full-consensus AR
protein NI3C suggest that the extended salt bridge
network positively influences the stability of the
protein. This protein can only be denatured by
heating in the presence of 4 M Gdn·HCl. NI3C was
designed based mainly on sequence statistics,
suggesting that this charge network among pre-
viously randomized residues must also be a
hidden design feature of natural ARs. In naturally
occurring AR proteins, this feature is no longer
visible because the sequences have drifted due to
functional selection. Designing such charge inter-
action networks may thus be a strategy for the
development of extremely stable proteins for
biomedical and other biotechnical applications.
However, since many of these residues normally
participate in binding, a compromise between
function and thermal stability by surface charge
interactions will have to be found.
Materials and Methods
Expression and purification
The full-consensus NI3C ankyrin was expressed in E.
coli strain XL-1 blue in LB medium supplemented with 1%
glucose, 100 μg/ml ampicillin and 15 μg/ml tetracycline.
After growing to an OD600 of approximately 0.8–1.0 at
37 °C, the cultures were induced with 0.5 mM IPTG, and
growth continued for 5 h. After centrifugation and
resuspension in 50 mM Tris, 500 mM NaCl and 20 mM
imidazole at pH 8.0, the cells were disrupted using a
French press. The protein was purified in self-packed
columns containing a Ni-NTA matrix (Qiagen) in accor-
dance with the manufacturer's instructions. The protein
was further purified by gel filtration on a HiLoad 26/60
Superdex 75 (Pharmacia Biotech) with an ÄKTA Prime
system (Amersham, Pharmacia Biotech) in 10 mM Hepes
and 10 mM NaCl (pH 7.4) and concentrated to 20 mg/ml
using a Centricon (Millipore USA) with 3-kDa molecular
mass cutoff.
Crystallization
Crystals for X-ray diffraction data collection were
grown in 24-well crystallization plates using the hang-
ing-drop vapor-diffusion method. A 1-μl protein solution
was mixed with 1 μl of reservoir solution containing 2.7 M
(NH4)2SO4 and 100 mM Tris (pH 8.5). The crystals grown
under these conditions were soaked in reservoir solution
supplemented with 20% glycerol as cryoprotectant and
flash-cooled in a nitrogen stream at 100 K. The X-ray
diffraction data of one single crystal were collected using
CuKα radiation generated by a Nonius FR591 rotating
anode generator.
Structure solution and refinement
Diffraction data up to 2.05 Å resolution on a total of 180
frames were recorded within an oscillation range of 1°.
The data were processed with program XDS.33 A
Matthews coefficient of VM=2.4 Å
3 Da−1 suggested one
molecule in the asymmetric unit. Initial phases were
obtained by molecular replacement using the program
Table 2. Statistics for data collection and refinement
Data collection
Space group P61
Cell dimensions a=74.48 Å, b=74.48 Å, c=50.99 Å,
α=β=90°, γ=120°
Resolution limits (Å) 64.5–2.05
Observed reflections 78,634 (overall); 10,232 (unique)
Completeness (%) 99.8 (98.2)
Redundancy 7.7 (7.1)
Rsym (% on I) 7.3 (37.0)
Refinement
Resolution range (Å) 64.5–2.05
R-factor/Rfree (%) 18.6/22.6
Ordered water molecules 110
RMSD from ideal geometry
Bond length (Å) 0.010
Bond angles (°) 1.109
Average B-factor (Å2) 26.3
Residues in the most favored
region (%)
91.9
Residues in the additionally
allowed region (%)
8.1
Residues in the generously
allowed region (%)
0.0
Residues in the disallowed
region (%)
0.0
Numbers inside parentheses refer to the highest resolution shell
(2.1–2.05 Å).
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AMoRe,34 with the structure of E3_5 (PDB code 1MJO) as
a searchmodel. The structure was refined to final R-factors
of Rwork=18.6% and Rfree=22.6% in the space group P61
using the program REFMAC5.35 Model building was
performedwith programO.36 Statistics for diffraction data
and structure refinement are summarized in Table 2. The
program PROCHECK37 was used to evaluate deviations
from standard geometries, and the programs HBPLUS38
and SC20 were used to analyze the hydrogen-bonding
pattern and calculations of surface complementarities.
Although the SC program was originally developed to
calculate the surface complementarity between separated
subunits, we used this method to investigate intramole-
cular shape complementarities. For this purpose, the
molecule was split into fragments by inserting artificial
chain breaks between residues 31/32, 64/65, 97/98 and
130/131. The SCN-1, SC1–2, SC2–3 and SC3-C values refer to
the interface SC values of neighboring repeats. Figures
were generated with PyMOL.39
Thermal denaturation experiments
Thermal denaturation experiments were performed
with a Jasco J-715 instrument (Jasco, Japan). CD data
were recorded at a protein concentration of 40 μM in the
temperature range between 5 °C and 95 °C within
90 min at a wavelength of 222 nm (measuring interval,
10 s; bandwidth, 2 nm). The buffers contained 20 mM
Hepes, 4 M Gdn·HCl (pH 7.4) and salt concentrations of
between 30 and 750 mM sodium chloride or of between
10 and 250 mM sodium sulfate. The same buffers
without Gdn·HCl were used for heat denaturation
experiments with E3_19. Ionic strengths were calculated
as follows: I=1/2∑icizi2, where c=concentration and
z=charge of ion.
Protein Data Bank accession number
Coordinates and diffraction data have been deposited at
the PDB under accession number 2QYJ.
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INTRODUCTION 
 
 
Physical and simple physiological barriers are an organisms` first line of defence. The 
epidermis (outer layer) and dermis (inner layer) provide mechanical barriers that prevent 
entry of microbes and retard bacterial growth by keeping their environment slightly acidic 
(pH 3-5). Mucus membranes entrap foreign microorganisms hampering them to attach to 
the underlying epithelial layer, and the normal flora competes with microbes for 
attachment sites as well as nutrients. Cilia in the lungs actively propel microorganisms 
out of the body. Physiologic barriers such as high body temperature, low pH in the 
stomach, digestive enzymes and chemical mediators like interferons and complement 
inhibit or prevent growth of several microorganisms. These relatively simple non-specific 
factors and mechanisms are constitutively acting against foreign microorganisms even in 
the absence of hostile stimuli or from signals that result from an anti-inflammatory 
response [1]. 
Further non-specific host defence lines include circulating phagocytic cells, 
inflammatory barriers as well as broadly acting proteolytic enzymes that are released by 
neutrophils. These mechanisms also belong to the first line of defence although they use 
a specific set of signalling molecules and target specific receptors. 
 
 
 
1. The cellular non-specific host response 
The most abundant circulating granulocyte cell type of the innate immune system are 
neutrophils (90%), besides eosinophils (2-5%) and basophile granulocytes (less than 
0.2%) [2]. Neutrophils and sometimes eosinophils are recruited from the circulation to 
the site of infection as a first line of defence against foreign invaders [3], [4], [5]. Their 
primary defence mechanism is the release of nitrogen and oxygen radicals, potent 
antimicrobial compounds and peptidases. They also remove pathogens by phagocytosis. 
Neutrophils secrete a variety of cytokines, peptidases and chemokines that alter the 
connective tissue for the recruitment of inflammatory and immune cells [4], [6]. 
Although neutrophils are powerful and crucial effector cells in the host defence against 
infection, they also have the potential to damage host tissues and cells, since molecules 
released to thwart invaders cannot differentiate self from foreign. 
Besides neutrophils, different cell types including macrophages, mast cells, 
basophiles and eosinophiles secrete a variety of cell-type specific mediators and 
signalling molecules, which activate resting cells, lead to the production of other 
signalling molecules or to the expression of surface receptor molecules. Colony 
stimulating factors released by macrophages1 do not only act on progenitor cells, and 
cause proliferation and differentiation, but additionally act on mature cells, promoting 
phagocytosis, enzyme production and neutrophil adhesion [7], [8]. Neutrophil adhesion 
and O2- release is also initiated by endothelial cells [9]. On the other side, tumor necrosis 
                                                 
1
 Granulocyte macrophage colony stimulating factor; GM-CSF 
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factor alpha2 released by neutrophils can activate and stimulate endothelial cells to 
express adhesion molecules [10] or to induce apoptosis [11]. Mast cells accumulate a 
broad array of mediators and signalling molecules, in particular histamine. Various 
peptidases and TNF-α, released by mast cells cause the major signs of inflammation. 
Similarly to mast cells, activated eosinophils and basophiles release a variety of cell 
specific cytotoxic molecules such as major basic protein, eosinophil peroxidase, and 
proinflammatory cytokines (IL-33, IL-4, IL-6, IL-16, TNF-α, GM-CSF) and monocyte 
chemoattractant protein 1 [12], [13], [14] . Basophile restricted IL-4 and IL-13 stimulate 
the differentiation of Th2 cells and IgE
4 synthesis [15]. 
 
 
1.1 Polymorph nuclear neutrophils5 
The lifespan of circulating non-stimulated neutrophils is rather short. They have a 14 day 
development phase in the bone marrow followed by a stay in a temporary storage pool 
before getting released into the blood. In the absence of any bacterial infection they 
return to the bone marrow or enter the liver after 12-14 hours to undergo apoptosis 
[16], [17]. The shrinkage into apoptotic bodies and the subsequent phagocytosis by local 
macrophages prevents the onset of tissue damage by lytic factors [18]. 
The pool of circulating non-stimulated neutrophils can differentiate into resting 
polymorph nuclear neutrophils upon recognition of a priming stimulus and requires 
subsequent stimuli to become active PMN. Three different states of PMN are known: the 
resting, primed and activated state. The priming process has been demonstrated by in 
vitro administering PMN with sub-stimulatory concentrations of pharmacological agents 
allowing the cells to respond to a second stimulus. One characteristic feature of PMN is 
the release of reactive oxygen and nitrogen species, called the oxidative burst. At the 
very end of the priming events, it is executed upon formyl-methionyl-leucyl-
phenylalanine (fMLP) exposure after a pre-treatment of a number of inflammatory 
mediators such as TNF-α, GM-CSF, lipopolysaccharides or a low dose of fMLP [19], [20]. 
Formylated peptides released by foreign organisms or by opsonins are recognized by PMN 
surface receptors [20]. Above a certain threshold of bound peptides the primed state is 
induced by a rapid increase of cytoplasmic Ca2+ concentrations and the simultaneous 
decrease of the cytoplasmic pH [21], [22], [23]. Interestingly, fMLP induced PMN move 
up the chemoattractant gradient towards higher concentrations, whereas GM-CSF 
induced cells start to migrate randomly, showing that bacterial derived stimuli (fMLP) 
generate a stronger and more directed response [24]. 
 
 
1.2 The oxidative burst 
The transition of neutrophils from a resting state in the circulation to an activated state at 
the site of infection is triggered by an ordered sequence of signals of circulating priming 
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 Tumor necrosis factor alpha; TNF-α 
3
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4
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and extravascular stimuli. This prevents premature degranulation and collateral host 
tissue damage upon release of the non-specific arsenal of antimicrobial weapons such as 
reactive oxygen and nitrogen species, cytotoxic and proteolytic enzymes. 
IL-18, a member of the IL-1 family, is involved in the induction of the oxidative 
burst [25] and to be an important neutrophil mediator in inflammatory diseases [26]. It 
is concomitantly released with IL-1β and other cytokines such as GM-CSF and TNF-α from 
endothelial or epithelial cells that sense bacterial antigens for example by Toll-like 
receptors or intracellular pathogen associated molecular pattern detection platforms such 
as the inflammasomes (see chapter 4). Besides the importance of soluble factors that 
trigger the release of reactive oxygen and nitrogen species, PMN only release their 
destroying cargo at the region of maximal chemoattractant concentration in a primed 
state. This strongly implies the involvement of membrane bound receptors, which 
themselves trigger the initiation of degranulation upon contact formation [4]. 
The nicotinamide adenine dinucleotide phosphate (NADPH) oxidase catalyzes 
chemical reactions of the oxidative burst. It is a multimeric protein complex that 
assembles on the membrane after cell priming. The importance and proper functionality 
of the NADPH oxidase is exemplified by its dysfunction causing chronic granulomatous 
disease (recurrent infections due to incapability of phagocytes to kill invading microbes) 
[27]. 
The phagocyte NADPH oxidase generates superoxide anions using molecular 
oxygen and NADPH according to the following reaction 
 
NADPH  +  2 O2   NADP
+
  +  2 
•
O2- +  H
+
 
 
To prevent host tissue damage by the release of the highly reactive oxygen radicals, 
cells, that are capable of phagocytosis, “kill” the engulfed bacterium within protected 
areas. The lytic and killing process of microorganisms takes place in phagocytic vacuoles 
called phagosomes [28]. The NADPH oxidase hereby is the major machinery that initially 
releases superoxide anions into the phagocytic space. 
 
 
1.3 Proteolytic defence 
 
1.3.1 Peptidases within PMN granules 
Primary granules from neutrophils are the storage place for bactericidal peptides and 
proteins. Besides myeloperoxidase [29], lysozyme, defensins and permeability increasing 
proteins, the granules harbour the serine peptidases cathepsin G6, neutrophil elastase7 
and proteinase 38 [28], [30]. Protein concentrations inside the granules of up to 500 
mg/ml are reported [31]. Furthermore, secondary and tertiary granules contain iron and 
copper sequestering lactoferrin, lysozyme and gelatinase [32]. Interestingly, the 
antimicrobial α-defensin comprises 30-50% of the total protein in azurophilic granules 
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[33]. Myeloperoxidase, which is considered a key constituent in the neutrophil cytotoxic 
armament, accounts for up to 5% of the total cell proteins [34]. 
Even though NE is not the most abundant peptidase, it is a key component 
regarding tissue remodelling, destruction and disease amplification. NE enhances tumor 
growth factor-β19 secretion via the MyD88 / IRAK pathway (see chapter 4) [35]. TGF-β1 
contributes to the initiation of inflammatory events and plays important roles in tissue 
repair and fibrinolysis [36]. Since TGF-β1 is up-regulated in bronchial tissue from patients 
with severe asthma, NE is supposed to contribute to pathogenesis [37], [38]. 
 
1.3.2 Regulatory functions of neutrophil elastase and cathepsin G 
Among all serine peptidases, NE is thought to be one of the major cytotoxic molecules 
because of its abundance and powerful degrading activity against a wide substrate 
variety. One of NE natural targets is elastin, an extremely stable component of the 
connective tissue. Elastin retains its integrity by boiling in 0.1 M NaOH at 95°C or 
successive one hour autoclave periods and can hardly be cleaved by any other peptidase 
except collagenase, cathepsin G and proteinase 3, although less effectively [39], [40]. 
Besides elastin, extracellular matrix proteins such as collagen, fibrin and proteoglycans, 
plasma proteins like coagulation factors and complement, IgG and IgM, peptidase 
inhibitors and various cytokines are natural targets of neutrophil elastase [41]. NE and 
CG even exert chemotactic functions by mediating the conversion of the biologically low 
activity precursor prochemerin to chemerin, a chemotactic protein for dendritic cells and 
macrophages [42]. NE-controlled proteolytic cleavage leads in most cases to loss of 
function, only complement and peptidases get activated. 
Host tissues are protected from unregulated proteolytic activity by several soluble 
peptidase inhibitors. These include α1-antipeptidase, secretory leukopeptidase inhibitor, 
elafin, α2-macroglobulin and eglin [43], [44], [45], [46]. Nevertheless, NE uses an 
elaborate repertoire to circumvent this inhibition machinery: neutrophils in their tissue 
resident state are able to create a peptidase-inhibitor-free microenvironment that 
encompasses the surface to which they are adherent [47]. Secondly, α1-antipeptidase 
and secretory leukopeptidase inhibitor are sensitive to oxidants released by neutrophils 
[48]. Thirdly, NE is relatively resistant to anti-peptidases if bound to elastin and similarly 
in a membrane bound form on the surface of activated neutrophils [49], [50]. The 
inactivation through oxidation is of particular significance in lung diseases of smokers 
[51]. Even though NE seems to be an inexorable peptidase, its destructive potential 
mainly becomes noticeable in pathological states (see section 1.4.3). 
The difference between turnover rates of collagen and elastin remodelling at sites 
of tissue repair after injury or infection compared to normal turnover rates in healthy 
human beings can vary significantly. Elastase activity in wound healing processes and 
inflammatory responses is tightly controlled by the overwhelming amount of natural 
elastase inhibitors [43], [44], [45], [46]. However, several pathological states are known 
in which the uncontrolled cleavage of natural elastase target molecules causes severe 
collateral damage to various tissues. 
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Human cathepsin G is found in the azurophilic granules of PMN. It is a serine peptidase 
with chymotrypsin activity [60]. It is an important enzyme modulator in inflammatory 
processes. Hereby, the low specific immune response elicited by PMN is linked to cells of 
the adapted immune system, in particular B cells, CD4
+ and CD8
+ T cells (CD = cluster of 
differentiation) and natural killer cells [61]. Furthermore, CG released from granulocytes 
binds to human natural killer cells and causes their enhanced cytotoxicity [62]. CG also 
acts as chemoattractant for circulating monocytes [63]. 
The imbalance between peptidases and their natural inhibitors may result in the 
uncontrolled digestion of most proteins of the extracellular matrix. Thus, CG, PR3, but 
foremost NE contribute to the development of connective tissue diseases like emphysema 
and rheumatoid arthritis [63], [64], [65]. However, α1-antipeptidase, secretory 
leukopeptidase inhibitor, elafin and α2-macroglobulin restrict and tightly control the 
digestive action of CG and other neutrophil serine peptidases [43], [44], [45], [46]. The 
numerous consequences of diseases that are linked to the dysregulation of CG and NE 
are briefly outlined in the following section. 
 
1.3.3 Diseases 
Interestingly, the cumulation of different pathological states mainly concerns the lungs. 
Several diseases such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, 
emphysema, systemic inflammatory response syndrome, and more severe states thereof 
(acute lung injury, and adult respiratory distress syndrome), are directly or indirectly 
affected through the uncontrolled activity of NE, which is known to aggravate the state of 
the disease [52], [53], [54], [55], [56]. 
It is known that NE enhances TGF-β1 secretion via the MyD88 / IRAK pathway 
[35]. TGF-β1 contributes to the initiation of inflammatory events and plays important 
roles in tissue repair and fibrinolysis [36]. Furthermore, TGF-β1 release stimulates airway 
remodelling by inducing smooth muscle cell growth. The consequences of this process are 
fatal. The smooth muscle cells themselves are able to secrete various cytokines that 
might play a role in sub-mucosal inflammation and airway responsiveness, and they 
cause strengthened airway constriction leading to decreased cartilage volume. Such 
changes in the microvasculature are associated with increased airway vascularity, 
oedema, mucus production and the recruitment of inflammatory cells, which, of course, 
promote TGF-β1 release in a self-amplifying cycle [57]. Since TGF-β1 is up-regulated in 
bronchial tissue from patients with severe asthma, NE is supposed to contribute directly 
and indirectly to pathogenesis [37], [38]. 
Cystic fibrosis is a genetic disorder in which abnormal ion transport in the lungs 
leads to mucus accumulation predisposing patients to infection and neutrophilic 
inflammation [58]. The disease is further characterized by an increased level of NE and 
an imbalance between the metallopeptidases-8 and -9 and their natural inhibitor, named 
tissue inhibitor of metallopeptidase-1. This imbalance is based on proteolytic inactivation 
of the tissue inhibitor by NE and the activation of the precursor metallopeptidases [59]. 
NE, unlike other peptidases from granulocytes, is widely considered a key 
component regarding benign tissue remodelling on one side or malignant tissue 
destruction on the other side, and of course its involvement in a broad variety of 
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diseases. This circumstance raised great interest in medical and pharmacological studies, 
which tackled the search for powerful elastase inhibitors. 
 
 
 
2. Rationale and aim of the project 
The aim of this project is to find selective inhibitors against human neutrophil elastase 
and cathepsin G, starting from the scaffold of the naturally occurring sunflower trypsin 
inhibitor 1. The primary focus is to determine the structure-function relationship and the 
structural principles that govern specificity for this type of inhibitors. 
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Abstract 
The 14 amino acid long naturally occurring sunflower trypsin inhibitor (SFTI-1) scaffold is a 
popular, small and bi-cyclic peptide that has thoroughly been investigated with respect to its 
inhibitory potency and selectivity for trypsin, cathepsin G and human matriptase as well as its 
susceptibility for modifications. In this work, SFTI-1 was redesigned into a potent cathepsin 
G inhibitor (Ki = 11 nM, POL4634) and a neutrophil elastase inhibitor (Ki = 35 nM, 
POL4957). They were crystallized in complex with cathepsin G, porcine pancreatic elastase 
and human neutrophil elastase. The structural analysis in combination with inhibitory data 
suggests that imposed conformational restraints of the peptidase have more impact on the 
inhibitory activity of the non-covalently binding peptidomimetic inhibitors than measurable 
inhibitor-peptidase-interaction parameters.  
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Introduction 
Naturally occurring peptidase inhibitors are conformationally restricted and show remarkable 
stability towards heat, proteases and denaturing agents [Makhatadze, 1993], [Colgrave, 2004]. 
These beneficial properties can often be attributed to disulfide cross-linking or backbone 
cyclization, which compensate the lack of a hydrophobic core. The pancreatic trypsin 
inhibitors from the Kunitz- and Kazal-types, the soybean Bowman-Birk inhibitors and the 
cyclotides [Makhatadze, 1993], [Qi, 2005], [Avrutina, 2005], [Craik, 1999] are molecules that 
show these properties. Disulfide bridges and hydrogen bonds rigidify the fold and restrict the 
canonical peptidase-binding loop into an extended conformation forming an anti-parallel β-
sheet in the proper conformation to facilitate hydrogen bond formation within the enzyme 
binding site [Laskowski, 2000], [Apostoluk, 1998], [Tyndall, 2005]. 
The bi-cyclic trypsin inhibitor from sunflower seeds (SFTI-1) consists of 14 amino 
acids and folds into a short anti-parallel β-hairpin structure. SFTI-1 is cross-linked by a single 
disulfide bridge and its binding loop shows high sequence and structural similarity to 
Bowman-Birk inhibitors [Luckett, 1999]. The stability and small size of SFTI-1 as well as the 
availability of structural data makes it an interesting molecular template for drug design 
applications. SFTI-1 exhibits a strong inhibitory activity against trypsin Ki = 0.3 – 1x10-10 M 
[Luckett, 1999], [Daly, 2006], [Garcia Boy, 2009] and cathepsin G (Ki < 1.5x10-10 M) 
[Luckett, 1999] but only very weak affinity against elastase (Ki ~ 1x10-4 M) [Luckett, 1999]. 
Several studies show, that SFTI-1 is well suited as a template for the design of β-hairpin 
peptidomimetics, maintaining strong inhibitory activity against trypsin, cathepsin G or 
matriptase [Descours, 2002],[Legowska, 2009], [Li, 2007]. The serine peptidases cathepsin G, 
human leucocyte elastase and proteinase 3 are secreted by neutrophils at sites of 
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inflammation. They play a critical role in the activation of cytokines and growth factors and 
stimulate various cellular receptors (reviewed in [Wiedow, 2005]). 
The focus of our study was the structural analysis of a redesigned SFTI-1 inhibitor in 
complex with cathepsin G, human neutrophil elastase and porcine pancreatic elastase. Kinetic 
experiments showed strong inhibitory potency against cathepsin G and neutrophil elastase 
while trypsin could not be inhibited with the modified inhibitors. The redesign of SFTI-1 
included four changes: (i) Ile7 was changed to Asp7, because cathepsin G, in contrast to 
trypsin, revealed a patch of positive charge density around the S2` binding site. (ii) The β-turn 
forming tripeptide Pro13-Asp14-Gly1 in the non-prime site of SFTI-1 was replaced by the 
shorter DPro13-LPro1 dipeptide with the aim to improve the stability and to lock the inhibitor 
in a favorable conformation. (iii) Arg2 in P4 was replaced by Phe2 to satisfy the requirements 
of the hydrophobic S4 pocket of cathepsin G. (iv) Lys5 in P1, the selectivity discriminating 
residue for trypsin-like peptidases [Daly, 2006], [Descours, 2002], was substituted with the 
non-standard aliphatic amino acid norleucine (Figure 1). Norleucine lacks the terminal ε-
amino group and disables the formation of a selectivity determining salt bridge at the bottom 
of the S1 pocket. The cyclic and non-covalent cathepsin G inhibitor POL4634 finally 
consisted of 13 amino acids including the two non-natural amino acids norleucine and D-
proline at positions 5 and 13, respectively. 
We determined the crystal structures of the SFTI-1 derivative POL4634 in complex 
with cathepsin G and porcine pancreatic elastase and of the SFTI-1 derivative POL4957 in 
complex with human neutrophil elastase and analyzed the respective binding interfaces. These 
complex structures not only revealed the necessary structural features of the inhibitors that are 
required for binding, but also the necessary structural predisposition of the binding site. The 
conformation of the inhibitor hereby plays an essential role leading to decreased affinity when 
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the binding site of the enzyme imposes a conformational strain. Moreover, we were able to 
solve the structure of POL4634 bound to PPE in three different states (i) in its cyclic form, (ii) 
in its cyclic form before nucleophilic attack and (iii) in a cleaved state that represents a stable 
acyl-enzyme intermediate state. 
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Results 
1. Crystal structure of POL4634 in complex with cathepsin G. 
The crystal structure of cathepsin G in complex with POL4634 was determined at 1.8 Å. The 
superposition of this complex structure and cathepsin G in complex with Suc-Val-Pro-Lysp-
(Oph)2 (PDB-ID: 1AU8) resulted in an rmsd of 0.35 Å for all Cα-atoms except for residues 
36 to 38 and indicated that both structures were almost identical. The crystallographic data are 
shown in Table 1. The inhibitor POL4634 formed a distorted anti-parallel β-sheet that was 
stabilized by six intra-molecular hydrogen bonds, involving main-chain atoms from residues 
Phe2I, Thr4I, Pro8I, Ile10I, and Tyr12I as well as side chain atoms from Thr4I and Ser6I. In 
addition, a disulfide bridge between Cys3I and Cys11I cross-linked the adjacent β-strands 
(Figure 2A). However, the increased distance between Cys3I-Sγ and Cys11I-Sγ (3.1 Å) and 
the alternative side chain conformation of Cys3I suggested a partial opening of this disulfide 
bridge due to radiation damage. The cyclic POL4634 β-hairpin contained two loops that were 
located in the prime- and non-prime cathepsin G binding pockets. The prime-site loop was 
stabilized by the LPro8-LPro9 dipeptide and adopted a cis-peptide conformation comparable to 
the naturally occurring SFTI-1 inhibitor in complex with trypsin [Luckett, 1999]. The binding 
interface between POL4634 and cathepsin G included eleven hydrogen bonds, a surface area 
of 668.6 Å2 and a shape complementarity (SC) of 0.677 (Table 2). The POL4634 inhibitor 
occupied the cathepsin G S4 to S2' binding pockets (Figure 2A). The intra-molecular β-sheet 
conformation of POL4634 predefined the orientation of the residues Pro1I to Nle5I, which 
interacted with residues Ser218 to Ser214 from cathepsin G in the canonical anti-parallel β-
sheet conformation [Garavilla de, 2005]. Phe2I (P4) T-stacked on the side chain of Phe172 
and together with Tyr12I, they were involved in van der Waals interactions with hydrophobic 
residues in the non-prime-site pocket. Cys3I (P3), Thr4I (P2) and Ser6I (P1`) formed main 
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chain and side chain hydrogen bonds and stabilized the central part of POL4634 while Nle5I 
occupied the S1 binding site. Asp7I (P2`) was surrounded by the side chains of Arg41, 
Arg143, and Lys192 of the S2` binding pocket (Figure 2A). However, Asp7I did not directly 
interact with any of these positively charged side chains but formed a water-mediated salt 
bridge with Arg143. The residues Pro8 to Pro13 faced the solvent. The electron density of 
norleucine suggested a planar, sp2 hybridized Nle5I-C atom. Its carbonyl oxygen made 
hydrogen bonds with the backbone amide groups of Gly193, Asp194 and Ser195 that form the 
oxyanion hole.  
Ser40 of cathepsin G was located in a loop region that adopted substantially different 
conformations in the complexes with POL4634 and Suc-Val-Pro-Lysp-(Oph)2 (PDB-ID: 
1AU8). Whether these different conformations could be attributed to inhibitor binding 
remained unclear, because residues 36B to 38 were involved in a crystal contact. Pro36B-O 
formed a hydrogen bond with Gly173-N (2.8 Å) from the symmetry related molecule 
(generated by the symmetry operator –X+1/2, -Y, Z+1/2). The superposition of the complex 
structures of the macrocyclic inhibitor POL4634, the tripeptidic inhibitor Suc-Val-Pro-Lysp-
(Oph)2 and the aliphatic inhibitor JNJ-10311795 [Zani, 2009] (PDB-ID: 1T32) in complex 
with cathepsin G revealed conformational differences in the S1 pocket. The replacement of 
lysine with a norleucine in P1 caused a shift of the Glu226 side chain at the bottom of the S1 
pocket, because Glu226 could no longer form a polar interaction with the side chain of the 
inhibitor. In addition, the active site of cathepsin G in complex with hydrophobic ligands such 
as norleucine or the naphthalene moiety of the JNJ-10311795 inhibitor (Figure 3) did not 
harbor water molecules. 
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2. Crystal structure of POL4634 in complex with porcine pancreatic elastase. 
The crystal structure of PPE in complex with POL4634 was determined at 1.8 Å resolution 
with three PPE/POL4634 complexes in the asymmetric unit. The crystallographic data are 
shown in Table 1. Similarly to the complex structure of cathepsin G, POL4634 in complex 
with PPE formed a distorted anti-parallel β-sheet that was stabilized by intra- and 
intermolecular hydrogen bonds and a disulfide bond between Cys3I and Cys11I. Details of the 
inhibitor-enzyme-interaction parameters are listed in Table 2. The three PPE/Pol4643 
complexes revealed substantial differences at the P1 site (Figure 4). The electron density 
contoured at 1.0σ around P1 showed the inhibitor bound in three different states: (i) an intact 
peptide bond of chain L (Figure 4B), (ii) a partially sp3 hybridized peptide bond of chain M 
(Figure 4C) and (iii) a broken peptide bond of chain N featuring an acyl enzyme intermediate 
state between the active site SerC195 and the backbone of NleN5 (Figure 4D). (A, B and C 
refer to the peptidase chains; L, M and N refer to the corresponding inhibitor chains). A 
comparison of the inhibitor-enzyme-interaction parameters reflected the different states of the 
inhibitor chains: Whereas the closed chains L and M revealed more intermolecular hydrogen 
bonds and a significantly higher shape complementarity than the opened chain N, they 
displayed a lower number of intramolecular hydrogen bonds and a smaller buried interaction 
surface (Table 2). POL4634 acts as a reversible non-covalently binding inhibitor for PPE and 
cathepsin G and represents an enzyme-substrate inhibitory complex, as it was described by 
Luckett et al. for SFTI-1 in complex with trypsin [Luckett, 1999]. In contrast to cathepsin G, 
where POL4634 features an enzyme-substrate inhibitory complex without connecting electron 
density between norleucine in P1 and the active site Ser195, the three NCS related 
PPE/POL4634 copies reveal three different states of the inhibitor cleavage process. 
 
Cathepsin G inhibitor derived from SFTI-1 
 49 
3. Crystal structure of POL4957 in complex with human neutrophil elastase. 
The crystal structure of HNE in complex with POL4957 was determined at 1.75 Å resolution 
and contained one apo-enzyme and two holo-enzymes in the asymmetric unit. Superpositions 
of the structures with and without POL4957 in comparison to HNE (PDB-ID 1HNE) showed 
rmsd values between 0.200 and 0.435 indicating that the structures were almost identical. 
However, the residues Leu143 to Ile151 formed a loop, which assumed slightly different 
conformations in the three molecules of the asymmetric unit. This loop of a symmetry related 
molecule (symm. op. X + 0.5, Y + 0.5, Z + (1 0 0)) is involved in crystal contacts with the 
active site pocket of the apo-enzyme and prevented binding of the inhibitor. The inhibitor 
POL4957 formed a distorted anti-parallel β-sheet that was stabilized by seven intra-molecular 
hydrogen bonds, involving main-chain atoms from residues Nle2I, Thr4I, Pro8I, Gln10I, and 
Tyr12I as well as side chain atoms from Thr4I and Ser6I. Cys3I and Cys11I cross-linked the 
adjacent β-strands with a disulfide bond (Figure 2B). The binding interface of POL4957 and 
the peptidase included a surface area of 613.7 Å2 and 620.1 Å2, a shape complementarity (SC) 
of 0.702 and ten and eight hydrogen bonds for the inhibitor chains I and J, respectively (Table 
2). The inhibitor POL4957 occupied the HNE S4 to S2` binding pockets and interacted with 
the residues Ser214 to Gly218 of HNE in the canonical anti-parallel β-sheet conformation. 
Nle2I (P4) is in van der Waals contact with Leu99B and Phe215 in the non-prime-site pocket. 
Cys3I (P3), Thr4I (P2) and Ser6I (P1`) formed main chain and side chain hydrogen bonds and 
stabilized the central part of POL4957 while Ala5I (P1) pointed into the S1 binding site. The 
long aliphatic side chain of oGly7I (octyl-glycine) (P2`) faces the solvent. However, its 
electron density was too weak to clearly identify interacting residues of the hydrophobic 
prime-site groove. The amide backbone of Ala5I was involved in four hydrogen bonds with 
Ser214 and the amide groups of Gly193, Asp194 and Ser195 that form the oxyanion hole. 
Although the distances of Ser195-Oγ to the Ala5I carbonyl atom were close (2.46 Å and 2.54 
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Å of chains I and J, respectively), the electron density of alanine in P1 suggested a planar, sp2 
hybridized carbonyl atom.  
 
4. Kinetic analysis of the inhibition of POL4634 and POL4957 on cathepsin G, elastases 
and trypsin 
The inhibitory potency of POL4634 and POL4957 was tested against human cathepsin G, 
porcine pancreatic elastase (PPE), human neutrophil elastase (HNE) and bovine trypsin 
(Figures 5A-D and 6A-D). The substrates used for monitoring the activity of cathepsin G, 
PPE and trypsin were Suc-Ala-Ala-Pro-Phe↓AMC, Suc-(OMe)-Ala-Ala-Pro-Val↓AMC and 
Boc-Gln-Ala-Arg↓AMC respectively. Arrows in the substrate acronyms indicate the scissile 
bonds. The amino-methyl-coumarin (AMC) leaving group was detected fluorometrically at 
λex 360/λem 465. Initial inhibition tests with POL4634 and POL4957 showed that the formation 
of product in the presence of inhibitor was linear from the beginning of the reaction. Neither 
POL4634 nor POL4957 inhibited trypsin at a concentration of 16 uM, corresponding to a 
9000 fold inhibitor excess (Figure 5D and 6D). For cathepsin G, HNE and PPE, initial 
velocities at variable substrate and inhibitor concentrations were treated as steady-state rates. 
The best fit model for cathepsin G inhibition by POL4634 with Suc-Ala-Ala-Pro-Phe↓AMC 
at pH 6.5 was linear, competitive tight binding with a Ki = 11nM (Figure 5A). A Ki = 35 nM 
was determined for HNE using POL4957 (Figure 6B). The cross-inhibition of HNE and PPE 
with POL4634 and of cathepsin G with POL4957 was weak (Figures 5B, 5C and 6A). The 
specific velocity plots, typical for linear competitive inhibition, are shown in the inset of 
Figures 5 and 6. PPE inhibited with POL4634, initial velocity data were fitted to equation 3 
(materials and methods). Figure 2C presents POL4634 in complex with cathepsin G and PPE 
and SFTI-1 in complex with trypsin in a superposition. Table 3 summarizes the inhibitory 
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data. The kinetic analysis classifies POL4634 as a compound with excellent inhibitory 
potency for cathepsin G. 
 
5. Cross comparison of inhibitors 
POL4634 inhibited cathepsin G (Ki = 11 nM) and PPE (Ki = 2.2 uM) but not HNE. POL4957, 
inhibited PPE (Ki = 21.4 nM) and HNE (Ki = 35 nM), cathepsin G, however, was only weakly 
inhibited (Ki > 6uM). In order to explain the differences in inhibitory potency between 
POL4634, POL4957 and the peptidases, we modeled POL4634 on the basis of POL4957 and 
assumed that this model inhibitor is able to assume the conformation of POL4957 bound in 
the active site pocket of HNE. Hence, Nle2I was replaced with phenylalanine, Ala5I with 
norleucine, oGly7I with aspartate and Gln11I with isoleucine. Correspondingly, POL4957 
was modeled on the basis of POL4634 into the active-site pockets of cathepsin G and PPE. 
Modeled POL4634 in the active site of HNE suggested sterical clashes of 
phenylalanine (2I) with Arg191 in the non-prime-site pocket and of norleucine (5I) in the 
active-site pocket. Aspartate (7I) and isoleucine (11I) were not in van der Waals contact with 
residues of the active-site pocket. Modeled POL4957 in the active sites of cathepsin G and 
PPE did not indicate any sterical clashes between the exchanged inhibitor residues and the 
active site pockets. Norleucine (2I) and alanine (5I) accommodated well within the 
hydrophobic non-prime-site pockets and the active sites. While aspartate could make water-
mediated salt bridges with Arg41 and Arg143 in the prime-site pocket of cathepsin G, the 
aliphatic octyl chain was expected to be highly unfavorable in this patch of positive charge 
density. However, octyl-glycine could well accommodate within the hydrophobic prime-site 
groove of PPE. The replacement of isoleucine (11I) by glutamine suggested additional 
hydrogen bonds with Gln96 in cathepsin G and van der Waals contacts in PPE. 
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These structural findings are well in agreement with our inhibition studies: Neutrophil 
elastase is not inhibited by POL4634 due to expected sterical clashes of norleucine in the 
active site pocket and phenylalanine (P4) in the non-prime-site pocket. Cathepsin G is only 
weakly inhibited by POL4957 because of highly unfavorable interactions of the octyl-side 
chain with the positively charged S2` binding site. PPE is inhibited by POL4634 and 
POL4957. Both inhibitors do not clash within the active site of PPE. The loss of hydrophobic 
interactions in the S1 binding site due to the exchange of norleucine by alanine may be 
supercompensated by the gain of hydrophobic interactions through the aspartate-octyl-glycine 
exchange in P2` resulting in 100 fold lower Ki of POL4957. 
 
6. Binding modes of POL4634 and POL4957 
The superposition of cathepsin G and PPE revealed the structural features that accounted for 
the different shapes of the active sites. (i) The non-prime-site loop of PPE contained a serine 
residue (Ser217), which displaced arginine (Arg217A) from where the corresponding lysine 
residue in cathepsin G (Lys217) was located; (ii) the prime-site loop, comprising residues 32 
to 42, was perpendicularly oriented relative to the active site cleft of cathepsin G, giving the 
groove a curved, narrow and deep appearance. In PPE however, this loop pointed away from 
the active site cleft and was almost parallel oriented relative to the active site cleft, which gave 
the groove a more elongated, wider and shallower appearance (Figure 7A). Consequently, 
POL4634 bound in an extended conformation in PPE and in a curved conformation (Figure 
7B) in the active site cleft of cathepsin G without significant differences in the interface 
interaction parameters. 
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Discussion 
The high resolution structure of POL4634 in complex with cathepsin G and kinetic inhibitory 
data illustrate the successful redesign from a potent trypsin to a potent cathepsin G inhibitor. 
This was mainly achieved by the substitution of lysine to norleucine in P1, which prevents the 
formation of a salt bridge in the active site pocket and the substitution of arginine to 
phenylalanine in P4, which better accounts for the hydrophobic S4 site. These major 
mutations completely abolish trypsin inhibition and result in a potent cathepsin G inhibitor (Ki 
= 11 nM). The replacement of the β-turn forming Pro13-Asp14-Gly1 with the DPro-LPro motif 
does not affect the trypsin inhibition. This is a surprising finding, since Descours et al. showed 
that the DPro-LPro SFTI-1 variant displayed even stronger inhibitory potency towards trypsin 
[Descours, 2002]. 
The inhibitory potency of POL4634 against cathepsin G and PPE and POL4957 
against HNE agrees very well with previously reported inhibition studies of SFTI-1 
derivatives. The P1 lysine has been shown to be highly important as a selectivity determining 
feature for trypsin inhibition. Its exchange to alanine in SFTI-1 variants significantly 
decreased the affinity from 3x10-11 M to 1.9x10-7 M [Daly, 2006], or in shorter inhibitor 
variants from 1.03x10-7 M to >1x10-5 M [Descours, 2002]. The exchange of lysine to 
phenylalanine of another SFTI-1 variant was shown to decrease the affinity towards cathepsin 
G [Legowska, 2010]. In addition to lysine in P1, arginine in P4 of SFTI-1 explores a 
hydrophobic area of the active site clefts of PPE, cathepsin G and trypsin. Hence, the 
replacement of the P4 arginine by valine increased the inhibitory potency towards PPE from 
3.5x10-5 M to 3x10-7 M [Hilpert, 2005], and the replacement by alanine decreased the 
inhibitory potency towards trypsin from 3x10-11 M to 4x10-10 M [Daly, 2006]. Taking these 
data into account, we concluded that the combination of norleucine in P1 and phenylalanine in 
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P4 of the SFTI-1 variant POL4634 is mainly responsible to ensure potent cathepsin G 
inhibition and to abolish trypsin inhibition.  
The kinetic data showed that POL4634 is an inhibitor for PPE in the high nanomolar 
range. However, the structural comparison of the binding interfaces of PPE and cathepsin G 
does not explain the difference of almost two orders of magnitude in affinity. Intra-molecular 
hydrogen bond patterns, sizes of the buried surface areas and shape complementarities are 
similar (Table 2) and the overall curved shapes of the active sites enables POL4634 to form an 
extended inter-molecular hydrogen bonding pattern in the canonical anti-parallel β-sheet 
conformation in both peptidases. To fit into the active site of PPE, however, POL4634 must 
adopt a more straight conformation. The prime site and more pronounced the non-prime site 
flanking loops (residues 32 to 42 and 216 to 218, respectively) narrow and apparently 
straighten the groove which makes it impossible for POL4634 to bind in a similarly curved 
manner as in cathepsin G (Figure 7A). Therefore, we propose that the difference in affinity 
must originate from a conformational restraint imposed by the peptidase. The bent 
conformation of POL4634 bound to cathepsin G as well as the similarly bound POL4957 
inhibitor in the active site of HNE supposedly represent the energetically most favorable 
conformation of these inhibitors while an elongated conformation in the case of PPE suggests 
an energetically less favorable conformation, loss in entropy and thereby a decreased 
inhibitory potency. This hypothesis is supported by the crystal structure of SFTI-1 in complex 
with trypsin [Luckett, 1999] and the NMR structure of SFTI-1 (PDB ID: 1JBN). The solution 
structure and the complex structure show the same inhibitor conformation, which suggests 
that SFTI-1 is bound to trypsin in its energetically most favorable conformation. 
Superimposing SFTI-1 onto POL4634 reveals a similarly bent conformation of POL4634 in 
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complex with cathepsin G and therefore suggests a favorable conformation (along with high 
inhibitory potency) in the complex structure. 
A number of naturally occurring or engineered elastase (PPE and HNE) specific 
inhibitors are known to date (SLPI, elafin, MCoTI-II or greglin from Schistocerca gregaria) 
[Zani, 2009], [Thongyoo, 2009], [Brillard-Bourdet, 2006]. The structures of OMTKY3 and 
1/2SLPI in complex with HNE (PDB-ID: 1PPF and 2Z7F, respectively), elafin in complex 
with PPE (PDB-ID: 1FLE) all show a scaffold protein with a disulfide bridge stabilized large 
binding loop. Apparently, no conformationally constrained β-turns flank the inhibitor peptide 
stretch that interacts with the enzymes. This feature allows for flexibility and adaptability 
while little conformational strain is imposed by the enzymes` active site on the inhibitor upon 
binding.  
POL4634 in the cleaved form in contrast to the non-cleaved form suggests a poorer fit 
in the active site groove of PPE. Although the interaction area is larger, it displays only a few 
intermolecular hydrogen bonds, and a lower shape complementarity value compared to the 
non-cleaved form. Thus, the cleavage event by PPE shifts the enzyme-inhibitor complex from 
a high-energy “closed” state, representing a tight binding mode, to a low-energy “open” state 
(cleaved peptide bond, representing a loose binding mode. We speculate that this 
conformational relaxation of POL4634 promotes the dissociation from the peptidase. 
Although no signs of inhibitor cleavage were observed, we cannot exclude that POL4634 is 
not cleaved by cathepsin G over a long period of time. 
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Summary 
In summary, we conclude that the inhibitor potency does not exclusively depend on extensive 
inter-molecular hydrogen bonding networks, interaction areas and shape complementarities 
but, as a superior criterion, on a conformational strain on the inhibitor imposed by the 
peptidase. The structural study of the redesigned SFTI-1-based inhibitor POL4634 in complex 
with cathepsin G and PPE in combination with inhibitory data clearly illustrates that the 
lowest energy conformation of the free inhibitor is an important determinant for inhibitor 
potency. The future redesign of SFTI-1-based inhibitors must consider the conformational 
states by providing more flexibility to the frameworks which better allow adapting to the 
given spatial arrangement of the active sites of elastases and other enzymes. 
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TABLES 
Table 1: Data and refinement statistics 
Data PPE Cathepsin G 
space group P321 (145) P212121 (19) 
cell parameters a = b = 95.1; c = 70.1 
α = β = 90; γ = 120 
a = 39.8; b = 127.0; c = 
43.5 
α = β = γ = 90° 
resolution 19.75 – 1.8 43.5 – 1.8 
obs. Reflections 65110 20946 
completeness (%) 99.1 (98.8)a 98.4 (83.9)a 
redundancy 5.64 6.68 
Rsym (% on I) 8.3 (43.5)a 10.6 (34.3)a 
I/σI 14.89 (4.55)a 13.03 (4.64)a 
Refinement   
molecules / AU 3 1 
R / Rfree (%) 15.5 / 19.5 17.8 / 21.8 
waters 645 201 
bond length (Å) 0.017 0.010 
bond angles (°) 1.827 1.242 
residues in most favoured regions 651 (88.0%) 220 (97.8%) 
generally allowed regions 82 (11.1%) 5 (2.2%) 
disallowed regions 7 (0.9%) 0 
twinning fraction 0.47  
twin law h,-h-k,-l  
a: refers to resolution shell 1.8 – 1.9 Å 
Data for HNE to be appended 
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Table 2: Summary: interactions of inhibitors and peptidases 
 HB 
Intermol. 
HB 
Intramol. 
SC BSA (Å2) 
CatG 11 6 0.677 668.6 
PPE (A/L) 9 3 0.748 735.6 
PPE (B/M) 13 5 0.752 728.9 
PPE (C/N) 6 9 0.681 793.1 
HNE (I) 10 7 0.702 613.7 
HNE (J) 8 7 0.702 620.1 
Trypsin (SFTI-1) 11 8 0.731 690.1 
SC: shape complementarity; BSA: buried surface area 
 
 
Table 3: Summary of inhibitory data for cathepsin G, neutrophil elastase, pancreatic 
elastase and trypsin 
 POL4634 POL4957 
Cathepsin G Ki = 11 nM ±0.6 Ki > 6000 nM 
Neutrophil elastase Weak inhibition Ki = 35 nM ±5 
Pancreatic elastase Ki = 2190 nM ±67 Ki = 21 nM ±1.5 
Trypsin No inhibition detected No inhibition detected 
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Figures and Figure captions 
Figure 1) 
 
 
 
Primary sequences with superscript numbering of the sunflower trypsin inhibitor SFTI-1, 
POL4634 and POL4957. Thin lines denote cysteine bridges, strong lines denote a covalent 
link between the first and last amino acid. Positions around the P1 active site pocket residue 
are indicated. 
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Figure 2A 
 
Figure 2B) 
 
Figure 2C) 
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Figure 2) 
A) POL4634 in light blue shown as sticks in complex with cathepsin G (dark blue) shown as 
ribbon representation. Hydrogen bonds are indicated with dashed lines. Phe2, Nle5 and Asp7 
point into the S4, S1 and S2` pockets, respectively, indicated with solid lines. Residues of 
POL4634 are labelled in italics. 
B) POL4957 in light green shown as sticks in complex with human neutrophil elastase (dark 
green) shown as ribbon representation. Hydrophobic residues of HNE within the active site 
groove are shown as sticks. 
C) Superposition of POL4634 in complex with cathepsin G and PPE and SFTI-1 in complex 
with trypsin. Cathepsin G, PPE and trypsin are shown in cartoon representation in dark blue, 
orange and magenta, respectively. The inhibitor chains are represented as lines with their 
backbone atoms coloured in light blue, yellow and magenta, respectively. The catalytic triad 
of trypsin (Asp57, His102 and Ser195) is shown as sticks. 
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Figure 3) 
 
S1 pocket of cathepsin G with superimposed inhibitors. POL4634 is depicted in light blue, 
Suc-Val-Pro-LysP-(OPH)2 in green (PDB-ID: 1AU8) and JNJ-10311795 in grey (PDB-ID: 
1T32). The green water molecules Wat134 – Wat136 belong to PDB-ID 1AU8 and make 
hydrogen bonds to the ε-amino group of the phosphonate-lysine of Suc-Val-Pro-LysP-(OPH)2-
inhibitor and Glu226. Glu226 can adopt different conformations in combination with a salt 
bridge forming (lysine) or hydrophobic (norleucine) P1 residue. 
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Figure 4) 
 
Close-up view into the scissile Nle5-Ser6 peptide bond of POL4634 bound to cathepsin G and 
PPE. A, B) The peptide bonds of POL4634 in complex with cathepsin G (A) and PPE (B) are 
intact, no sign of sp3-hybridization. C) Connecting density between NleM5-C and Ser195-Oγ 
of POL4634 in complex with second PPE molecule suggests partial sp3-hybridization. D) 
Acyl-enzyme intermediate between open POL4634 and the active site serine. Hydrogen bonds 
are indicated; all figures show electron density contoured at 1.0σ. 
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Figure 5) 
 
Preliminary inhibitory data 
Inhibition profile of POL4634 for cathepsin G, neutrophil elastase, pancreatic elastase and 
trypsin. Data were obtained fluorometrically with λex/λem = 360/465 nm. Best-fit kinetic 
parameters are shown. A) cathepsin G (227 nM) and the substrate Suc-Ala-Ala-Pro-
Phe↓AMC at pH 6.5; [S] = 715 uM, Km = 667 uM. B) Neutrophil elastase (11 nM) and the 
substrate Suc-(OMe)-Ala-Ala-Pro-Val↓AMC at pH 7.5; [S] = 715 uM, Km = 820 uM. C) 
Pancreatic elastase (195 nM) and the substrate Suc-(OMe)-Ala-Ala-Pro-Val↓AMC, at pH 7.5; 
[S] = 996 uM, Km = 231 uM. D) Trypsin (1.75 nM) and the substrate Boc-Gln-Ala-
Arg↓AMC, at pH 7.5; [S] = 140 uM, Km = 10 uM. The inset shows the specific velocity plot 
at five substrate and five inhibitor concentrations. 
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Figure 6) 
 
Preliminary inhibitory data 
Inhibition profile of POL4957 for cathepsin G, neutrophil elastase, pancreatic elastase and 
trypsin. Data were obtained fluorometrically with λex/λem = 360/465 nm. Best-fit kinetic 
parameters are shown. A) cathepsin G (227 nM) and the substrate Suc-Ala-Ala-Pro-
Phe↓AMC at pH 6.5; [S] = 715 uM, Km = 667 uM. B) Neutrophil elastase (11 nM) and the 
substrate Suc-(OMe)-Ala-Ala-Pro-Val↓AMC at pH 7.5; [S] = 715 uM, Km = 820 uM. C) 
Pancreatic elastase (195 nM) and the substrate Suc-(OMe)-Ala-Ala-Pro-Val↓AMC, at pH 7.5; 
[S] = 996 uM, Km = 231 uM. D) Trypsin (1.75 nM) and the substrate Boc-Gln-Ala-
Arg↓AMC, at pH 7.5; [S] = 140 uM, Km = 10 uM. The inset shows the specific velocity plot 
at five substrate and five inhibitor concentrations. 
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Figure 7A) 
 
Figure 7B) 
 
Figure 7) 
Cathepsin G inhibitor derived from SFTI-1 
 67 
A) Superposition of the active sites of cathepsin G and PPE with POL4634. The active site 
groove of cathepsin G is shown as cartoon in dark blue covered with a surface mesh. PPE is 
shown as cartoon coloured in raspberry. The prime-site loop of cathepsin G, shown in red, is 
perpendicularly oriented relative to the prime-site loop of PPE and the active site groove. 
Arg217A in the non prime-site loop of PPE is shown as sticks in red. POL4634 is shown as 
ribbon in light blue and yellow, respectively. 
B) Schematic drawing of the POL4634 inhibitor in the active sites of cathepsin G and PPE, 
respectively. 
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Materials and methods 
Inhibitors 
The inhibitor POL4634 was provided by Polyphor, Allschwil Switzerland. 
Substrates 
All substrates were purchased from Peptanova, Sandhausen, Germany.  
Enzymes 
Human neutrophil cathepsin G was purchased from Lee Biosolutions, INC. St. Louis, USA. 
Porcine pancreatic elastase was purchased from Worthington Biochemical Corporation, 
Lakewood, USA. Bovine trypsin was purchased from Roche, Switzerland. 
Enzyme Solutions 
Human cathepsin G, porcine pancreatic elastase and bovine trypsin were dissolved in 50mM 
sodium acetate, pH 5.5 containing 150mM NaCl to a final concentration of 4 mg per ml. 
Small aliquots of this stock solution were stored at -80°C until used. 
For cathepsin G, 10µl of stock solution were diluted in 2000µl AHNP-buffer (150mM sodium 
acetate, pH 6.5, 150mM HEPES, 300mM NaCl, 0.001% Pluronic). For porcine pancreatic 
elastase and bovine trypsin 10µl stock of solution were diluted in 2000µl assay buffer (50mM 
Tris-HCl, pH 7.5, 100mM NaCl, 0.01% Triton). 
 
General Assay Conditions 
The kinetic mechanism of the inhibition by POL4634 was studied using the substrates Suc-
Ala-Ala-Pro-Phe↓AMC, Suc-(OMe) Ala-Ala-Pro-Val↓AMC and Boc-Gln-Ala-Arg↓AMC (all 
Peptanova, Sandhausen, Germany) for human cathepsin G, porcine pancreatic elastase and 
bovine trypsin respectively. All kinetic experiments were carried out in black 96-well Greiner 
CellStar plates in a total reaction volume of 100 µl and substrate hydrolysis was followed 
flurometrically at λex /λem = 360/465 nm using a Tecan Genious™ plate reader. 
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Determination of Km 
In parallel to each inhibition assay, the Michaelis constant (Km) was determined under the 
assay conditions. The linear increase of the fluorescence was monitored at 12 different 
substrate concentrations (0 – 1600 µM). The Michaelis-Menten equation (Equation 1) was 
fitted to the steady-state (ν) rates to calculate Km by nonlinear regression.  
[ ]
[ ]m
V S
K S
ν =
+
  Equation 1 
Active Site Titration of Porcine Elastase 
The concentration of the active sites in the PPE samples were determined flurometrically by 
titration with the irreversible inhibitor Suc-(OMe)-Ala-Ala-Pro-Val-CH2Cl. After incubation 
of 30 min at room temperature the reaction was assayed. The residual activity was plotted 
against the amount of Suc-(OMe)-Ala-Ala-Pro-Val-CH2Cl and the concentration of PPE was 
determined by means of a linear fit of the data points. The procedure was repeated twice to 
confirm its reproducibility. 
 
Inhibition Assay 
Inhibitor and substrate solutions were premixed to a volume of 50 µl and the reaction was 
started with 50 µl enzyme solutions to a total reaction volume of 100 µl. DMSO concentration 
in the assay was kept constant throughout one entire measurement. 
 
Data Analysis and Assignment of the Inhibition Mechanism 
The kinetic mechanism of pancreatic Elastase was investigated in two steps using Suc-(OMe)-
Ala-Ala-Pro-Val↓AMC at pH 7.5. In a first step the inhibition type was diagnosed using a 
combination of five substrate concentrations (0.25 to 5 times Km), and five inhibitor 
concentrations in the range 0.1 to 6.7 µM. Analysis of initial velocity data for the 25 
combinations of substrate and inhibitor concentrations was performed with the specific 
velocity plot, a graphical method suitable for diagnosing linear and hyperbolic inhibition 
mechanisms (Baici, 1981). This method is based on the general modifier mechanism shown in 
Scheme 1. Here, E represents the free enzyme, S the substrate, I the inhibitor, and P 
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collectively the products of the reaction. Other symbols are as follows: Ki = [E][I]/[EI], the 
competitive inhibition constant, αKi = [ES][I]/[ESI], the uncompetitive inhibition constant, Ks 
= [E][S]/[ES], the substrate dissociation constant; αKs = [EI][S]/[ESI]; kcat, the catalytic 
constant. The dimensionless coefficients α and β characterize the proportion of competitive 
and uncompetitive character in the inhibition mechanism (Scheme 1) 
 Scheme 1 
The specific velocity equation is as follows: 
o
1 1 [ ][ ] 1
[ ] [ ]11 1
i i i
i
i i
II
K Kv K
I Iv
K K
α σ
σβ β
α α
 
− + 
 
= +
++ +
  Equation 2 
 
where ν0 and νi are the initial velocities in the absence and in the presence of inhibitor, 
respectively, σ = [S]/Km, and other symbols as described above. From the specific velocity 
plot and its secondary plots, sufficiently precise values of α and β could be calculated. In a 
second step, an accurate value of Ki was obtained by fitting equation 2 (Szedlacsek et al., 
1988) to initial velocity data measured at fixed enzyme and substrate concentrations and 
several POL4634 concentrations (Figures 5 and 6) by nonlinear regression using GraphPad 
Prism version 5 for Windows, GraphPad Software, San Diego, California USA 
(www.graphpad.com). The variables ν0 and νi are the initial velocities in the absence and in 
the presence of inhibitor, respectively, [E]t is the total enzyme concentration, [I]t is the total 
inhibitor concentration, σ = [S]/Km and α and β are explained above. 
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For cathepsin G initial velocity data were directly fitted to equation 2, with α = ∞ and β = 0 
for linear competitive inhibition. 
 
Crystallisation 
PPE was purchased from Worthington Elastase (New Jersey, USA) and cathepsin G from 
Elastin Products (Missouri, USA) and crystallized without further purification. PPE was 
dissolved in 10 mM sodium acetate, pH 5.0, and cathepsin G was dissolved in 50 mM 
ammonium sulphate, 50 mM Tris, pH 8.0 at final concentrations of 0.8 mM. The proteases 
were incubated with two-fold molar excess of POL4634 (dissolved in 4 % DMF/water). Due 
to the limited water solubility of POL4634 the protease/inhibitor mixtures were turbid at the 
beginning of the incubation period, but turned clear after one to two hours incubation at room 
temperature. Crystals were obtained using the vapor diffusion method with 96-well sitting 
drop plates (Greiner bio-one, Germany) containing mixtures of 100 nl protein solution and 
100 µl reservoir solution. Crystals of PPE/POL4634 complexes were obtained within 2 weeks 
at 17 % PEG 8000, 20 mM TAPS, pH 9.0. The cathepsin G/POL4634 complex was 
crystallized at 25 % PEG 8000, 150 mM ammonium sulphate, 50 mM Tris, pH 8.5. The 
crystals were flash frozen in liquid propane in the mother liquor supplemented with 20 % 
glycerol as a cryo-protectant. 
 
Structure solution and refinement 
The X-ray data was collected at 100 K at the Swiss synchrotron light source (Villigen, 
Switzerland) at a wavelength of 1.0 Å. Data were processed with the program XDS [Kabsch, 
1993]. Initial phases were obtained by molecular replacement using the program PHASER 
[McCoy, 2007] using known PPE (PDB-ID: 3EST) and cathepsin G (PDB-ID: 1T32) 
structures as search templates. The three-dimensional structures were refined using 
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REFMAC5 [CCP4] and SHELXL [Sheldrick, 1997], and the model building was performed 
using the program COOT [Emsley, 2004]. Restraints for the non-natural amino acids DPro and 
NLE were generated using the PRODRG server [Schuettelkopf, 2004]. All figures were made 
using Pymol [DeLano, 2002]. 
 
Structure analysis 
The shape complementarity (SC) was calculated using SC [CCP4]. In order to calculate the 
SC, D-proline was renamed into PRO, octyl-glycine and norleucine were modified into 
leucines and all double conformations were eliminated. Hydrogen bonds were analyzed with 
HBPLUS [McDonald, 1993] and the interface was calculated using the PISA server v1.18 
[Krissinel, 2007]. 
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INTRODUCTION 
 
 
The superfamily of N-terminal nucleophile aminohydrolases1 is divided into seven families 
according to the structural classification of proteins database (SCOP): the class II 
glutamine amino-transferases, the penicillin acylase, the penicillin V acylase, the 
proteasome subunits, the (glycosyl)-asparaginase, the γ-glutamyl trans-peptidase-like 
and the SPO2555-like families. The enzymes all share a common αββα-sandwich-core 
fold, but have their unique substrate preferences. The enzymes either posses an amino-
terminal serine, threonine or cysteine residue that act as primary nucleophile. 
 The heterooctameric structure of DmpA2 from Ochrobactrum anthropi has been 
solved by Bompard-Gilles et al. [1]. Each of the four αβ-subunits forms the αββα-
sandwich fold and exposes an active site serine residue, which is situated at the amino-
terminus of the β-subunit. The enzyme undergoes self-processing. The SCOP database 
currently classifies DmpA in its own superfamily named DmpA/ArgJ-like DmpA-like refers 
to the family name and DmpA/ArgJ to the name of its fold. 
 
BapA3 from Sphingosinicella xenopeptidilytica 3-2W4 shares 42.2% sequence identity 
with DmpA. Both enzymes are structurally and functionally very similar. Originally, BapA 
was discovered by growing a heterogeneous mixture of microbial cultures taken from a 
waste water treatment plant in β-dipeptide and β-tripeptide supplemented minimal 
media. After several enrichment cycles, the bacterial strain 3-2W4 was isolated and later 
characterized by DNA sequencing as “Sphingomonas” strain. At this stage, the newly 
discovered enzyme was not characterized, but it could be tracked and isolated without 
difficulty by measuring its cleavage activity of p-nitroanilide coupled beta-amino acids 
during multi-step purification procedures. Its presence was detected by measuring the 
absorbance of free p-nitroanilide at 405 nm. Finally, enriched protein fractions were 
digested and sequenced. A database search with the N-terminal sequence fragment 
revealed a so far unknown enzyme, subsequently named BapA, according to its β-amino-
peptidase activity. Native BapA, similarly to DmpA, undergoes self-proteolytic cleavage 
and exposes an amino-terminal active site serine residue, which is situated at the amino-
terminus of the β-subunit. Two subunits each form a compact αββα-sandwich fold that is 
characteristic for Ntn hydrolases [2]. 
Both hydrolases, BapA and DmpA, exhibit rather unusual peptidase, esterase and 
amidase specificities. BapA was first characterized by Geueke et al. in 2005. The authors 
show the unusual substrate specificity of BapA for substrates with β-amino acids at the 
amino-terminus with highest preference for aliphatic and aromatic residues [2], [3]. 
Interestingly, peptide substrates with N-terminal α-amino acids are not cleaved. DmpA, 
however, also accepts beta-amino-acid substrates, but the N-terminal residue is limited 
to either a beta-glycine or beta-alanine. Furthermore, DmpA accepts substrates with N-
terminal alpha-amino acids with both D- and L-configuration [1]. 
                                                 
1
 N(amino) terminal n(amino) hydrolase; Ntn 
2
 L-aminopeptidase-D-amidase/D-esterase; DmpA 
3
 Beta-peptidyl aminopeptidase (hydrolase); BapA 
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Table 1_3) annotated protein database (PDB) files of Ntn hydrolases 
 PDB 
ID 
Protein and redundant PDB entry Active 
form 
Pro-
form 
spacer SCOP 
1 1B65 L-aminopeptidase DmpA (αβ)4 (α)4 no X 
2 2PVA penicillin V acylase 2Z71, 2QUY, 
1GM7, 2OQC (B. subtilis), 3PVA (B. 
sphaericus) 
(α)4 nd. no 3 
3 2BJF 
2BJG 
bile acid hydrolase with taurine and 
deoxycholate 
(α)4 nd. no 0 
4 2GL9 Glycosylasparaginase (αβ)2 nd. nd. 0 
5 1E3A 
1GK9 
penicillin G acylase (PA) (E. coli) PA 
with substrate 1FXH, 1FXV, 1JX9, 
1K5Q 
(αβ) (α) yes 2 
6 1OQZ glutaryl-7-aminocephalosporanic acid 
acylase1GK0, 1OR0 
(αβ)2 (α) yes 2 
7 2NQ0 γ-glutamyltranspeptidase (Helico-
bacter pylori) 2QM6, 2QMC (2QM6 
with glutamate) 
(αβ) (α) no 6 
8 2V4I glutamate N-acetyl transferase 2 
2VZK 
nd. nd. nd. 0 
9 1KUU MTH1020 from Methanobacterium 
thermoautotrophicum 
nd. nd. nd. 0 
10 2NTK PurO (Methanothermobacter Ther-
moautotrophicus) 
α nd. no 0 
11 1GK0 glutarylamidase (Pseudomonas sp.) 
glutarylamidase (Pseudomonas 
diminuta) 
(αβ)2 
(αβ) 
(α)2 
(α) 
Yes 
yes 
2 
12 1JN9 putative asparaginase, ybik gene (E. 
coli) 1KZX (2ZAL with aspartate) 
(αβ) nd. no 5 
13 2E0W γ-glutamyltranspeptidase (E. coli) (αβ) (α) no 6 
14 1G0U proteasome component of 20S 1G65, 
2GPI, 2GPL 
   4 
15 2ZAK isoaspartyl peptidase / L-
asparaginase Ec AIII (3C17) 
(αβ) (α) no 0 
16 2GEZ plant asparaginase (αβ) (α) no 0 
17 1APY 
1APZ 
human aspartylglucosaminidase + 
reaction product 
(αβ)2 (α) / 
(α)2 
no 5 
nd: not determined or indicated in literature; SCOP classification: 1: Class II glutamate 
amidotransferase; 2: Penicillin acylase, catalytic domain; 3: Penicillin V acylase; 4: 
Proteasome subunits; 5: (Glycosyl) asparaginase; 6: Gamma glutamyltranspeptidase-
like; 7: SPO2555-like; 0: not annotated in SCOP data-base; X: no Ntn hydrolase 
according to SCOP. 
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1. Ntn hydrolases 
17 different proteins (Table 1_3, 49 proteins in total) of the class of Ntn hydrolases are 
currently annotated in the protein databank. 
 
The first notion of Ntn hydrolases dates back to the year 1995, when the crystal 
structures of glutamine PRPP amidotransferase, penicillin acylase and the proteasome 
component 20S were determined [4], [5], [6]. Those enzymes share the same fold and 
use the side chain of an amino-terminal residue of a β-sheet as a nucleophile for their 
catalytic activity. At that time, Brannigan et al. were the first to suggest the name Ntn 
(N-terminal nucleophile) hydrolase and the classification of the aforementioned proteins 
into this superfamily [7]. 
 
 
1.1 The Ntn fold 
The core of the Ntn hydrolase consensus fold comprises two layers of five antiparallel β-
sheets that are flanked by two α-helices (schematically illustrated in Figure 1_3). The 
overall fold is known as αββα-sandwich. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1_3) 
Consensus fold of Ntn hydrolases: triangles represent β-sheets, circles represent α-
helices. The αββα-sandwich fold comprises two layers of five anti-parallel β-sheets that 
are flanked by two α-helices. The numbered secondary structure elements occur in the 
same position and sequence in penicillin acylase, glutamine 5-phosphoribosyl-1-
pyrophosphate amido-transferase, glycosyl asparaginase and proteasome subunits. The 
β-sheets A, B and C and the helix αA are structurally conserved but not always in the 
same sequence order. The figure is adapted and modified from Bompard-Gilles et al, 
2000 [1]. 
 
It is important to note that the connectivity and the number of additional secondary 
structure elements differ from protein to protein. Penicillin G acylase for example 
comprises additional α-helices and β-sheets and its Ntn fold consists only of a single 
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chain (β-chain), in contrast to DmpA, which is composed of two chains (α- and β-chain) 
upon self-processing. Thus, the consensus fold depicted in Figure 1_3 is a simplified view 
and not necessarily correct in particular cases. However, it facilitates protein family 
classifications displaying this consensus fold. 
 
 
1.2 Multimeric states of Ntn hydrolases 
Ntn hydrolases exist in diverse multimeric states. The inactive monomeric, dimeric or 
tetrameric single precursor polypeptide chains are autoproteolytically processed into (αβ) 
heterodimers, tetramers or octamers, respectively. Studies of Ntn hydrolases on the 
assembly formation in the context of the self-processing have not been reported so far, 
hence, it is not known whether the dimeric or tetrameric inactive quaternary structures of 
the precursor must form prior to the autoproteolytic cleavage of every subunit, or 
whether monomeric species undergo the autoproteolytic cleavage prior to the quaternary 
assembly formation. Some members of the Ntn superfamily, however, are active as 
single polypeptide chains (see Table 1_3). The only known reported exception is glutaryl-
7-aminocephalosporin acylase, which is monomeric in its pro-form and dimerizes into a 
(αβ)2 heterotetramer upon activation [8]. Penicillin V acylase and bile acid hydrolase are 
homotetramers [9], [10]. They are active upon leader peptide cleavage and do not 
require further self-processing reactions. Thus, the precursor processing for these two 
enzymes already results in active Ntn hydrolases (Table 1_3). 
 
 
1.3 Pro-form activation 
The superfamily of Ntn hydrolases is highly heterogeneous with respect to polypeptide 
processing and oligomerization. Typically, Ntn hydrolases are synthesized as pre-pro-
polypeptide chains including an N-terminal periplasmic pre-leader sequence. Penicillin 
acylase from E. coli is the only known example that requires the pre-sequence for 
enhanced and correct folding [8]. Other Ntn hydrolases are expressed as pro-polypeptide 
precursors which undergo a single autoproteolytic cleavage reaction. It is not known, 
whether the maturation process into subunits of heterodimers is a consequence of the 
formation of multimeric states before self-processing or whether the assembly formation 
is a prerequisite for the self-processing. However, cephalosporin acylase and glutaryl-7-
aminocephalosporanic acid acylase are further processed by a second intermolecular 
cleavage reaction releasing a short internal spacer sequence [8], [11], [12]. 
 
Recently, Michalska et al. published a general mechanism for the pro-form activation on 
the structural basis of a plant-type L-asparaginase [13]. It has been proposed that the 
first common step of the auto-proteolytic cleavage is an NO (serine or threonine) or 
NS (cysteine) acyl shift through the formation of an oxyoxazolidine or oxythiazolidine 
intermediate. Hereby, the “acyl-group” represented by the C-terminal end (peptide bond) 
is transferred from the “N-terminus” onto the oxygen or sulphur atom of the side chain, 
temporarily featuring an ester or thioester bond. Correspondingly, the first half-reaction 
is called acyl shift. This rearrangement is achieved via the deprotonation of the active site 
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residue by a not further specified “general base” that can either be a hydrogen bonded 
water molecule or a basic residue. The deprotonated active site residue then attacks the 
carbonyl carbon of the peptide bond N-terminal of the active site residue. The 
oxyoxazolidine or oxythiazolidine transition state is stabilized by the oxyanion hole 
formed by Asn67 and a water molecule. Structural rearrangements lead to the formation 
of the (thio)-ester acyl enzyme intermediate. Then, the ester bond is hydrolyzed and the 
carboxy-terminal end is released. This pathway is illustrated in Figure 2_3. A number of 
distorted high-energy trans-peptide bonds in aspartylglucosaminidase, glutaryl-7-
aminocephalosporanic acid acylase and cephalosporin acylase have been reported that 
are made responsible for the efficient displacement of the carboxy-terminal tail of the α-
subunit form the active site cleft [8], [12], [14]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2_3) 
Proposed autoproteolysis mechanism of an L-asparaginase. The oxyoxazolidine 
intermediate state is formed by the active site serine or threonine residue; cysteine 
forms the oxythiazolidine intermediate state. The nucleophilic “X” denoted in green either 
represents sulphur (cysteine) or oxygen (serine / threonine), “B” denoted in blue is the 
general base; R = H (Ser), R = CH3 (Thr). The figure is adapted and modified from [13]. 
 
 
1.4 Catalytic mechanism 
In contrast to the autoproteolytic pro-form activation, a consensus mechanism for the 
catalytic activity of mature Ntn hydrolases has not been proposed in the literature so far. 
This might be due to the different nature and chemistry of the substrates and the number 
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of available structures with a substrate, substrate analogue or inhibitor bound. Currently, 
five such complex structures can be retrieved from the protein database (bile acid 
hydrolase, penicillin G acylase, γ-glutamyltranspeptidase, putative asparaginase and 
human aspartylglucosaminidase) (see Table 1_3) and all these Ntn hydrolases exhibit 
different functions, making it difficult to propose a general mechanism. 
 
 
1.5 Beta-aminohydrolase A 
BapA features two interesting properties. Firstly, it binds penicillin based antibiotics, in 
particular ampicillin and β-lactamase hydrolyzed ampicillin, and secondly, BapA exhibits 
reversible beta-peptidyl aminohydrolase activity. Thus, BapA is also able to perform β-
peptide synthesis [22]. Since its discovery, BapA has been thoroughly characterized with 
respect to its substrate specificities [3] and it has been investigated for industrial 
synthesis of short beta-peptides. Currently, the most interesting synthesis compound 
candidate is L-carnosine (β-Gly-α-His-dipeptide) (Figure 3_3). L-carnosine has a positive 
effect on the repair of injured intestinal epithelial cells [15], a down-regulating effect on 
the release of pro-inflammatory cytokines [16] and anti-ageing effects [17]. Therefore, 
circumventing chemical syntheses which require organic solvents and heavy metal 
catalysts would be highly desired to be able to supply the cosmetics market for L-
carnosine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3_3) 
Schematic representation of alpha- and beta-amino acid polypeptides. Side chains are 
denoted with R1, R2 and R3. The wavy line indicates the putative BapA peptide cleavage 
site. 
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2. Rationale and aim of the project 
The aim of the project is to solve the crystal structures of BapA, its non-cleaved pro-form 
and additionally various mutants to elucidate the essential residues for the self-
processing, the substrate cleavage as well as the residues that determine the β-amino 
acid substrate specificity. 
 
This project was carried out in collaboration with the EAWAG, Dübendorf, Switzerland 
(group of Dr. H-P. Kohler) and the ETH, Zürich, Switzerland (group of Prof. Dr. D. 
Seebach). 
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MATERIALS AND METHODS 
 
 
Protein production and purification 
The production and purification of BapA from Sphingosinicella xenopeptidilytica is 
described in detail in [3], [18]. The functional characterization of beta-peptides is 
described in [18] and [22]. 
 
 
Crystallization of proBapA 
The active site serine (S250) was mutated to alanine to prevent autoproteolytic 
activation. This form will subsequently be named proBapA, implying the S250A mutant. 
ProBapA was crystallized in 24-well sitting drop plates (HR3-160 Cryschem, Aliso Viejo, 
CA, USA) using the vapour diffusion method at a protein concentration of 13.5 mg/ml in 
2 µl drops (1 µl protein, 1 µl reservoir) in 1.0 – 1.2 M ammonium sulphate buffered at pH 
7.0 to 7.5 (0.1 M HEPES (2-[4-(2-hydroxyethyl)piperazin-1yl]ethanesulfonic acid) at 4°C. 
 
 
Data collection and processing of proBapA 
ProBapA crystals were cryo-protected with 30% glycerol, flash frozen in liquid nitrogen 
and measured at the Swiss synchrotron light source (PSI Villigen, Switzerland). 
Diffraction data up to 1.8 Å resolution on a total of 720 frames were recorded with an 
oscillation range of 0.5° per frame. The data were processed with the program XDS [19]. 
Initial phases were obtained by molecular replacement using a truncated model of 
tetrameric BapA (residues 1-230 and 250-371) as search model with the program 
PHASER [20]. The structure (1 molecule / asymmetric unit) was refined to final R-factors 
of Rwork = 17.4% and Rfree = 19.4% in the space group P212121, using the program 
package PHENIX [21]. Statistics for diffraction data and structure refinement are 
summarized in Table 2_3. 
 
 
Crystallization of BapA 
Crystallization screenings for BapA were performed with a high throughput robot 
crystallization facility (Mycrosys 1000, Cartesian Technologies, Irvine CA, USA), on 96-
well plates (Crystal Quick Plate, Greiner BioOne, Germany) at 20°C, stored and visualized 
by a Crystal Farm (Imaging Systems, Bruker Nonius; San Diego, CA, USA). Initial 
crystallization trials were performed with BapA at a concentration of 15 mg/ml at 20°C 
with mixing ratios of 50 nl protein / 150 nl reservoir, 100 nl protein / 100 nl reservoir and 
150 nl protein / 50 nl reservoir. The experiment was performed in sitting drop plates 
allowing crystallization using the vapour diffusion method. The Clear Strategy ScreenTM 
I/II (MDL, Newmarket, Suffolk UK) in the pH range from 5.5 to 8.5 and the Sigma-Fluka 
Factorial Screen (#82009) were used. The first crystals were observed one weak after 
having set up the plates. 
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After several optimization trials, BapA at a concentration of 13 mg/ml was crystallized in 
24-well HR3-160 Cryschem sitting drop plates (Aliso Viejo, CA, USA) in a temperature 
controlled room at 22°C in 30% - 50% ammonium sulphate (saturated solution at 4°C) 
at pH 7.0 – 8.5. The protein was dispensed in 2 µl drops (1:1 protein - reservoir ratio). 
 
 
Data collection and processing of BapA 
Crystals grown in 1.5 M ammonium sulphate, 100 mM HEPES pH 7.5, cryo-protected with 
30% glycerol and flash frozen in liquid nitrogen were measured at the Swiss synchrotron 
light source (PSI Villigen, Switzerland). Diffraction data up to 1.45 Å resolution on a total 
of 720 frames were recorded with an oscillation range of 0.5° per frame. The data was 
processed with the program XDS [19]. Initial phases were obtained by molecular 
replacement using the program PHASER [20] and the structure of DmpA (protein 
database code 1B65) as search model. Figure 4_3 shows the electron density map after 
refinement. The asymmetric unit contains one molecule, which was refined to final R-
factors of Rwork = 15.0% and Rfree = 16.8% in the space group P21 using the program 
package PHENIX [21]. Statistics for diffraction data and refinement are listed in Table 
2_3. 
 
BapA 
 87 
Table 2_3) Statistics of data collection and refinement 
Data BapA proBapA 
Space group P21 (SG 4) P212121 (SG 19) 
Cell parameters (Å) a=87.4; b= 96.7, c= 
101.4, β = 108.2 
a=99.7; b= 113.7; c= 
126.0 
Resolution (Å) 1.45 (1.45-1.47) 1.8 (1.8-1.9) 
Observed reflections 901804 579571 
Completeness (%)a 98.5 (92.3) 99.1 (99.2) 
Redundancy 3.23 4.4 
Rsym (% on I)a 4.6 (43.3) 7.1 (47.3) 
I/σIa 16.88 (2.68) 15.64 (3.96) 
R / Rfree (%) 15.0 / 16.8 17.4 / 19.4 
Ordered waters 1871 978 
Bond lengths (Å) 0.004 0.012 
Bond angles (°) 0.803 1.143 
Average B factor (Å2) 13.68 16.41 
Res. most favoured regions 96.08 (1371) 96.49 (1346) 
Res. generally allowed regions 3.43 (49) 2.8 (39) 
Residues in disallowed regions 0.49 (7) 0.72 (10) 
a: numbers in parenthesis indicate statistics in the last resolution shell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4_3) 
2Fo-fc electron-density map of BapA contoured at 1.6σ, calculated using data at 1.45 Å 
resolution. 
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* * * * * 
 
The following two manuscripts describe in detail the structure of the unprocessed 
(S250A) form of BapA (α)4, the native form (αβ)4, the residues that are essential for the 
self-processing, catalytic mechanism and substrate specificity, and a detailed overview of 
the proposed mechanisms for self-processing and catalytic substrate cleavage is 
provided. We also solved the structures of ampicillin, enzymatically (β-lactamase) 
hydrolyzed ampicillin and pefabloc SC (serine peptidase inhibitor) in complex with BapA 
and suggest the prerequisites for beta-peptidic substrates to be cleaved. In fact, we try 
to answer the question why BapA specifically cleaves beta-peptides and how this is 
(mechanistically) achieved, and why BapA does not cleave alpha-peptides. Moreover, the 
results are compared with data of the previously described DmpA protein, the closest 
known homologue of BapA. 
 
The manuscripts are formatted as they were submitted to “STRUCTURE”. 
 
 
* * * * * 
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HIGHLIGHTS 
• BapA of the DmpA-like family is not a “ser-only” β-aminopeptidase 
• BapA employs an unusual Glu-Ser-Ser-Glu catalytic tetrad for autoproteolysis and 
catalysis 
• The length and conformation of the active site loop determines the substrate specificity 
 
 
RUNNING TITLE 
Structure of the β-aminopeptidase BapA 
 
 
SUMMARY 
The β-aminopeptidase BapA from Sphingosinicella xenopeptidilytica belongs to the N-
terminal nucleophile (Ntn) hydrolases of the DmpA-like family and has the unprecedented 
property of cleaving N-terminal β-amino-acid residues from peptides. We determined the 
crystal structures of the native (αβ)4 heterooctamer and of the 153 kD precursor homotetramer 
at a resolution of 1.45 Å and 1.8 Å, respectively. Mutational analyses of BapA strongly 
support a mechanism of autoproteolysis and catalysis based on a tetrad involving the residues 
Glu133, Ser250, Ser288 and Glu290. Structural and functional data provide insight into the 
discriminating structural features determining the substrate specificity of DmpA-like 
enzymes. Our results indicate that the “Ser-only” catalytic mechanism proposed for members 
of the DmpA-like family needs to be reevaluated. 
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INTRODUCTION 
The class of β-aminopeptidases so far comprises five functionally characterized hydrolytic 
enzymes, i.e. three BapA variants from Sphingosinicella xenopeptidilytica 3-2W4 (Geueke, 
2005) and S. microcystinivorans Y2 (Geueke, 2006) and from Pseudomonas sp. MCI3434 
(Komeda, 2005) as well as BapF from Pseudomonas aeruginosa PAO1 (Fuchs, 2011) and 
DmpA from Ochrobactrum anthropi (Fanuel, 1999b). These enzymes share the exceptional 
ability to cleave synthetic β-peptides, which consist of backbone-elongated β-amino-acid 
residues that are not processed by common proteolytic enzymes (Frackenpohl, 2001), 
(Geueke, 2007), (Wiegand, 2002). Due to their structural properties and high proteolysis 
resistance, β-peptides are considered promising building blocks for the design of novel 
peptidomimetics (Aguilar, 2007), (Seebach, 2008). The first and so far only structure of an 
enzyme with β-aminopeptidase activity is DmpA (Bompard-Gilles, 2000). DmpA has an 
αββα-sandwich architecture, which is strongly reminiscent of the fold of classical Ntn 
hydrolases (Brannigan, 1995). However, DmpA is classified as a novel member of the Ntn 
hydrolase family due to a different connectivity of the secondary structure elements 
(Bompard-Gilles, 2000), (Oinonen, 2000). 
Ntn hydrolases, in general, are synthesized as inactive precursor polypeptides with or 
without a periplasmic leader sequence. They undergo post-translational autoproteolytic 
cleavage into heterodimers. The primary nucleophile that initiates this cleavage is either a 
serine, threonine or cysteine residue, which, upon self-processing, becomes the essential N-
terminal nucleophile for the catalytic activity. This autoproteolytic activation step is a 
characteristic trait of all Ntn hydrolases (Brannigan, 1995), (Kim, 2003), (Saarela, 2004), 
(Michalska, 2008). Various biochemical studies showed that Ntn hydrolases occur in different 
oligomeric states, such as heterodimers (e.g. penicillin G acylase(McVey, 2001), 
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heterotetramers (e.g. glutamyltranspeptidase from Helicobacter  pylori (Boanca, 2006)), 
heterooctamers (e.g. penicillin V acylase from Bacillus sphaericus (Suresh, 1999)) or, 
exceptionally, as very large assembly in the proteasome (Baumeister, 1997). The substrate 
specificities of Ntn hydrolases vary considerably. Generally, these enzymes catalyze the 
hydrolysis of amide bonds. However, the ornithine acetyltransferase (orf6) from the 
clavulanic-acid-biosynthesis gene cluster is an exception. The enzyme has the same fold as 
DmpA, but catalyzes the reversible transfer of an acetyl group from N-acetylornithine to 
glutamate (Elkins, 2005). Among the Ntn hydrolases, penicillin acylases and β-
aminopeptidases have particularly high biocatalytic potential (Bruggink, 1998), (Barends, 
2004), (Heck, 2007), (Heck, 2009), (Heck, 2010). 
The backbone length of the N-terminal amino acid of the substrate molecule has a 
strong impact on the enzymatic activity of β-aminopeptidases. Whereas DmpA hydrolyzes D- 
and L-configured α-amino-acid amides, esters and peptides as well as peptides carrying small 
N-terminal β-amino acids such as β-homoglycine and β3-homoalanine (Fanuel, 1999a), 
(Heck, 2006), BapA from S. xenopeptidilytica exhibits hydrolytic activity with strict 
preference for variable N-terminal β-amino acids and, remarkably, does not hydrolyze α-
peptides (Geueke, 2006), (Heck, 2006). Until now, the natural substrates of β-
aminopeptidases remain unknown and structural data about exclusively β-peptide-cleaving 
enzymes are not available. 
Here and in Heck et al. (this issue) we present the first high-resolution crystal 
structures of the β-aminopeptidase BapA, which has exclusive catalytic activity for β-peptide 
substrates. Our comprehensive structural and functional study about this novel 
aminopeptidase includes the crystal structures of the active form, its precursor and of the 
active form in complex with the serine-peptidase inhibitor AEBSF, ampicillin and ampicillin-
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derived penicilloic acid. The analysis of these BapA structures provides insight into the 
mechanisms of autoproteolysis and substrate processing, and shows the determinants of the 
enzyme`s substrate specificity and enantiomer selectivity. Moreover, our mutational analysis 
indicates that BapA, DmpA and other so far not characterized DmpA-like aminopeptidases, 
do not, as reported, act with a “Ser-only” active-site-residue configuration. Instead of a single 
catalytically active amino-acid residue, these enzymes seem to employ highly conserved 
tetrads for the self-processing and the catalytic substrate hydrolysis. 
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RESULTS 
Crystal structure of native BapA 
BapA crystallized in the space group P21 and contained one (αβ)4 heterooctameric molecule 
(153 kD) in the asymmetric unit. The high-resolution crystal structure (1.45 Å) of BapA was 
determined by molecular replacement as described in the Methods section. Each heterodimer 
comprised a large α-polypeptide chain (residues 1-249) and a small β-polypeptide chain 
(residues 250-373). The molecule assumed a globular disk-like shape in its precursor form 
with subunits arranged in a D2 or 222-symmetry mode, creating three perpendicular two-fold 
symmetry axes (Figure 1A). Each αβ-subunit adopted an αββα-sandwich fold that was 
formed by two layers of four and five parallel/antiparallel β-sheets flanked by two helices on 
each side (Figure 1B). The connectivity of the secondary structure elements in BapA differed 
from the classical Ntn hydrolase fold, but it was identical to the fold of DmpA. The total 
interface area between all subunits comprised 7880.2 Å2 in BapA and suggested a very stable 
and permanent octameric state in solution that was elucidated experimentally by gel filtration 
(data not shown). The model was refined to final R/Rfree values of 13.5% and 15.3%. 
Crystallographic data are listed in Table 1. The BapA molecule contained four active sites, 
each of which was located at the interface of three adjacent subunits forming the substrate-
binding pockets. In analogy to other Ntn hydrolases, Ser250 became the N-terminal catalytic 
nucleophile of the β-polypeptide chain upon precursor processing (Figure 2A). Glu133, 
Ser250, Ser288 and Glu288, that we propose to participate in the catalytic mechanism, were 
located on the same subunit (Figure 1A). A water molecule (Bav = 18.1 ±1.1) was in close 
contact to the carboxyl group of Glu133 in each of the active sites. The shape of the active 
sites of BapA with their buried catalytic residues excluded the action of associated peptidases 
that could be involved in the autoproteolytic cleavage. 
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Crystal structure of the unprocessed BapA precursor (proBapA) 
The homotetrameric unprocessed precursor form of BapA (proBapA) was obtained by the 
replacement of Ser250 for alanine, which prevented the primary cleavage of the enzyme-
subunits into α- and β-polypeptides. This mutation allowed the structural investigation of the 
precursor form, because the native BapA was immediately processed after translation. The 
enzymatically inactive proBapA crystallized in the space group P212121 and contained one 
homotetrameric molecule in the asymmetric unit. The high-resolution crystal structure (1.8 Å) 
of proBapA was determined by molecular replacement as described in the Methods section. 
The model was refined to final R/Rfree values of 15.5% and 18.0%. Crystallographic data are 
listed in Table 1. Overall, the globular shape and the contact area between the subunits 
strongly resembled BapA. The displacement of the linker connecting the designated α- and β-
chains (residues 231 – 249) represented the major structural difference between native BapA 
and proBapA (Figure 1C). In proBapA, this segment, which contained two prolines with 
dihedral angles in allowed Ramachandran regions (Pro240 phi -64.5°/psi -30.9° and Pro245 
phi 62.6°/psi 140.6°) either assumed a helical conformation due to partial crystal contacts, or 
it was largely unstructured. However, in BapA, the same segment assumed a β-sheet-like 
conformation and the prolines were located in the turns. No further significant deviations from 
ideal geometry in this linker segment were found. Together with the linker displacement, the 
re-positioning of Ser250 represented a minor but functionally highly important structural 
change at the active site. Comparing the distances of the Ala250-backbone-amide nitrogen of 
proBapA and the α-amino group of Ser250 of native BapA to the OH-group of Ser288, 
Ser250 rotated around its C-Cα bond upon self-processing causing a reduction of the distance 
from 3.67 ±0.04 Å (NH-Ala250 – OH-Ser288) to 2.79 ±0.01 Å (NH3+-Ser250 – OH-Ser288) 
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(Figures 2A and 2B). The inter-residue distances between Glu133, Glu290 and Ser288 did 
not significantly change between BapA and proBapA.  
 
 
Catalytic residues for self-processing and catalysis 
We exchanged six amino-acid residues in the vicinity of the catalytic nucleophile Ser250 for 
alanine residues. The consequences of these mutations on the autoproteolysis of the precursor 
polypeptide were judged based on the time-dependent appearance of individual α- and β-
chains on SDS-PAGE gels. Native BapA was already fully processed after purification, while 
the BapA mutants did not self-process at all or only partially within 192 hours (Table 2). In 
fact, the exchange of Ser250, Ser288 or Glu290 for alanine completely abrogated precursor 
cleavage: neither the individual α- and β-polypeptide chains could be detected on SDS-PAGE 
gels (Figure 3) nor did the mutant enzymes exhibit any residual enzymatic activity after 192 
hours of incubation (Table 2). The BapA mutants E133A, K248A and N249A were clearly 
delayed in self-processing (SDS-PAGE for K248A not shown). Nevertheless, activity 
measurements after 192 hours of incubation revealed that K248A and N249A mutants were as 
active as native BapA, but the exchange of Glu133 completely abolished any activity (Table 
2). 
Because the BapA mutants E133A, S250A, S288A and E290A did not undergo the complete 
processing step, the effects of their mutations on substrate binding and conversion could not 
be investigated. In order to study the mechanism of substrate cleavage independently from 
precursor processing, we co-expressed the individual α- and β-polypeptide chains of BapA 
from a Duet expression vector and introduced the same mutations that were previously 
investigated for their effects on self-processing. We ensured by sequence analysis that the 
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newly introduced N-terminal methionine residue of the β-polypeptide chain was 
posttranslationally removed by E.coli. The cell-free extracts containing the respective BapA 
Duet mutants were then tested for their catalytic activity with the substrate H-β3hAla-pNA. 
The mutants E133A Duet and S250A Duet were inactive, whereas the mutants S288A Duet 
and E290A Duet exhibited <1% and 24% activity, respectively, compared to wild-type BapA 
Duet (Table 2). 
 
 
Mechanism of self-processing 
Based on the structural data and our mutational studies, we propose the following self-
processing mechanism: Glu133 represents the only amino acid in the vicinity of Ser250 to 
enhance the nucleophilicity of Ser250-Oγ. It supposedly acts as a base and initiates the first 
step of the cleavage process through the catalytic water molecule (Figure 4A, precursor state). 
However, the residual autoprocessing ability of the BapA E133A mutant indicates that the 
activation of Ser250 can be partially circumvented by water molecules and hydroxyl ions 
from the environment (Figure 3). We speculate that the nucleophilic attack of Ser250-Oγ on 
the preceding peptide bond and the subsequent formation of the oxy-oxazolidine intermediate 
is facilitated by the ε-amino group of Lys248, which points towards the active-site pocket and 
reversibly acts as proton donor to the carbonyl group of Asn249 (Figure 2B). This reversible 
protonation might influence the rate of the autoproteolytic cleavage by promoting the 
formation of the oxy-oxazolidine intermediate state. Moreover, the scissile peptide bond is 
stabilized by a salt bridge formed between Glu133 and Lys248. Transitions within the oxy-
oxazolidine intermediate state, which are characterized by a change from a peptide bond to an 
ester bond, lead to the formation of the acyl enzyme (Figure 4A, steps 1 and 2). Finally, the 
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N-terminal nucleophile Ser250 is exposed through reversible protonation steps within 
tetrahedral intermediates that are stabilized by the ε-amino group of Lys248 and the amide 
proton of Gly289 (Figure 4A, steps 3 and 4). Overall, proBapA requires the four residues 
Glu133, Ser250, Ser288 and Glu290 in order to be fully processed whereas Lys248 and 
Asn249 fulfill accessory functions. 
 
 
Catalytic substrate-cleavage mechanism 
The substrate molecule freely diffuses into the active-site pocket of BapA and a salt bridge is 
formed between its amino terminus and Glu133 of BapA (Figure 4B, Michaelis complex). 
Glu290 supposedly activates Ser250-Oγ for the nucleophilic attack on the carbonyl group of 
the substrate, while Ser288-OH and the α-amino group of Ser250 enable the proton transport 
of this event chain. Leu135-NH and Asn207-NH2 stabilize the negative charge of the 
oxyanion of the tetrahedral intermediate (Figure 4B, step 1), which collapses to the acyl 
enzyme under release of the C-terminal substrate moiety. Glu133 subsequently activates the 
catalytic water molecule, which hydrolyzes the acyl enzyme (Figure 4B, step 2). The amino-
acid configuration of the BapA active site generally offers two pathways for the activation of 
Ser250-Oγ and the subsequent hydrolysis of the acyl enzyme. Instead of the previously 
described Ser250-Ser288-Glu290 triad, Ser250-Oγ could alternatively be activated by Glu133 
and the catalytic water molecule for the initial nucleophilic attack on the carbonyl group of the 
substrate. In this case, the hydrolysis of the acyl enzyme would subsequently be initialized by 
Glu290 (Figure S1). Similarly to the last steps during self-processing, reversible protonation 
steps within tetrahedral intermediates lead to the rupture of the acyl enzyme and to the release 
of the substrate`s N-terminal amino acid (Figure 4B, steps 3 and 4). Overall, the self-
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processing and the catalytic cleavage mechanisms are very similar. However, they differ 
between the protonation states of Glu133. During self-processing, Glu133 is deprotonated 
upon formation of the acyl enzyme and remains deprotonated until the release of the linker 
segment. On the other hand, the protonation of Glu133 during substrate hydrolysis breaks the 
salt-bridge interaction with the hydrolyzed, but still covalently bound N-terminal substrate 
moiety and enables its unimpaired release upon hydrolysis of the acyl enzyme. In summary, 
BapA hydrolyzes substrates with a catalytic tetrad composed of the residues Glu133, Ser250, 
Ser288 and Glu290. Noteworthy, Ser250 involves its OH-group and its α-amino group during 
the catalytic cycles. 
 
 
Comparison between the substrate-binding pockets of BapA and DmpA 
The superposition of the structures of native BapA, DmpA (PDB ID 1b65) and a so far 
uncharacterized protein from Pyrococcus horikoshii (PH0078, PDB ID 2drh) showed a good 
overlap of the corresponding catalytic residues. However, the sizes of the substrate-binding 
pockets differed notably (Figure 5). In BapA, a 310-helix comprising the residues Glu120 to 
Arg126 created a wide substrate-binding pocket, which was largely occluded by loops in 
DmpA (Gln131 to Trp137) and PH0078 (Glu120 to Ser128). From this superposition we 
concluded that Trp137, which pointed into the active-site cavity of DmpA, restricted catalysis 
to the removal of sterically undemanding N-terminal amino acids. To confirm this hypothesis, 
we exchanged Trp137 for alanine by site-directed mutagenesis in order to widen the substrate-
binding pocket of DmpA and thus make it accessible for bulkier substrates. Hereby, it is 
important to mention that the point mutation W137A negatively affected the self-processing 
rate of the DmpA precursor polypeptide into the individual α- and β-polypeptides. In contrast 
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to the native BapA and DmpA proteins that were fully processed after the purification 
procedure, DmpA W137A was only half-processed after purification and three days of 
incubation at pH 7.2 and 37°C. A survey of the kinetic parameters of the conversion of the β3-
homoamino-acid p-nitroanilides H-βhGly-pNA, H-β3hAla-pNA, H-D-β3hAla-pNA, H-
β3hPhe-pNA and H-D-β3hPhe-pNA by BapA, DmpA and DmpA W137A is shown in Table 
3. While BapA converted the aromatic β3-homophenylalanine p-nitroanilides of L- and D-
configuration with kcat/KM values of 14,500 and 940 M-1s-1, respectively, the conversion of 
these two enantiomers by DmpA was negligible (kcat/KM < 10 M-1s-1). The single amino-acid 
exchange of Trp137 for alanine in DmpA drastically altered the substrate specificity of DmpA 
W137A leading to more than 280- and 670-fold increased catalytic efficiencies for the 
conversion of the substrates H-β3hPhe-pNA and H-D-β3hPhe-pNA, respectively. On the other 
hand, DmpA W137A converted substrates with small side chains, i.e. H-βhGly-pNA, H-
β3hAla-pNA and H-D-β3hAla-pNA, less efficiently than wild-type DmpA and displayed 
overall kcat/KM-values similar to BapA for these substrates (Table 3). 
 
 
Sequence comparison of putative β-aminopeptidases and implications on their substrate 
specificity 
In addition to the five functionally characterized β-aminopeptidases (Geueke, 2006), 
(Komeda, 2005), (Fuchs, 2011), (Fanuel, 1999a), (Heck, 2006), a BLAST search revealed a 
large number of protein sequences showing high similarity to the sequence of BapA from S. 
xenopeptidilytica. They mainly originated from Gram-negative bacteria, among them many 
pathogenic species such as Burkholderia mallei, B. pseudomallei and various strains of 
Pseudomonas aeruginosa, but also from archaea (e.g Pyrococcus horikoshii), fungi (e.g 
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Aspergillus oryzae) and yeast (e.g Yarrowia lipolytica). Strikingly, the region downstream of 
the N-terminal catalytic nucleophile (ranging from Ser250 to Ser290) and the region around 
the salt-bridge-forming residue Glu133 were highly conserved among all compared 
sequences, indicating that these regions are crucial for catalysis (Figure 6). Glutamate at 
position 290 of BapA was less, but functionally conserved. In contrast to these highly 
conserved regions, the compared sequences showed great variability over a stretch of 15 to 20 
amino acids upstream of Glu133. As shown in Figure 5, this sequence stretch corresponded to 
the active-site loop (310-helix in BapA), which defined the width of the enzymes` substrate-
binding pockets and their substrate specificities (Table 3). 
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DISCUSSION 
In this study, we report the crystal structures of the native and precursor form of BapA from S. 
xenopeptidilytica. Native BapA revealed a heterooctameric organization comprising four 
heterodimers in a globular D2-symmetry arrangement. Each heterodimer assumed an αββα-
sandwich fold, which was very similar to the core-fold of classical Ntn hydrolases 
(Brannigan, 1995), (Oinonen, 2000). ProBapA revealed a homotetrameric organization with 
the same globular arrangement and core-fold. The displacement of the linker segment between 
the α- and β-subunits (residues 231 – 249) represented the major structural difference 
between native BapA and proBapA. Although this segment contained two prolines in allowed 
Ramachandran regions and no further significant deviations from ideal geometry, we expect 
these prolines to provide the initial driving force for the large conformational change from a 
helical to a β-sheet-like conformation in the autoprocessing step. Similar observations of 
strained conformations of linker sequences with prolines that are supposed to regulate the 
autoprocessing of Ntn hydrolases are reported for the Ntn hydrolases glutaryl 7-
aminocephalosporanic acid acylase (Kim, 2003) and cephalosporin acylase (Kim, 2006). 
BapA differed from other classical Ntn hydrolases by the connectivity of the 
secondary structure elements, but had the same fold as DmpA from O. anthropi (Bompard-
Gilles, 2000). Therefore, BapA belongs to the DmpA-like family. DmpA is reported to be 
closely related to the superfamily of Ntn hydrolases and to exhibit a single-residue catalytic 
mechanism, in which the N-terminal nucleophile (Ser250), incorporated in a β-sheet, uses its 
own α-amino group as Brønsted base for activation (Bompard-Gilles, 2000). 
BapA and DmpA shared 41.8% sequence identity and were structurally and 
biochemically closely related. The catalytic residues of BapA overlapped extremely well with 
corresponding conserved amino acids of DmpA, although their substrate specificities vary 
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(Heck, 2006). We therefore propose that substrate conversions by DmpA and BapA involve a 
similar mechanism. We showed that the residues Glu133, Ser250, Ser288 and Glu290 of 
BapA (corresponding to Glu144, Ser250, Ser288 and Asp290 of DmpA) have important 
functions for the self-processing and the catalytic mechanism. The crystal structure of native 
BapA revealed short hydrogen-bond distances of 2.8 Å between Ser250-NH3+ and Ser288-OH 
and of 2.6 Å between Ser288-OH and the carboxyl group of Glu290, suggesting that the 
catalytic nucleophile Ser250-Oγ is activated by Glu290 and Ser288. These assumptions are in 
accordance with our kinetic analysis that showed 100-fold and 4-fold decreased activities, 
when Ser288 and Glu290 were exchanged for alanines, respectively. Nevertheless, the 
residual catalytic activity of the S288A Duet mutant indicates that either Ser250 is indeed 
capable of self-activation as postulated by (Bompard-Gilles, 2000), or that Glu133 exhibits 
very weak activity. In comparison the native enzyme, Glu133 and Ser250 of the S288A Duet 
mutant only seem to play a minor role for the activation of the catalytic nucleophile. In fact, 
this loss of activity is not surprising. We assume the α-amino group of Ser250 to be mostly 
protonated (pKa > 9). Therefore, the amino group is unlikely to act as a base abstracting a 
proton from Ser250-OH and to provide the major driving force for the activation of its own 
nucleophile. 
The major consequence arising with our study is that the proposed “Ser-only” catalytic 
mechanism of DmpA must be reconsidered. Our results strongly suggest that BapA and 
DmpA feature catalytic tetrads (Glu-Ser-Ser-Glu and Glu-Ser-Ser-Asp, respectively) rather 
than single catalytic serine residues. This clearly extends the currently proposed catalytic 
mechanism of DmpA. The importance of these catalytic residues for BapA, DmpA and other 
DmpA-like proteins is further supported by their high conservation on the structural (Figure 
5) and on the sequence level (Figure 6). Interestingly, despite the close structural similarity of 
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the αββα-sandwich fold, the Ntn hydrolase superfamily comprises enzymes with different 
catalytic mechanisms. The prototypic Ntn hydrolase penicillin G acylase is reported to have a 
single catalytic serine residue (Duggleby, 1995), the γ-glutamyltranspeptidase from H. pylori 
reveals a threonine-threonine catalytic dyad (Boanca, 2007) and the 20S proteasome from T. 
acidophilum employs a catalytic tetrad with a threonine residue as primary nucleophile 
(Löwe, 1995). 
The superposition of the available crystal structures of β-aminopeptidases and a 
comparison of the biochemically characterized enzymes with related amino-acid sequences 
showed that despite the highly conserved positions of the catalytic amino-acid residues, the 
size and chemical environment of the substrate-binding pocket largely differs among these 
proteins. We expect a non-conserved sequence stretch, assuming different conformations 
within the substrate-binding pocket, to mainly determine the substrate specificity of proteins 
of the DmpA-like family. The wide substrate-binding pocket of BapA allows the enzyme to 
catalyze reactions of peptides with bulky N-terminal β-amino-acid residues, while Trp137 in a 
loop occludes this pocket and restricts DmpA to hydrolyze substrates with sterically 
undemanding N-terminal amino acids. However, by exchanging Trp137 for alanine, DmpA 
could be rationally engineered to an altered enzyme with catalytic properties that are more 
similar to BapA than to DmpA. Another interesting candidate to study the influence of 
modifications within the substrate-binding pocket on catalysis is the biochemically non-
characterized protein PH0078 from P. horikoshii (PDB ID 2drh). The active-site loop of 
PH0078 assumes a similar conformation within the substrate-binding pocket like the 
corresponding loop of DmpA but exposes a sterically less demanding serine residue instead of 
a tryptophane towards the active-site residues. Therefore, we expect PH0078 to exhibit a 
substrate profile, which is similar to the one of the DmpA mutant W137A. Further specific 
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amino-acid exchanges in this particularly variable region might lead to the creation of β-
aminopeptidases with interesting novel specificities. The structure-based rational design of 
modified β-aminopeptidases represents a promising approach to improve the properties of the 
available enzymes with respect to biocatalytic applications, such as the enzyme-catalyzed 
synthesis of β-peptides or the production of enantiopure β-amino acids. 
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EXPERIMENTAL PROCEDURES 
Generation of the BapA Duet expression constructs and mutants 
The gene sequences coding for the individual α- and β-polypeptide chains of BapA were 
amplified by PCR from the plasmid p3BapA containing bapA from S. xenopeptidilytica 3-
2W4 without its periplasmic signal sequence (Geueke, 2006) and separately cloned into a 
pETDuet-1 vector (Novagen, Madison, USA). Sequences of primers and information about 
site-directed mutagenesis can be found in the supplemental data. 
 
 
Expression and purification of BapA for biochemical assays and protein crystallization 
The production and purification of the β-aminopeptidase BapA from S. xenopeptidilytica 3-
2W4 and DmpA from O. anthropi was done following established procedures (Geueke, 
2005), (Geueke, 2006), (Fanuel, 1999b). All mutants of BapA and DmpA were purified 
accordingly to purity levels > 70%. Cell-free extracts and partially purified proteins were 
analyzed by SDS-PAGE using pre-cast 10% Novex tricine gels (Invitrogen AG, Basel, 
Switzerland) according to the manufacturer`s instructions. The protein gels were stained with 
Coomassie Brilliant Blue and the relative intensities of the protein bands were determined 
with a GS-800 calibrated imaging densitometer and the software Quantity One (Bio-Rad, 
Reinach, Switzerland). The β-polypeptide chain of the partially purified BapA S250 Duet was 
transferred from the gel to PVDF membranes by electroblotting and the N-terminus was 
sequenced at the Functional Genomics Center Zürich (Switzerland). 
Before crystallization, the purified protein was dialyzed against a 0.5 mM Tris/HCl buffer (pH 
8) and concentrated to 15 mg/ml prior to crystallization. Crystals were grown in 2 µl drops 
with a 1:1 ratio of mother liquor (1.8 M ammonium sulfate and 100 mM Tris/HCl, pH 8.0) to 
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purified BapA in 24-well Cryschem sitting-drop plates (Hampton Research, Aliso Viejo, CA, 
USA) using the vapor-diffusion method at 20°C. Within one day, crystals of BapA grew as 
stacked layers of thin plates. Sequential macroseedings with crystal fragments that were 
transferred to new wells containing 1.5 M ammonium sulfate, 100 mM Tris/HCl (pH 8.0), 
yielded single three-dimensional, mostly plate-shaped crystals of up to 300 × 300 × 30 µm in 
size. Cryo-protected crystals (mother liquor and 30% glycerol) were flash-frozen in liquid 
nitrogen. 
 
 
Structure determination 
Data were collected at the Swiss Light Source beamline PX on a 6M Pilatus detector in a 
cryostream at 100 K at 1 Å wavelength. The data sets were indexed, integrated and scaled 
with XDS (Kabsch, 1993). The structure of BapA was solved by molecular replacement with 
PHASER (McCoy, 2007) using one subunit (α- and β-chain) of the heterooctameric structure 
of DmpA (PDB ID 1b65). The search probe was additionally tailored at the C-terminus of the 
α-chain (residues 224 to 245). The structure of proBapA was solved by molecular 
replacement with PHASER using one subunit (α- and β-chain) of native BapA. The C-
terminal tail of the α-chain (residues 231-249) was omitted in this search probe. Unambiguous 
solutions of proBapA and native BapA were obtained, including an extended region of 
positive difference electron density (Fo-Fc) in the initial map (model phases of BapA and 
DmpA, respectively) that corresponded to the omitted amino acid linker sequences. Each 
polypeptide chain comprised 373 amino acids. The final model of proBapA contained 
residues 1-236 / 248-371 for chain A, 1-236 / 248-317 for chain B, 1-238 / 248-371 for chain 
C and 1-371 for chain D. The final model of native BapA contained residues 1-245 / 250-371 
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for chain A, 1-243 / 250-371 for chain B, 1-245 / 250-371 for chain C and 1-239 / 250-371 for 
chain D. The refinement of the structures was carried out through multiple cycles of manual 
adjustments and rebuilding using COOT (Emsley, 2004), and refinement was carried out 
using PHENIX (Adams, 2010). Interface area calculations were performed using the Pisa 
server v.1.18. Superpositions for figures were done using SSM (Krissinel, 2004). Figures 
were created with the program Pymol (DeLano). 
 
 
Activity assays 
The β-aminopeptidase-catalyzed conversion of the β3-homoamino-acid p-nitroanilides H-
βhGly-pNA, H-β3hAla-pNA, H-D-β3hAla-pNA, H-β3hPhe-pNA and H-D-β3hPhe-pNA was 
determined spectrophotometrically by monitoring the release of free p-nitroaniline at a 
wavelength of 405 nm (ε405 = 8,800 M-1cm-1) for one minute. For the determination of kinetic 
constants, the assay mixtures contained different molar concentrations of the substrates in a 
100 mM potassium phosphate buffer at pH 7.2 at 37°C; 10% DMSO was added as co-solvent. 
The standard assay contained 5 mM H-β3hAla-pNA as substrate. The reactions were initiated 
by the addition of one of the purified enzymes BapA, DmpA or DmpA W137A, or by the 
addition of cell-free extract containing recombinantly expressed enzyme. The initial rates of 
the enzyme-catalyzed release of p-nitroanilide were calculated and fitted to the Michaelis-
Menten model by non-linear regression analysis with the VisualEnzymics software 
(Softzymics, Princeton, NJ, USA) for the program IGOR Pro (WaveMetrics, Oswego, OR, 
USA). 
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PDB ACCESSION NUMBERS 
The structures of proBapA and native BapA and proBapA are accessible under the PDB ID 
3n2w and 3n5i, respectively. 
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FIGURE LEGENDS 
Figure 1: Structural overview of native BapA and proBapA  
(A) Cartoon representation of the (αβ)4-BapA heterooctamer viewed along the P axis 
(perpendicular to the paper plane). The Q and R axes are shown as dotted lines. The 
individual subunits A, B, C and D, each comprising an α- and a β-polypeptide chain, are 
shown in cyan, blue, orange and red, respectively. The blow-up frame shows the catalytic 
residues Glu133, Ser250, Ser288 and Glu290 of the subunit A as sticks in yellow and the 
residues of the substrate-binding pocket as sticks in grey (subunit A: Thr76, Thr100, Leu135, 
Leu287; subunit C: Thr316; subunit D: Leu84, Val88, Gln90, Leu92, Phe124, Ser125, 
Leu127, Leu128, Leu303). 
(B) Cartoon representation of one αβ-subunit. The secondary structure elements contributing 
to the Ntn fold are colored in red and blue. 
(C) Active-site pocket of BapA before and after the autoproteolytic cleavage: The catalytic 
residues Glu133, Ser250, Ser288 and Glu290 are shown in yellow. The linker segment 
(residues 231 to 249) is shown in its precursor (magenta) and processed form (blue). The 
residues Pro240 and Pro245 were located within a helical loop conformation in the precursor, 
which upon autoproteolytic processing assumed a β-sheet-like conformation. Hydrogen bonds 
are indicated with dotted lines; the given distances refer to the linear Cα-shifts of Pro240 and 
Pro245. 
Structure of the beta-aminopeptidase BapA 
 116 
Figure 2: Close-up view into the active sites of native BapA and proBapA 
(A) Native BapA: rotation of Ser250 around the C-Cα-bond decreased the NH3+250-OH288 
distance from 3.7 Å to 2.8 Å. The 2fofc electron density map is contoured at 1.5 σ.  
(B) BapA precursor mutant S250A (proBapA): The catalytic residues Glu133, Ser288, 
Glu290 and Ser250/Ala250 are shown as sticks in yellow and the catalytic water molecule is 
shown as a red sphere. The carboxy-terminal residues of the α-chain before the 
autoproteolytic cleavage are shown in magenta. Distances (indicated by dotted arrows) of the 
ε-amino-group of Lys248 to the carboxyl-group of Glu133 and the carbonyl-group of Asn249 
vary between the subunits from 3.6 – 5.2 Å and 3.0 – 5.5 Å, respectively. 
 
 
Figure 3: SDS-PAGE analysis of five processing-deficient or slow-processing BapA point 
mutants. 
The mutant proteins (0.6 mg/ml) were incubated in 50 mM Tris/HCl buffer (pH 8) at 37°C. 
Samples were taken after 0 h (0), 54 h (1), 120 h (2) and 192 h (3). 
 
 
Figure 4: Schematic drawings of the self-processing and the catalytic substrate-cleavage 
mechanisms. 
(A) Formation of the oxy-oxazolidine through the activation of Ser250-Oγ by Glu133 and the 
catalytic water molecule to allow for nucleophilic attack on the preceding peptide bond to 
Asn249. Step 1: Indirect protonation of the secondary amino group of the oxy-oxazolidine 
intermediate by Glu133, presumably influenced by Glu290. Stabilization of the oxyanion by 
the backbone amide group of Gly289 and the ε-amino group of Lys248. Step 2: Collapse of 
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the tetrahedral intermediate into the acyl enzyme and subsequent attack of the acyl enzyme by 
the activated catalytic water molecule, initiated by Glu290. Step 3: Indirect protonation of the 
amino group of Ser250 by Glu290 and Ser288 and rupture of the tetrahedral intermediate 
through subsequent proton and electron transfer reactions. Step 4: Release of the carboxy-
terminal tail of the α-polypeptide chain and protonation of the amino group of Ser250. 
(B) Michaelis complex: Formation of a salt bridge between Glu133 and the substrate`s amino 
terminus. Activation of Ser250-Oγ by Glu290, and initiation of the nucleophilic attack on the 
carbonyl group of the substrate. Step 1: Stabilization of the oxyanion by the backbone amide 
group of Leu135 and the δNH2-group of Asn207. Substrate cleavage and formation of the acyl 
enzyme through proton transfers within the tetrahedral intermediate. Step 2: Activation of the 
catalytic water molecule by Glu133 and initiation of the acyl-enzyme hydrolysis. Step 3: 
Indirect protonation of the amino group of Ser250 by Glu290 and Ser288 and rupture of the 
tetrahedral intermediate through subsequent proton and electron transfer reactions. The salt-
bridge interaction between Glu133 and the substrate`s amino terminus is abolished. Step 4: 
Release of the cleaved product and reconstitution of the active-site residues for another 
catalytic cycle. 
Solid arrows denote electron-pair shifts, dashed arrows denote catalytic influence; hydrogen 
bonds are indicated by dotted lines. R249 = Asn249, R251 = Leu251, R = N-terminal amino-
acid residue of the substrate, Rx = side chain of the N-terminal amino acid, Ry = C-terminal 
substrate moiety. 
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Figure 5: Close-up view into the active-site pocket of native BapA and superposition of 
BapA with DmpA and PH0078. 
Stereo representation of the active sites of DmpA from O. anthropi (PDB ID 1b65) and a non-
characterized protein form P. horikoshii (PH0078, PDB ID 2drh), superposed onto BapA 
from S. xenopeptidilytica and viewed 180° rotated around the Q-axis (cf. Figure 1A). The 
active-site loops containing Ser128 (PH0078) and Trp137 (DmpA) are part of the highly 
variable sequence stretch of 15 to 20 amino acids upstream of the conserved Glu133 (BapA 
numbering, see Figure 6). The subunits A and D of BapA are shown in cyan and red, the 
active-site loops as well as the residues of DmpA and PH0078 are shown as sticks in orange 
and violet, respectively. The active-site residues Glu133, Ser250, Ser288 and Glu290 of BapA 
are shown as sticks in yellow. They correspond to Glu135/Glu144, Ser239/Ser250, 
Ser277/Ser288 and Asp279/Asp290 of PH0078 and DmpA, respectively. 
 
 
Figure 6: Partial alignment of β-aminopeptidase-like sequences 
Sequence alignment of BapA from S. xenopeptidilytica with four previously characterized β-
aminopeptidases (2-5) and selected, non-characterized protein sequences that were retrieved 
from a BLAST search (6-18). Two sections of the alignment are shown (amino acids 104 – 
145 and 250 – 290). Identical amino acids are highlighted in black, similar amino acids are 
highlighted in grey. The numbering refers to BapA from S. xenopeptidilytica. Trp137 of 
DmpA from O. anthropi, which was selected as a target for mutagenesis, and Ser128 of the 
unknown protein PH0078 from P. horikoshii (NP_142096) are underlined and printed in bold. 
The alignment was created with the program ClustalW (Thompson). (1) BapA from 
Sphingosinicella xenopeptidilytica 3-2W4 (AAX93858), (2) DmpA from Ochrobactrum 
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anthropi (CAA66259), (3) BapA from Sphingosinicella microcystinivorans ABC59253, (4) 
BapA from Pseudomonas sp. MCI3434 (BAE02664), (5) BapF from Pseudomonas 
aeruginosa PAO1 (NP_250177). Non-characterized protein sequences from (6) 
Agrobacterium tumefaciens C58, (7) Burkholderia mallei ATCC 23344, (8) Mycobacterium 
gilvum PYR-GCK, (9) Mycobacterium smegmatis MC2 155, (10) Myxococcus xanthus DK 
1622, (11) Photorhabdus asymbiotica, (12) Pseudomonas entomophila L48, (13) 
Pseudomonas fluorescens Pf-5, (14) Pseudomonas putida KT2440, (15) Stigmatella 
aurantiaca DW4/3-1, (16) Pyrococcus horikoshii OT3, (17) Aspergillus oryzae RIB40, (18) 
Yarrowia lipolytica. 
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TABLE LEGENDS 
Table 1: Data collection and refinement statistics (molecular replacement) 
Values in parentheses represent data for the highest resolution shell. One crystal was used for 
each dataset. a Rsym = ∑ |Ii -<I>| / ∑ <I> where I is the measured intensity of each reflection 
and <I> is the intensity from multiple observations of symmetry-related reflections. b R-factor 
= ∑ |Fobs| - |Fcalc| / ∑ |Fobs| where Fobs and Fcalc are the observed and the calculated structure 
factor amplitudes, respectively. c Rfree is the R-factor calculated with reflections chosen at 
random and omitted from refinement. 
 
 
Table 2: Mutations in BapA and their impact on precursor cleavage and substrate 
hydrolysis 
a
 The activities of the purified enzymes were measured after 192h of incubation under 
standard assay conditions (see Methods section) and related to the activity of native BapA 
(100%) treated under the same conditions. b Due to the reduced or absent autoprocessing, the 
activities of the mutants E133A, S250A, S288A and E290A were measured from cell-free 
extracts containing the respective recombinantly expressed BapA Duet variants and related to 
the activity of cell-free extract containing native BapA Duet (100%). 
 
 
Table 3: Kinetic analyses of the conversion of different β3-homoamino-acid p-
nitroanilides by the purified β-aminopeptidases BapA, DmpA and DmpA W137A 
a
 The enzyme activities measured at pH 7.2 and 37°C showed a linear dependency on the 
substrate concentration between 0.1 and 5 mM. The kcat/KM values were calculated according 
Structure of the beta-aminopeptidase BapA 
 121 
to the equation kcat/KM = v/[Eo]*[S]), where v is the rate of the reaction, [S] the concentration 
of the substrate and [Eo] the stoichiometric concentration of active centers (MBapA: 38,610, 
MDmpA: 40,440, MDmpA W137A: 40,330). b For the calculation of the kinetic parameters, only the 
processed enzyme fraction in the protein solution was taken into account. 
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TABLES 
Table 1: Data collection and refinement statistics (molecular replacement) 
 Native BapA proBapA 
Data collection   
Space group P21 P212121 
Cell parameters: a, b, c 
(Å) 
87.4, 96.7, 101.4, 
β = 108.2 
99.7, 113.7, 126.0 
Resolution range (Å) 48.8 – 1.45 (1.47 – 1.45) 29.4 – 1.8 (1.9 – 1.8) 
Completeness (%) 98.5 (92.3) 99.1 (99.2) 
Redundancy 3.24 (2.33) 4.40 (4.46) 
Rsym a 4.2 (43.3) 7.1 (47.3) 
I / σI 17.0 (2.7) 15.6 (4.0) 
Refinement   
Resolution (Å) 1.45 1.8 
N° unique reflections 278534 131659 
N° free reflections 6964 2634 
Rwork b / Rfree c 13.5 / 15.3 15.5 / 18.0 
N° of atoms   
 Protein 10836 10639 
 Ligand / ions 83 44 
 Water 1741 1124 
B-factors   
 Protein 18.58 21.54 
 Ligand / ions 30.61 37.60 
 Water 31.06 31.79 
R.m.s deviations   
 Bond lengths (Å) 0.011 0.009 
 Bond angles (°) 1.445 1.138 
Ramachandran   
 Most favored (%) 1375 (96.6%) 1348 (96.9%) 
 Generously allowed (%) 44 (3.1%) 39 (2.8%) 
 Disallowed (%) 4 (0.3%) 4 (0.3%) 
Values in parentheses represent data for the highest resolution shell. One crystal was used for 
each dataset. a Rsym = ∑ |Ii -<I>| / ∑ <I> where I is the measured intensity of each reflection 
and <I> is the intensity from multiple observations of symmetry-related reflections. b R-factor 
= ∑ |Fobs| - |Fcalc| / ∑ |Fobs| where Fobs and Fcalc are the observed and the calculated structure 
factor amplitudes, respectively. c Rfree is the R-factor calculated with reflections chosen at 
random and omitted from refinement. 
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Table 2: Mutations in BapA and their impact on precursor cleavage and substrate hydrolysis 
Residue Point mutation Precursor cleavage Enzymatic activity Residue essential for 
  (autoproteolysis) (catalysis) autoproteolysis catalysis 
 wt complete 100% a   
Glu133 E133A slow inactive a,b no yes 
Lys248 K248A slow 100% a no no 
Asn249 N249A slow 100% a no no 
Ser250 S250A no cleavage inactive b yes yes 
Ser288 S288A no cleavage <1% b yes yes 
Glu290 E290A no cleavage 24% b yes yes 
a
 The activities of the purified enzymes were measured after 192h of incubation under standard assay conditions (see Methods section) and related 
to the activity of native BapA (100%) treated under the same conditions. b Due to the reduced or absent autoprocessing, the activities of the mutants 
E133A, S250A, S288A and E290A were measured from cell-free extracts containing the respective recombinantly expressed BapA Duet variants 
and related to the activity of cell-free extract containing native BapA Duet (100%). 
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Table 3: Kinetic analyses of the conversion of different β3-homoamino-acid p-nitroanilides by the purified β-aminopeptidases BapA, DmpA 
and DmpA W137A 
Substrate BapA DmpA DmpA (W137A) b 
 
KM 
[mM] 
Vmax 
[µmol 
*min-1mg-1] 
Kcat/KM 
[M-1s-1] 
KM 
[mM] 
Vmax 
[µmol 
*min-1mg-1] 
Kcat/KM 
[M-1s-1] 
KM 
[mM] 
Vmax 
[µmol 
*min-1mg-1] 
Kcat/KM 
[M-1s-1] 
H-βhGly-pNA 6.6 ±2.3 0.65 ±0.15 64 ±37 0.016 
±0.001 
55.8 ±0.8 2,400,000 
±200,000 
2.9 ±0.2 20.1 ±0.5 4600  
±400 
H-β3hAla-pNA 1.1 ±0.2 16.4 ±0.9 9600  
±1800 
0.063 
±0.002 
109 ±1 1,200,000 
±100,000 
0.50 ±0.02 40.0 ±0.3 53,800 
±2,100 
H-D-β3hAla-pNA   < 10 a 17.0 
±2.7 
1.3 ±0.2 52 ±15 0.38 ±0.13 0.017 
±0.002 
30  
±13 
H-β3hPhe-pNA 3.5 ±1.3 79.3 ±14.5 14,500 
±7,800 
  <10 a 0.85 ±0.09 3.5 ±0.1 2,800 
±400 
H-D-β3hPhe-pNA   940 ±3 a   < 10 a 2.7 ±0.4 26.7 ±2.0 6,700 
±1600 
a
 The enzyme activities measured at pH 7.2 and 37°C showed a linear dependency on the substrate concentration between 0.1 and 5 mM. The 
kcat/KM values were calculated according to the equation kcat/KM = v/[Eo]*[S]), where v is the rate of the reaction, [S] the concentration of the 
substrate and [Eo] the stoichiometric concentration of active centers (MBapA: 38,610, MDmpA: 40,440, MDmpA W137A: 40,330). b For the calculation of 
the kinetic parameters, only the processed enzyme fraction in the protein solution was taken into account.
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Figure 1C 
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Figure 2A 
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Figure 3 
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Figure 4A 
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Figure 5 
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SUPPLEMENTAL INFORMATION 
 
The supplemental information includes one figure showing the alternative catalytic 
mechanism (Figure S1) and sequences of primers for cloning and site-directed mutagenesis. 
 
SUPPLEMENTARY FIGURE 
Figure S1 
 
Figure S1: Schematic drawing of the alternative catalytic substrate-cleavage mechanism 
Michaelis complex: Formation of a salt bridge between Glu133 and the substrate`s amino 
terminus. Activation of Ser250-Oγ by Glu133 and the catalytic water molecule, and initiation 
of the nucleophilic attack on the carbonyl group of the substrate. Step 1: Stabilization of the 
oxyanion by the backbone amide group of Leu135 and the δNH2-group of Asn207. Substrate 
cleavage and formation of the acyl enzyme through proton transfers within the tetrahedral 
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intermediate. Step 2: Activation of the catalytic water molecule by Glu290 and initiation of 
the acyl-enzyme hydrolysis; Ser288 and the amino group of Ser250 enable the proton transfer. 
Step 3: Indirect protonation of the amino group of Ser250 by Glu290 and Ser288 and rupture 
of the tetrahedral intermediate through subsequent proton and electron transfer reactions. Step 
4: Release of the cleaved product and reconstitution of the active-site residues for another 
catalytic cycle. 
Solid arrows denote electron-pair shifts, dashed arrows denote catalytic influence; hydrogen 
bonds are indicated by dotted lines. R249 = Asn249, R251 = Leu251, R = N-terminal amino-
acid residue of the substrate, Rx = side chain of the N-terminal amino acid, Ry = C-terminal 
substrate moiety. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Sequences of primers for cloning and site-directed mutagenesis were as follows: 
bapA α-chain: fwd 5`-GGAATTCCATGGGGCCGCGCGCTCGCGATCT-3`, 
bapA α-chain: rev 5`-GGAATTGGATCCTAATTCTTGTCCTGCGGCTTGCCT-3`, 
bapA β-chain: fwd 5`-GGAATTCCCATATGTCGCTGCTGATCGTGATCGCT-3` 
bapA β-chain: rev 5`-GGAATTCTCGAGTCACCGGCGCGGAAACCGCGCCT-3` 
 
The designated point mutants were generated by site-directed mutagenesis using the 
QuikChange multi-site-directed mutagenesis kit (Stratagene, La Jolla, USA) with the 
following primers: 
BapA S250A: 5`-CCGCAGGACAAGAATGCGCTGCTGATCGTG-3` 
BapA S250C: 5`-CCGCAGGACAAGAATTGCCTGCTGATCGTG-3` 
BapA E133A: 5`-CCGGTGGTCGCCGCAACGCTCGACAAC-3` 
BapA N249A: 5`-CAAGCCGCAGGACAAGGCTTCGCTGCTGATCGTG-3` 
BapA S288A: 5`-GCGGGGGCGCTTGCGGGTGAGTTCGCG-3` 
BapA E290A: 5`-GCGCTTTCGGGTGCGTTCGCGCTCGCC-3` 
BapA Duet S250A: 5`-GGAGATATACATATGGCGCTGCTGATCGTG-3` 
BapA Duet S250C: 5`-GAAGGAGATATACATATGTGCCTGCTGATCGTGATC-3` 
BapA Duet E133A: 5`-CCGGTGGTCGCCGCAACGCTCGACAAC-3` 
BapA Duet S288A: 5`-GCGGGGGCGCTTGCGGGTGAGTTCGCG-3` 
BapA Duet E290A: 5`-GCGCTTTCGGGTGCGTTCGCGCTCGCC-3` 
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HIGHLIGHTS 
• The β-aminopeptidase BapA is an Ntn hydrolase with β-lactam binding properties 
• Ampicillin and ampicillin-derived penicilloic acid are competitive inhibitors of BapA 
• Salt bridge formation to BapA Glu133 is essential for ligand binding and positioning  
• Conformational flexibility of β-peptides is required for substrate conversion by BapA 
 
RUNNING TITLE 
Crystal structures of BapA-inhibitor complexes 
 
SUMMARY 
β-Aminopeptidases have exclusive biocatalytic potential because they react with peptides 
comprised of β-amino acids that serve as building blocks for the design of non-natural 
peptidomimetics. In the present study, we identified the β-lactam antibiotic ampicillin and the 
ampicillin-derived penicilloic acid as novel inhibitors of the β-aminopeptidase BapA from 
Sphingosinicella xenopeptidilytica (Ki values of 0.69 and 0.74 mM, respectively). We report 
crystal structures of BapA in non-covalent complexes with these inhibitors, and with the 
serine-protease inhibitor AEBSF. All three inhibitors showed similar binding characteristics: 
The aromatic part of the molecule extended into a hydrophobic binding pocket of the active 
site and the free amino group formed a crucial salt bridge with Glu133 of BapA. The exact 
position of the inhibitors and structural details of the ligand-binding pocket illustrate the 
substrate specificity and the enantioselectivity of BapA-catalyzed reactions. 
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INTRODUCTION 
The incorporation of backbone-elongated β-amino acids with proteinogenic side chains 
(Seebach et al., 2004) (Figure 1) gives peptides that may form unique secondary structures 
and that are resistant to degradation by most proteolytic enzymes (Frackenpohl et al., 2001; 
Wiegand et al., 2002). These properties give rise to interesting new biomedical applications 
for β-peptides as bioactive α-peptide mimetics (Aguilar et al., 2007; Seebach and Gardiner, 
2008; Steer et al., 2002). To date, five sequence-related enzymes have been biochemically and 
functionally characterized; they posses the unusual property of cleaving N-terminal β-amino-
acid residues from linear β- and mixed β,α-peptides that are otherwise resistant to proteolytic 
breakdown (Fanuel et al., 1999; Fuchs et al., 2010; Geueke et al., 2005; Heck et al., 2006; 
Komeda and Asano, 2005). Due to their common catalytic activity these β-peptide-converting 
catalysts are referred to as β-aminopeptidases (Geueke and Kohler, 2007). The growing 
demand for β-amino-acid-based building blocks (Liljeblad and Kanerva, 2006) has led to the 
development of biocatalytic applications for β-aminopeptidases, such as the preparation of 
enantiopure β-amino acids and the synthesis of β- and mixed β,α-peptides (Heck et al., 2007; 
Heck et al., 2010a; Heck et al., 2010b; Heck et al., 2009).  
 
Alignment searches revealed many sequences from bacterial and eukaryotic genomes that 
have similarity with the known β-aminopeptidases (Geueke and Kohler, 2007). Within these 
sequences, the catalytically relevant amino acids are highly conserved, indicating that the 
ability to process β-peptides is not restricted to the few described β-aminopeptidases (Merz et 
al., this issue). The large abundance of β-aminopeptidase-like sequences suggests that these 
enzymes have important cellular functions that are as yet unknown. Although peptides solely 
composed of linear β-amino-acid residues do not occur in nature, many β-amino acids are 
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constituents of a wide variety of different, often highly bioactive substances, such as 
microcystins (Dawson, 1998; Luukkainen et al., 1993), taxol (Juaristi, 2005), bestatin (Suda et 
al., 1976; Umezawa et al., 1976), and L-carnosine (Bauer, 2005; Guiotto et al., 2005). β-
Aminopeptidases may participate in the breakdown of such β-amino-acid-containing 
compounds to make them available for further metabolic conversions.  
 
Antibiotics of the penicillin family constitute one particular group among the plethora of 
natural compounds that contain β-amino-acid substructures. They are of special interest for β-
peptide research, because their characteristic β-lactam rings are cyclic derivatives of α,β-
diamino-acid moieties (Figure 2). However, note that the antibiotic ampicillin, in addition to 
the β-lactam-containing core structure 6-aminopenicillanic acid (6-APA), also consists of the 
α-amino acid phenylglycine and may hence be viewed as a dipeptide with an N-terminal α-
amino acid. The degradation of β-lactam-derived compounds is mainly catalyzed by two 
different classes of enzymes, namely by β-lactamases (EC 3.5.2.6) and by penicillin acylases 
(EC 3.5.1.11). β-Lactamases hydrolyze the amide bond of the β-lactam ring to a linear α,β-
diamino-acid derivative (penicilloic acid) (Deshpande et al., 2004; Matagne et al., 1999). 
Penicilloic acids are usually antimicrobially inactive, but interestingly they act as competitive 
inhibitors of the β-lactamase-catalyzed reaction (Kiener and Waley, 1978). Several hundred 
β-lactamase variants, which are grouped into four different classes, have been described in the 
last decades (Bush and Jacoby, 2010; http://www.lahey.org/studies). Their genes are easily 
transferred between bacteria by horizontal gene transfer, causing the dissemination of 
resistance (Barlow, 2009). The second class of β-lactam-converting enzymes comprises 
penicillin acylases, which hydrolyze the amide bond of β-lactam antibiotics that links the β-
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lactam core to a specific side chain (Chandel et al., 2008). Penicillin acylases are 
commercially important for the industrial chemo-enzymatic production of the β-lactam 
precursor 6-APA and of semisynthetic β-lactam antibiotics (Arroyo et al., 2003). 
 
Although penicillin acylases and β-aminopeptidases do not share high sequence similarity, 
both enzyme classes possess structural and catalytic features of the N-terminal-hydrolase 
(Ntn) superfamily (Oinonen and Rouvinen, 2000). The Ntn hydrolases adopt a characteristic 
four-layered αββα-sandwich structure. One Ntn-hydrolase unit is formed by two polypeptide 
chains (α and β) that result from posttranslational autoproteolytic cleavage of an inactive 
precursor polypeptide (Artymiuk, 1995; Brannigan et al., 1995). Self-processing of the 
precursor is promoted by a conserved serine, cysteine or threonine residue, which thereupon 
becomes the catalytic N-terminal nucleophile of the newly formed β-polypeptide chain. 
Crystal structures of the β-aminopeptidases DmpA from Ochrobactrum anthropi LMG7991 
(PDB ID: 1b65) (Bompard-Gilles et al., 2000b), BapA from Sphingosinicella 
xenopeptidilytica 3-2W4 (PDB ID: 3n2w), and of an immature BapA precursor mutant (PDB 
ID: 3n5i) (Merz et al., this issue) revealed that these enzymes are distinct from most other Ntn 
hydrolases by the orientation and connectivity of the secondary-structure elements; it is hence 
assumed that the topological and functional properties of Ntn hydrolases and of β-
aminopeptidases result from convergent evolution of different evolutionary origins (Cheng 
and Grishin, 2005).  
 
Based on point mutations at the BapA active site, we have devised a mechanism of the BapA-
catalyzed reaction (Merz et al., this issue). Essential functions were assigned to the N-terminal 
catalytic nucleophile Ser250 that is activated by the dyad Ser288/Glu290, and to Glu133 that 
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forms a salt bridge with the N-terminal amino group of the peptide substrate. However, the 
molecular determinants of the unusual β-peptide specificity of β-aminopeptidases have not 
been investigated in detail, since all attempts to obtain crystal structures of β-aminopeptidase-
ligand complexes and to identify β-aminopeptidase-specific inhibitors have as yet been 
unsuccessful. In the present study, we report the inhibition of BapA by the β-lactam antibiotic 
ampicillin and by an ampicillin-derived hydrolysis product. Furthermore, we present crystal 
structures of non-covalent BapA complexes with these inhibitors and with the broad-spectrum 
serine-protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF, trade name: 
pefabloc SC), providing structural details of ligand binding and mechanistic details of β-
peptide transformations catalyzed by β-aminopeptidases. 
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RESULTS AND DISCUSSION 
Crystal structure of BapA in complex with AEBSF 
Biochemical studies with the β-aminopeptidase BapA demonstrated the inhibition of the 
enzyme in the presence of high concentrations of the broad-spectrum serine-protease inhibitor 
AEBSF (Geueke et al., 2006). We determined the crystal structure of a non-covalent BapA-
AEBSF complex (BapA-AEBSF) at 1.8 Å resolution; crystallographic data are summarized in 
Table 1. One molecule of AEBSF was found in each of the four active sites at the interface of 
three adjacent subunits of the BapA (αβ)4-heterooctamer. The amino group of AEBSF formed 
a salt bridge with the carboxyl group of Glu133 and a hydrogen bond to a catalytically 
relevant water molecule (see Merz et al., this issue). Thr76, Thr100, Leu135, and Leu287 (e.g. 
subunit A) together with residues of the two neighboring αβ-subunits (e.g. subunit C: Thr316; 
subunit D: Leu84, Val88, Gln90, Leu92, Phe124, Ser125, Leu127, Leu128, and Leu303) 
constituted a hydrophobic pocket that supported ligand binding by van der Waals interactions 
(Figure 3). The aromatic ring of Phe124, which showed very weak electron density in the 
native structure of BapA (Merz et al., this issue), was well defined through a pi-stacking 
interaction with the aromatic ring of AEBSF. In contrast to the proposed irreversible 
inhibition mechanism of AEBSF, which proceeds by formation of a covalent bond between a 
catalytically active nucleophile and the sulfonyl group of the inhibitor (Powers et al., 2002), 
the structure of the BapA-AEBSF complex showed binding of the inhibitor in a non-covalent 
manner. While the fluoro-sulfonyl terminus pointed away from the catalytic nucleophile 
Ser250-Oγ into the hydrophobic binding pocket, the amino group of AEBSF formed a salt 
bridge to Glu133. 
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Inhibition of the BapA by penicillin-derived β-lactam antibiotics 
To investigate β-aminopeptidase-catalyzed biotransformations of cyclic β-amino acids and β-
lactams, we examined the potential of the β-aminopeptidases BapA and DmpA to process the 
penicillin derivatives ampicillin, penicillin G and carbenicillin. These compounds contain a β-
lactam ring as part of their common 6-APA core structure (Figure 2) and differ by their D-
phenylglycyl, phenylacetyl and D-phenylmalonyl acyl groups, respectively. With neither 
enzyme we observed deacylation or hydrolysis of the β-lactam amide bond, demonstrating 
that both BapA and DmpA lack penicillin-acylase and β-lactamase activity with the tested 
lactams. 
 
Furthermore, we tested the inhibitory effect of the three β-lactam antibiotics and of the 
ampicillin-derived penicilloic acid Amphyd (Figure 2) on the BapA- and DmpA-catalyzed 
conversion of the chromogenic reporter substrate H-β3hAla-pNA. Despite the structural 
similarity of ampicillin, penicillin G and carbenicillin with respect to their 6-APA core 
structure, only ampicillin inhibited substrate conversion by BapA with a Ki value of 0.69 mM 
(Table 2). Ampicillin differs from penicillin G and carbenicillin by the presence of an α-
amino group in its D-phenylglycyl moiety (Figure 2). With the penicilloic acid Amphyd a Ki 
value of 0.74 mM was observed; thus, the structural change associated with the conversion of 
ampicillin to Amphyd, i.e. hydrolytic opening of the β-lactam ring, did not affect the inhibitory 
effect on substrate conversion by BapA. In contrast to BapA, DmpA was not significantly 
inhibited by any of the three β-lactam derivatives or by the hydrolyzed species Amphyd. 
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Crystal structures of BapA in complex with ampicillin and Amphyd 
Crystal structures of BapA in non-covalent complex with ampicillin (BapA-Amp) and with 
the (5S)-epimer of enzymatically produced Amphyd (BapA-Amphyd) at 1.7 Å and 1.85 Å 
resolution, respectively, were obtained by soaking BapA crystals with the respective 
compounds; crystallographic data are summarized in Table 1. Both ligands interacted with 
the active site of the enzyme in a similar manner, forming a dense hydrogen-bonding network. 
The α-amino group of the D-phenylglycyl moiety of ampicillin formed a salt bridge with 
Glu133 and a hydrogen bond with the catalytically active water molecule (Figure 4A). As 
observed for the aromatic ring of AEBSF in the structure of the BapA-AEBSF complex, the 
phenyl ring of ampicillin extended into the hydrophobic pocket of the BapA active site (cf. 
Figure 3 and Figure 4). The backbone nitrogen of Leu135 and the carbonyl oxygen of 
Leu287 formed hydrogen bonds with the amide bond that links the acyl group to the 6-APA 
core of ampicillin. Furthermore, the carboxyl group attached to the thiazolidine ring formed a 
salt bridge with the side chain of Arg138. In the case of Amphyd, the main interactions 
between the D-phenylglycyl acyl group and the active site of BapA were similar to those 
observed for binding of ampicillin (cf. Figure 4A and 4B). Because of the missing β-lactam 
substructure, the core of Amphyd is more relaxed than that of ampicillin and the position of the 
thiazolidine is less rigid. Due to this structural difference, the interaction of the carboxyl 
group attached to the thiazolidine ring with Arg138 was not present in the BapA-Amphyd 
complex. Instead, the additional carboxyl group of Amphyd was in close proximity of Asn207-
NH2 and the amino terminus of Ser250, compensating for the missing salt bridge with 
Arg138. 
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Models of tetrahedral BapA-substrate complexes  
Based on structural similarities of the N-terminal moiety of Amphyd to a linear α-peptide, we 
modeled β3-homophenylalanine residues of L- and D-configuration onto the backbone of the 
ligand in the BapA-Amphyd complex. For model building, we positioned the carbonyl group of 
the substrate into appropriate distance (1.6 Å) and trajectory (105 ± 5°) (Bürgi and Dunitz, 
1983; Bürgi et al., 1974) for nucleophilic attack by Ser250-Oγ, and aimed for the best possible 
match of the β3-homophenylalanine residues on the electron density of Amphyd. Tetrahedral 
reaction intermediates were formed by the addition of Ser250-Oγ to the β3-
homophenylalanine residues. Rotation around the Cα-Cβ bond of the β-amino-acid backbone 
gives rise to two synclinal conformers ((+)-sc and (-)-sc) and an antiperiplanar conformer (ap) 
for a β-amino-acid residue (Seebach et al., 2004). It turned out that the (+)-sc conformer of L-
β3-homophenylalanine and the (-)-sc conformer of D-β3-homophenylalanine represents the 
only energetically favorable conformation of the respective compound that met the steric 
demands for successful formation of a tetrahedral enzyme-substrate intermediate (Figure 5A 
and Figure S1). Complex formation with the other conformers ((-)-sc and ap of L-β3-
homophenylalanine, (+)-sc and ap of D-β3-homophenylalanine) could be excluded due to 
massive steric repulsions between the side chain of the β-amino-acid residue and residues of 
the BapA active site (Table 3 and Figure S1). In the favored conformations, the hydrophobic 
side chains and the amino groups of the covalently bound L- and D-β3-homophenylalanine 
residues matched well with the positions of the ligands in the BapA-AEBSF, BapA-Amphyd, 
and BapA-Amp complexes (Figure 5A and 5B). The proximity of Asn207-NH2 and Leu135-
NH to the oxyanion of the modeled tetrahedral intermediates suggested that these residues 
stabilize the negatively charged tetrahedral intermediate during the catalytic reaction (for 
mechanistic details see Merz et al., this issue).  
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Implications of ligand binding for β-peptide conversions by BapA and DmpA  
The structures of the BapA-inhibitor complexes showed a good overlap of the amino group 
and the aromatic ring of AEBSF with the positions of the phenylglycine acyl groups of 
ampicillin and Amphyd (Figure 5). In combination with previous information on the substrate 
specificity of BapA for N-terminally unprotected β-peptides (Geueke et al., 2006; Heck et al., 
2006) and results obtained from a mutational analysis of BapA (Merz et al., this issue), the 
crystal structures of the BapA-ligand complexes (Figure 3 and Figure 4) and the inhibition of 
BapA by ampicillin-derived compounds (Table 2) provide strong evidence that the presence 
of a free amino group plays a key role for ligand recognition and binding by BapA. Due to 
their amino groups attached to aromatic rings through one or two CH2-groups, the β-lactam-
derived ligands (ampicillin and Amphyd) and AEBSF have structural similarity to β3-
homophenylglycine and β3-homophenylalanine residues, respectively (cf. Figure 2 and 
Figure 1). Therefore, the formation of non-covalent complexes between BapA and these 
ligands suggests that the binding of β-peptidic substrates is promoted by similar interactions 
within the BapA active site, i.e. (i) salt-bridge formation between Glu133 and the amino 
group of the substrate’s N-terminal β-amino-acid residue, and (ii) hydrophobic interactions 
between the ligand-binding pocket of BapA and the side chain of the substrate.  
 
Based on the models of the tetrahedral BapA-substrate intermediates (Figure 5A), we argue 
that the exclusive specificity of the enzyme for peptides with backbone-elongated N-terminal 
β-amino-acid residues is governed by the molecular geometry of the active site, in particular 
by the orientations and distances of the substrates’ functional groups to Glu133 and to Ser250-
Oγ. Our results show that compounds, such as ampicillin and Amphyd, mimicking the N-
termini of conventional α-peptides bind to the active site of BapA, but are not converted. 
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Hence, it seems that the lack of α-aminopeptidase activity of BapA is caused by the “rigidity” 
of the α-amino-acid backbone and by an insufficient distance between the functional groups 
(NH2 and CO); these limitations prevent appropriate positioning of the carbonyl group for 
nucleophilic attack under the restrictions given by the BapA active site. The extended 
backbone of β-amino-acid residues confers a degree of rotational flexibility around the Cα-Cβ 
bond, which is not present in α-amino-acid residues; due to the increase in backbone length 
and the additional degree of rotational freedom, a β-amino-acid residue is able to adopt a 
stable conformation allowing for nucleophilic attack by Ser250-Oγ, while maintaining the salt 
bridge to Glu133 as well as the stabilization of the tetrahedral intermediate by the 
Leu135/Asn207 oxyanion hole.  
 
In contrast to BapA, which exclusively cleaves peptides carrying N-terminal β-amino acids 
with aliphatic, aromatic or functionalized side chains, DmpA preferentially reacts with 
substrates carrying unsubstituted or sterically undemanding N-terminal β-amino acids (e.g. β-
homoglycine and β3-homoalanine), but also α-amino acids (Fanuel et al., 1999; Geueke et al., 
2006; Heck et al., 2006; Heck et al., 2010b). The superposition of DmpA on the modeled 
BapA-substrate intermediate perfectly illustrates this steric restriction of the DmpA active site 
(Figure 5B). While BapA has a rather open ligand-binding pocket, the active site of DmpA is 
largely occluded by a loop ranging from Gln131 to Trp137; in particular, the side chain of 
Trp137 protrudes far towards the catalytic nucleophile Ser250 and could hence (i) force 
substrates with N-terminal α-amino acids into a position that allows for nucleophilic attack of 
Ser250-Oγ, and (ii) restrict catalysis by DmpA to substrates with sterically undemanding side 
chains. In fact, the preference of DmpA to process substrates with small N-terminal β-amino 
acids could be changed towards substrates with larger side chains by the single amino-acid 
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mutation of Trp137 to alanine (Merz et al., this issue). Furthermore, we hypothesize that the 
bulky side chain of Trp137 also prevents the inhibition of DmpA by ampicillin or Amphyd, 
because both carry aromatic rings as part of their phenylglycyl moieties that are prone to clash 
with the side chain of Trp137 (Figure 5B). 
 
 
Enantioselectivity of the BapA-catalyzed reactions 
The BapA-catalyzed kinetic resolution of racemic β3-amino-acid amides with different 
aliphatic side chains has recently been demonstrated to proceed with high L-enantioselectivity 
(Heck et al., 2009). As shown in the models presented in Figure 5A, tetrahedral reaction 
intermediates could be formed between Ser250-Oγ of BapA and β3-amino-acid residues of 
both L- and D-configuration. Our models indicate that the distance between Glu133-COO- and 
the substrate’s amino terminus is larger for the complex with the (-)-sc conformation than for 
the one with the (+)-sc conformation of the substrate molecules, indicating a negative effect 
on the strength of the salt bridge for the former complex. Therefore, we propose that in the 
active site of BapA the (+)-sc conformation of an L-β3-amino-acid residue is energetically 
favored over the (-)-sc conformation of a D-β3-amino-acid residue. The enantiomeric excess 
of the L-β3-amino-acid product formed by the BapA-catalyzed kinetic resolution of racemic 
β3-amino-acid amides also depends on the size of the substrate’s side chain; substrates with 
small aliphatic substituents are more efficiently resolved by BapA than substrates with 
sterically demanding side chains (Heck et al., 2009). We propose that the correlation between 
decrease of enantioselectivity and increase of side-chain size of the N-terminal β-amino-acid 
residue is due to additional non-polar interactions of the hydrophobic ligand-binding pocket 
with large side chains of the substrate. Such hydrophobic effects will improve the stability of 
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complexes formed between BapA and large D-β3-amino-acid residues of the (-)-sc 
conformation and partially compensate for a weak salt bridge to Glu133. 
 
Besides its high catalytic activity with substrates composed of L-β3-amino acids, BapA slowly 
processes a diastereomeric mixture of the β2-dipeptide H-β2hPhe-β2hAla-OH with high D-
enantioselectivity (Heck et al., 2010b). In order to elucidate the structural details of this 
enantioselective reaction, we modeled the reaction intermediates formed by the nucleophilic 
addition of BapA Ser250-Oγ to the carbonyl group of the (+)-sc conformers of D- and L-β2-
homophenylalanine residues (Figure S2). Due to the previously mentioned flexibility of the 
Phe124 side chain, the tetrahedral reaction intermediate of D-β2-homophenylalanine could be 
placed in the active site of BapA. In contrast, reasonable placing of the tetrahedral reaction 
intermediate of the corresponding L-enantiomer was not possible because of a steric conflict 
between Cγ of the substrate’s side chain and Thr76 of BapA. This fully explains the high 
enantioselectivity towards these substrates. 
 
β2-Dipeptides with small and therefore less demanding side chains at the N-terminal amino-
acid residue are not converted by BapA, irrespective of their configuration(Heck et al., 
2010b). As suggested for the conversion of substrates carrying N-terminal D-β3-amino-acid 
residues with side chains of different sizes, the preference of BapA for bulky β2-amino-acid 
residues likewise can be explained by the stabilization of the enzyme-substrate complex by 
increased hydrophobic interactions between large amino-acid side chains and the ligand-
binding pocket. 
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Physiological significance of ampicillin binding and β-peptide conversion by BapA and 
other β-aminopeptidases 
The position and the orientation of ampicillin in the crystal structure of the BapA-Amp 
complex (Figure 4) explain why BapA exhibits neither penicillin-acylase nor β-lactamase 
activity. Most importantly, the observed distance of Ser250-Oγ to the carbonyl-carbon atom of 
the phenylglycyl moieties (2.6 Å) or to the one of the β-lactam ring (4.3 to 4.6 Å) was too 
large to allow a nucleophilic attack. Moreover, the observed angle between Ser250-Oγ and the 
carbonyl plane of the phenylglycyl acyl group (84.9 to 88.5°) and the one between Ser250-Oγ 
and the carbonyl plane of the β-lactam (81.4 to 83.5°) was not in accordance with the required 
trajectory of 105 ± 5°, at which nucleophilic attack of a carbonyl carbon may occur (Bürgi 
and Dunitz, 1983; Bürgi et al., 1974). Based on these structural and biochemical observations, 
we have rationalized why BapA is an ampicillin-binding, but not an ampicillin-converting 
enzyme. Although the present study outlines the structural determinants of the exclusive β-
peptide specificity of BapA, the natural substrates of this enzyme and of other β-
aminopeptidases as well as the physiological significance of ampicillin recognition and 
inhibition are as yet unknown and remain to be unraveled. The D-aminopeptidase (DAP) from 
O. anthropi, another well-studied example of an aminopeptidase with an unusual substrate 
specificity that is inhibited by ampicillin and other β-lactam-derived compounds (Asano et al., 
1992), exhibits sequence and structural similarities to β-lactamases and D,D-
carboxypeptidases, and was classified as a new member of the penicillin-recognizing enzyme 
family (Bompard-Gilles et al., 2000a). DAP could be converted to an enzyme with D,D-
carboxypeptidase activity and new penicillin-binding properties by directed mutagenesis 
(Delmarcelle et al., 2005). Although there are no obvious sequence similarities between BapA 
and β-lactam-converting or -binding enzymes, future investigations will need to address the 
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catalytic potential of the many uncharacterized proteins that were retrieved from sequencing 
projects and that are similar to the characterized β-aminopeptidases (Merz et al., this issue) 
towards transformations of β-lactams.  
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EXPERIMENTAL PROCEDURES 
General remarks  
AEBSF and the β-lactam antibiotics ampicillin, penicillin G, and carbenicillin were purchased 
from Sigma-Aldrich (Buchs, Switzerland). H-β3hAla-pNA was prepared chemically following 
a published procedure (Heck et al., 2006). The enzymatic conversions of the β-lactams were 
followed by HPLC analysis on a Dionex HPLC system equipped with a P680 pump, an ASI-
100 automated sample injector, an UltiMate 3000 thermostatted column compartment, and a 
UVD 340U photodiode array detector (Dionex, Sunnyvale, CA, USA). Samples (10 µl) were 
analyzed on a reversed-phase HPLC stationary phase Nucleodur C18-Pyramid (250 × 4 µm, 5 
µm particle size; Macherey-Nagel, Düren, Germany) that was equilibrated with 0.1% formic 
acid in water for 3 min at a column temperature of 20°C. The compounds were separated with 
a linear gradient of 0 to 60% acetonitrile within 15 min at a constant flow rate of 1 ml/min and 
detected at a wavelength of 205 nm. Mass spectra of all compounds were recorded with an 
API 4000 liquid chromatography/tandem MS system connected to an Agilent 1100 LC 
system. For protein determination, we used five-fold concentrated Bradford reagent (Bio-Rad, 
Rheinach, Switzerland) and bovine serum albumin (BSA) as a standard; absorbance 
measurements were performed at 595 nm with a Specord S 100 spectrophotometer (Analytik 
Jena, Jena, Germany). Proteins were analyzed by SDS-PAGE using pre-cast 10% Novex 
tricine gels (Invitrogen AG, Basel, Switzerland) according to the manufacturer’s instructions. 
The protein gels were stained with Coomassie Brillant Blue and the purities of the enzymes 
were estimated by calculating the relative intensities of the protein bands with a GS-800 
calibrated imaging densitometer and the software Quantity One (Bio-Rad, Rheinach, 
Switzerland). 
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Enzymatic production of Amphyd  
Amphyd was produced from ampicillin by enzymatic conversion with the β-lactamase that was 
encoded on the pET3c plasmid (Novagen, Madison, WI, USA), constitutively expressed in E. 
coli BL21(DE3) pLysS and partially purified by anion-exchange and hydrophobic-interaction 
chromatography. Ampicillin (50 mg) was dissolved in H2O (5.2 ml) and the enzymatic 
reaction was started by the addition of the β-lactamase-containing solution to yield a final 
protein concentration of 15 µg/ml. After 16 h of incubation at 30°C, the enzymatic reaction 
was stopped by removing all proteins > 10 kDa by centrifugation with Centricon YM-10 
centrifugal devices (10 kDa MWCO; Millipore Corp., Billerica, CA, USA). The formation of 
Amphyd was verified by HPLC-MS analysis (tR = 10.3 min, [M + H]+: 368.0 (calcd. M: 367.1), 
purity after peak integration > 90%). NMR analysis showed that the primary reaction product 
(5R)-Amphyd undergoes epimerization in aqueous solution at C-5 to form (5S)-Amphyd (see 
Supplemental Information available online). The solution containing Amphyd was frozen to -
80°C and freeze-dried. 
 
 
Expression and purification of BapA for protein crystallization 
The β-aminopeptidases BapA from S. xenopeptidilytica 3-2W4 was expressed without its N-
terminal 29-amino-acid signal sequence in a pET3c-expression system, purified from the E. 
coli host (Geueke et al., 2006) and crystallized (Merz et al., this issue). BapA crystals were 
soaked for 5 min in a solution of 1.5 M ammonium sulfate, 100 mM HEPES (pH 7.5) 
containing 50 mM freshly dissolved AEBSF and for 30 min in 1.5 M ammonium sulfate, 100 
mM HEPES (pH 7.5) containing saturating concentrations of ampicillin or Amphyd. After 
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cryo-protection in a solution containing 1.5 M ammonium sulfate, 100 mM HEPES (pH 7.5) 
and 30% glycerol, the crystals were flash-frozen in liquid nitrogen. 
 
 
Structure determination 
Data were collected at the Swiss Light Source beamline PX on a 6M Pilatus detector in a 
cryostream at 100 K at 1 Å wavelength. Diffraction data on a total of 720 frames were 
recorded with an oscillation range of 0.5° per frame. The data was processed with the program 
XDS (Kabsch, 1993). Initial phases were obtained by molecular replacement using the 
program PHASER (McCoy et al., 2007) and the structure of BapA (PDB ID: 3n2w) as search 
model. The asymmetric units each contained one molecule of the active BapA (αβ)4-
heterooctamer. The final model of BapA-AEBSF contained residues 1-245 / 250-371 for 
chain A, 1-245 / 250-317 for chain B, 1-245 / 250-371 for chain C, and 1-245 / 250-371 for 
chain D. The final model of BapA-Amp contained residues 1-245 / 250-371 for chain A, 1-
243 / 250-317 for chain B, 1-244 / 250-371 for chain C, and 1-245 / 250-371 for chain D. The 
final model of BapA-Amphyd contained residues 1-245 / 250-371 for chain A, 1-242 / 250-317 
for chain B, 1-244 / 250-371 for chain C, and 1-244 / 250-371 for chain D. The refinement of 
the structures was carried out with the program PHENIX (Adams et al., 2002). Model 
building and superpositions for figures were performed with the programs COOT (Emsley 
and Cowtan, 2004) and SSM (Krissinel and Henrick, 2004), respectively. Figures were 
created with the program Pymol (De Lano, 2002). 
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Expression of BapA and DmpA for enzymatic activity assays 
To exclude the possibility of β-lactamase cross-contamination from enzyme expression in a β-
lactamase-encoding pET3c expression system, the genes bapA from S. xenopeptidilytica 3-
2W4 and dmpA from O. anthropi LMG7991 were cloned into pET9c vectors yielding 
pAR116 and pAR114, respectively (Heck et al., 2006; Heck et al., 2010b). The enzymes were 
recombinantly expressed in E. coli BL21(DE3) pLysS and purified according to established 
procedures (Geueke et al., 2006; Heck et al., 2006). The lyophilized enzyme powders were 
dissolved in a 10 mM potassium-phosphate buffer at pH 7.2, and the protein contents of the 
enzyme stocks were determined spectrophotometrically.  
 
 
Penicillin-acylase and β-lactamase activity assay  
The reaction mixtures contained 1 mM of the β-lactam antibiotics ampicillin, penicillin G or 
carbenicillin in 100 mM potassium-phosphate buffer at pH 7.2 and 37°C. The enzymatic 
reactions were initiated by the addition of one of the enzymes BapA or DmpA. Samples were 
withdrawn at intervals over 24 h from the reaction mixtures and the enzymatic reactions were 
terminated by heating at 90°C for 3 min. The samples were analyzed by reversed-phase HPLC 
and HPLC-MS. 
 
 
Enzyme-inhibition assay 
The inhibitory effects of the β-lactam antibiotics ampicillin, penicillin G or carbenicillin and 
of the penicilloic acid Amphyd on the β-aminopeptidase-catalyzed conversion of the reporter 
substrate H-β3hAla-pNA were determined spectrophotometrically (Merz et al., this issue). The 
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assay mixtures contained the reporter substrate and the inhibitors in various molar ratios. 
Experimental data was fitted to the competitive inhibition model (Eq. 1) by non-linear 
regression analysis with the VisualEnzymics software (Softzymics, Princeton, NJ, USA) for 
the program IGOR Pro (WaveMetrics, Oswego, OR, USA). 
 
v =
Vmax ⋅ S[ ]
Km ⋅ (1+
I[ ]
K i
) + S[ ]
 (Eq. 1) 
 
 
 
PDB ACCESSION NUMBERS 
BapA in complex with AEBSF (BapA-AEBSF, PDB ID: 3n33); BapA in complex with 
ampicillin (BapA-Amp, PDB ID: 3ndv); BapA in complex with Amphyd (BapA-Amphyd, PDB 
ID: 3nfb). 
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FIGURE LEGENDS 
Figure 1: Similarities of L-α-amino acids and β-amino acids of corresponding 
configurations 
According to the nomenclature proposed by Seebach and coworkers β-amino acids with 
proteinogenic side chains (R) are referred to as β-homoamino acids (βhXaa residues) 
(Seebach et al., 2004). As with α-amino acids (Xaa residues), the notations H-β3hXaa-OH and 
H-β2hXaa-OH implicitly refer to the configurations of the stereocenters as shown in the 
formulae, i.e. L in the Fischer projection (strictly applied, the rules for this projection would 
lead to D-configuration only in the case of β2hAla). The CIP nomenclature (R/S-configuration) 
is not useful for amino acids in a biological context because it reverses, depending on the 
structures of the side chains. Thus, all Xaa residues have (S)-configuration, except for Cys and 
Sec; β3hXaa residues have (S)-configuration, except for Val, Ile, Ser, Thr, Cys, Sec, Met and 
Asp; β2hXaa residues have (R)-configuration, except for Ser and Thr. 
 
 
Figure 2: Chemical formulae of AEBSF and β-lactam-derived compounds 
Hydrolysis of the β-lactam amide bond of ampicillin by a β-lactamase leads to formation of 
the linear penicilloic acid (5R)-Amphyd, which subsequently undergoes epimerization at C-5 of 
the thiazolidine ring to form (5S)-Amphyd, the prevailing epimer in aqueous solution (as 
shown by NMR, see Supplemental Information available online). 6-APA is the common 
reaction product formed by the penicillin-acylase-catalyzed hydrolysis of penicillin-derived β-
lactam antibiotics. The β-amino-acid moieties of the compounds are highlighted in red. 
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Figure 3: Active site of BapA in complex with the serine-protease inhibitor AEBSF 
The essential catalytic residues of BapA (subunit A) and residues contributing to the 
hydrophobic ligand-binding pocket are shown as sticks in yellow and grey, respectively. The 
subunit localizations of the binding-pocket residues are indicated with subscript letters. 
AEBSF is depicted as sticks in light blue and the catalytically relevant water molecule is 
shown as a red sphere. The catalytic residues and AEBSF are contoured with a 2 Fofc 
electron-density map at 1.5 σ. Interactions between the amino group of AEBSF and the active 
site of BapA are indicated by dotted lines, distances are given in Å. 
 
 
Figure 4: Active site of BapA in complex with β-lactam-derived inhibitors 
(A) BapA in complex with ampicillin. 
(B) BapA in complex with the pencilloic acid Amphyd.  
The catalytic residues of BapA (subunit A) and selected residues of the ligand-binding 
pockets are shown as sticks in yellow and grey, respectively. The subunit localizations of the 
binding-pocket residues are indicated with subscript letters. Ampicillin and Amphyd are 
depicted as sticks in light blue and dark blue, respectively, contoured with a 2 Fofc electron-
density map at 1.5 σ. The catalytically relevant water molecule is shown as a red sphere. 
Interactions between the bound compounds and active-site residues of BapA are indicated by 
dotted lines, distances are given in Å. 
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Figure 5: Models of tetrahedral BapA-substrate intermediates 
(A) Tetrahedral reaction intermediates between Ser250-Oγ and β3-homophenylalanine 
residues of L-configuration ((+)-sc conformer; orange) and D-configuration ((-)-sc conformer; 
magenta). The models are based on the BapA-Amphyd crystal structure (grey); the ligand 
Amphyd is indicated as lines contoured with a 2 Fofc electron-density map at 1.5 σ. The 
catalytic residues of BapA are shown as yellow sticks and the catalytically relevant water 
molecule as a red sphere. The predicted salt bridge and hydrogen bonds of the oxyanion hole 
are indicated by dotted lines.  
(B) Superposition of the active sites of BapA-Amphyd (grey) on the crystal structure of DmpA 
(PDB ID: 1b65; dark red) shown in ribbon presentation. The catalytic residues Glu133, 
Ser250, Ser288 and Glu290 of BapA (yellow sticks) correspond to Glu144, Ser250, Ser288 
and Asp290 of DmpA (red sticks). The side chain of Trp137 of DmpA clashes with the BapA 
ligands AEBSF (light blue), Amphyd (dark blue), and the modeled BapA-L-β3-
homophenylalanine intermediate (orange; see A).  
Tetrahedral reaction intermediates between BapA Ser250-Oγ and the (+)-sc conformers of D- 
and L-β2-homophenylalanine residues are presented in Figure S2 (available online). 
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TABLE LEGENDS 
Table 1: Data collection and refinement statistics (molecular replacement) 
Values in parentheses represent data for the highest resolution shell. One crystal was used for 
each dataset. a Rsym = ∑ |Ii -<I>| / ∑ <I> where I is the measured intensity of each reflection 
and <I> is the intensity from multiple observations of symmetry-related reflections. b R-factor 
= ∑ |Fobs| - |Fcalc| / ∑ |Fobs| where Fobs and Fcalc are the observed and the calculated structure 
factor amplitudes, respectively. c Rfree is the R-factor calculated with reflections chosen at 
random and omitted from refinement. 
 
 
Table 2: Inhibition of the BapA by the β-lactam derivatives ampicillin and Amphyd 
The kinetic parameters Km, Vmax and Ki of the reactions were obtained after fitting initial 
velocities of the b-aminopeptidase-catalyzed conversion of the chromogenic substrate H-
β3hAla-pNA (pH 7.2, 37°C) (Heck et al., 2006) to a competitive inhibition model (Eq. 1, 
Experimental Procedures). Penicillin G and carbenicillin did not inhibit substrate conversion 
by BapA. 
 
 
Table 3: Survey of the conformers of BapA-substrate intermediates 
The tetrahedral reaction intermediates are formed through nucleophilic attack of Ser250-Oγ of 
BapA to β3-homophenylalanine residues of L- or D-configuration (see also Figure S1).  
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TABLES 
Table 1: Data collection and refinement statistics (molecular replacement) 
 BapA-AEBSF BapA-Amp BapA-Amphyd 
Data collection    
Space group P21 P21 P21 
Cell parameters: a, 
b, c (Å) 
87.4, 96.8, 101.3, 
β = 108.4° 
86.9, 96.4, 101.5, 
β = 108.4° 
88.3, 97.1, 102.2, 
β = 108.7° 
Resolution range 
(Å) 
48.0 – 1.8 (1.9 – 1.8) 48.8 – 1.7 (1.8 – 1.7) 49.3 – 1.85 (1.9 – 1.85) 
Completeness (%) 97.6 (94.7) 98.7 (94.4) 98.4 (99.2) 
Redundancy 3.78 (3.70) 3.32 (2.73) 3.78 (3.77) 
Rsym a 10.0 (49.7) 11.6 (58.1) 8.6 (45.5) 
I / σI 12.9 (3.1) 9.2 (2.2) 13.0 (4.0) 
Refinement    
Resolution (Å) 1.8 1.7 1.85 
N° unique 
reflections 
144691 172065 137077 
N° free reflections 1448 6884 1371 
Rwork b/ Rfree c 16.0 / 19.0 16.7 / 19.2 15.0 / 17.8 
N° of atoms    
 Protein 10708 10668 10680 
 Ligand / ions 238 168 194 
 Water 1265 1138 1229 
B-factors    
 Protein 19.61 18.81 19.58 
 Ligand/ion 27.85 25.61 26.17 
 Water 29.48 26.53 29.50 
R.m.s. deviations    
 Bond lengths (Å) 0.007 0.008 0.007 
 Bond angles (°) 1.05 1.104 1.05 
Ramachandran    
 Most favored 1391 (96.7%) 1385 (96.6) 1375 (96.4%) 
 Generously allowed 43 (3.0%) 44 (3.1%) 48 (3.3%) 
 Disallowed 4 (0.3%) 5 (0.3%) 4 (0.3%) 
Values in parentheses represent data for the highest resolution shell. One crystal was used for 
each dataset. a Rsym = ∑ |Ii -<I>| / ∑ <I> where I is the measured intensity of each reflection 
and <I> is the intensity from multiple observations of symmetry-related reflections. b R-factor 
= ∑ |Fobs| - |Fcalc| / ∑ |Fobs| where Fobs and Fcalc are the observed and the calculated structure 
factor amplitudes, respectively. c Rfree is the R-factor calculated with reflections chosen at 
random and omitted from refinement. 
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Table 2: Inhibition of the BapA by the β-lactam derivatives ampicillin and Amphyd 
Inhibitor Ki [mM] Km [mM] Vmax [µmol·min-1mg-1] 
Without - 1.1 ± 0.15 16.4 ± 0.86 
Ampicillin 0.69 ± 0.05 1.1 ± 0.09 16.3 ± 0.50 
Amphyd 0.74 ± 0.11 0.98 ± 0.16 16.8 ± 1.0 
 
The kinetic parameters Km, Vmax and Ki of the reactions were obtained after fitting initial 
velocities of the β-aminopeptidase-catalyzed conversion of the chromogenic substrate H-
β3hAla-pNA (pH 7.2, 37°C) (Heck et al., 2006) to a competitive inhibition model (Eq. 1, 
Experimental Procedures). Penicillin G and carbenicillin did not inhibit substrate conversion 
by BapA. 
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Table 3: Survey of the conformers of BapA-substrate intermediates 
Conformationa Color code in 
Figure S1 
Clashes between Cγ / 
Cδ and BapA residues  
Salt bridge to 
Glu133 
L-β3-Homophenyalanine residue 
(+)-sc 
 
Orange 
 
Cγ: - 
Cδ: - 
+ 
(-)-sc 
 
Magenta 
 
Cγ: - 
Cδ: Thr76, Gly289 
- 
ap 
  
Green Cγ: Leu135 
Cδ: Leu135, Thr100, 
Glu133 
- 
D-β3-Homophenyalanine residue 
(+)-sc 
 
Orange 
 
Cγ: Glu133 
Cδ: Glu133, Thr134, 
Leu135 
- 
(-)-sc 
 
Magenta 
 
Cγ: - 
Cδ: - 
+ 
ap 
 
Green Cγ: Thr76, Gly289 
Cδ: Thr76, Gly289 
- 
 
The tetrahedral reaction intermediates are formed through nucleophilic attack of Ser250-Oγ of 
BapA to β3-homophenylalanine residues of L- or D-configuration (see also Figure S1).  
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a
 Dotted lines represent non-covalent interactions. X indicates steric repulsions between the 
side chain of the substrate and residues of the BapA active site. Ry represents the C-terminal 
part of the substrate prior to formation of the acyl enzyme (see Merz et al., this issue). 
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FIGURES 
Figure 1 
 
 
 
 
Figure 2 
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Figure 3 
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Figure 4A 
 
 
 
Figure 4B 
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Figure 5A 
 
 
 
Figure 5B 
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SUPPLEMENTAL INFORMATION 
 
Supplemental Information includes two figures showing models of tetrahedral reaction 
intermediates of BapA Ser250-Oγ with β3-homophenylalanine residues (Figure S1) and β2-
homophenylalanine residues (Figure S2). The NMR analysis of the β-lactam derivatives used 
in this study is presented in the Supplemental Experimental Procedures. 
 
Supplemental Figures 
Figure S1: Models of tetrahedral reaction intermediates formed between BapA Ser250-
Oγ and the energetically favorable conformations of L- and D-β3-homophenylalanine 
residues, related to Table 3 
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Figure S1B 
 
Figure S1: Models of BapA-substrate intermediates 
(A) Tetrahedral reaction intermediates formed between BapA Ser250-Oγ and L-β3-
homophenylalanine. 
(B) Tetrahedral reaction intermediates formed between BapA Ser250-Oγ and D-β3-
homophenylalanine. 
The models are based on the crystal structure of BapA-Amphyd (grey). The catalytic residues 
of BapA (subunit A) and selected residues of the ligand-binding pocket are highlighted as 
sticks in yellow and grey, respectively; the subunit localizations of the labeled residues are 
indicated with subscript letters. The (+)-sc, (-sc) and ap conformers of the ligands are shown 
in orange, magenta and green, respectively; the conformer that best matches the active site of 
BapA is highlighted as sticks. The predicted salt bridge and hydrogen bonds of the oxyanion 
hole are indicated by dotted lines. For a schematic overview of the depicted conformers we 
refer to Table 3 in the main text. 
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Figure S2: Models of tetrahedral reaction intermediates formed between BapA Ser250-
Oγ and the (+)-sc conformers of L- and D-β2-homophenylalanine residues, related to 
Figure 5 
 
 
Figure S2: Models of tetrahedral reaction intermediates formed between BapA Ser250-
Oγ and β2-homophenylalanine residues 
The models are based on the crystal structure of BapA-Amphyd (grey). The (+)-sc conformers 
of the bound D- and L-β2-homophenylalanine residues are shown as sticks in magenta and 
orange, respectively. The catalytic residues of BapA (subunit A) and selected residues of the 
ligand-binding pocket are highlighted as sticks in yellow and grey, respectively; the subunit 
localizations of the labeled residues are indicated with subscript letters. The predicted salt 
bridge and hydrogen bonds of the oxyanion hole are indicated by straight, steric repulsions by 
bent dotted lines. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
NMR analysis of Amphyd  
The 1H, 13C and 15N NMR spectra used for stereochemical assignments were recorded at 
400.13, 100.61 and 40.56 MHz on a Bruker Avance-400 NMR spectrometer (Bruker Biospin 
AG, Fällanden, Switzerland). The 1H, the 1D NOESY spectra and the 1D 13C spectra, and the 
1H 13C HSQC, 1H 13C HMBC, 1H 1H DQF-COSY and 1H 15N HMQC (recorded with 15N at 
natural abundance) 2D correlation NMR experiments were performed at 298 K on a 5 mm 
broadband inverse probe with z-gradient (100% gradient strength of 53.5 Gcm–1) and 90° 
pulse lengths of 6.8 (1H), 14.5 (13C) and 21.3 s (15N). All NMR experiments were performed 
in D2O solutions using the Bruker standard parameter sets and pulse programs selecting 
coupling constants of 145 Hz (HSQC), 10 Hz (HMBC), 3 Hz (HMQC) and mixing times of 1 
s (1D NOESY, applying 50 ms selective 180º inversion pulses). The 1H and 13C chemical 
shifts were referenced relative to the signals of 3-trimethylsilyl tetradeutero sodium 
propionate (TSP) dissolved in D2O at 0.0 and -1.6 ppm, respectively. The 15N chemical shifts 
were referenced to a capillary containing neat nitromethane at 0.0 ppm. The relative amounts 
of products were determined by integration of 1H NMR signals of the H-9 / H-10 methyl 
groups. 
 
The 1H and 13C chemical shifts of the starting material ampicillin were readily assigned over 
the 2D correlated NMR experiments (Table S1 and S2), and the relative configuration of H-9 
and H-10 determined by NOE enhancements found between the pairs of protons H-3 / H-10 
and H-5 / H-9, whereas no close contacts were found for H-5 / H-10 (Table S3). The 1H 
chemical shifts evaluated for H-9 and H-10 completely agree with an earlier study (Tung et 
al., 2000). The 15N chemical shift of N-4 at -213 ppm is typical for the β-lactam nitrogen 
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(Table S1). For the structurally closely related penicillin G a value of -212 ppm was observed 
(Dodd et al., 2010). After some days in solution, additional 1H NMR resonances belonging to 
diastereotopic methyl groups were observed. These signals were assigned to a primary ((5R)-
Amphyd, amount in the 1% region) and a secondary hydration product ((5S)-Amphyd, traces). 
The resonances of these two products were observed as the main signals in the 1H NMR 
spectrum, when ampicillin was converted enzymatically by a β-lactamase (see Experimental 
Procedures). Two additional sets of 1H and 13C NMR resonances similar to the data found for 
ampicillin were found for the hydration products (5R)- and (5S)-Amphyd (Table S1). Whereas 
all 13C chemical shifts of the individual carbons and also the 15N NMR data of N-11 and N-18 
in these molecules remained very similar to the starting material ampicillin (Table S1), a low 
frequency shift of approximately 100 ppm was observed for N-4 of the hydration products 
compared with ampicillin, apparently induced by the ring opening reaction at of the β-lactam 
moiety. The relative configuration of the primary hydration product (5R)-Amphyd was 
established by NOE enhancements found between the pairs of protons H-3 / H-10 and H-5 / 
H-9, whereas no close contacts were found for H-5 / H-10 (the same NOE’s have previously 
been observed for ampicillin; Table S3). The NOE contact observed between H-3 and H-6 
implies a rotation around the C-5 / C-6 bond of the compound (Figure S3). For the second 
hydration product (5S)-Amphyd an NOE enhancement was observed between H-3 and H-5 
(and also to H-10), indicating an epimerization at C-3 or C-5. In fact, this kind of reaction is 
already mentioned in the literature (Deshpande et al., 2004; Robinson Fuentes et al., 1997); 
the postulated reaction mechanism is shown in Scheme S1. The ratio of (5R)-Amphyd / (5S)-
Amphyd shifted from 36 / 64 % (initial) to 15 / 85 % over 9 days. It has to be mentioned that 
further, not identified by-products were formed during this time period (amounts in the low % 
range). 
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SUPPLEMENTAL TABLES 
Table S1: 1H, 13C and 15N chemical shifts of ampicillin and its derivatives (5R)-Amphyd 
and (5S)-Amphyd 
Positiona δ (1H) / ppm δ (13C or 15N) / ppm 
 Ampicillin (5R)-
Amphyd 
(5S)-
Amphyd 
Ampicillin (5R)-
Amphyd 
(5S)-
Amphyd 
2    65.3 59.7 59.6 
3 4.19 3.09 3.32 74.3 76.4 76.7 
5 5.48 5.07 5.04 67.7 66.7 67.6 
6 5.47 4.29 4.89 59.0 60.9 56.4 
7    175.6 176.8 175.6 
8    175.6 176.4 175.5 
9 1.44 1.14 0.52 27.5 27.2 28.2 
10 1.52 1.21 1.48 31.3 27.0 29.0 
12    176.4 169.9 170.9 
13 4.68 5.21 5.28 59.2 58.1 58.3 
14    140.1 133.5 133.5 
15 7.43 7.58 7.58 128.1 129.2 129.1 
16 7.45 7.55 7.55 130.2 130.8 131.3 
17 7.40 7.52 7.52 129.6 131.5 131.5 
4    -213.2 -322.6 -310.6 
11    -269.8 -258.4 -264.0 
18    -349.8 n.d.b -339.4 
a
 For numbering of carbon atoms see Figure S3. 
b
 No correlation observed (signal too weak or 1H,15N coupling constant too small for 
efficient polarization transfer). 
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Table S2: 1H 13C HMBC and 1H 15N HMQC correlations used for NMR shift assignment 
in Table S1 
Compound Observed HMBC and HMQC correlations (w: weak) 
Ampicillin H-3C-(2, 5, 8, 9w, 10); H-5C-(6, 7); H-6C-(5, 7, 12w); H-9C-(2, 
3, 9); H-10C-(2, 3, 10); H-13C-(12, 14, 15); H-15C-(13, 14, 15, 17); 
H-16C-(14, 16); H-17C-(15) 
H-(3, 5, 6)N-(4); H-13N-(11, 18) 
(5R)-Amphyd H-3C-(2, 8, 9, 10w); H-5C-(2w, 3, 7); H-6C-(5, 7, 12w); H-9C-
(2, 3, 10); H-10C-(2, 3, 9); H-13C-(12, 14, 15); H-16C-(14, 16); H-
17C-(15) 
H-3N-(4); H-5N-(4); H-6N-(4, 11) 
(5S)-Amphyd H-3C-(2, 8, 9, 10w); H-5C-(7w); H-6C-(5, 7, 12w); H-9C-(2, 3, 
10); H-10C-(2, 3, 9); H-13C-(12, 14, 15); H-15C-(13, 15, 17); H-
16C-(14, 16); H-17C-(15) 
H-3N-(4); H-(5, 6)N-(4, 11); H-13N-(18) 
 
Table S3: 1H 1D NOESY signals used for assignments of stereochemistry 
Compound Observed 1D-NOESY correlations (w: < 1% NOE observed) 
Ampicillin H-3H-(10); H-9 H-(3, 5); H-10 H-(3, 9)  
(5R)-Amphyd H-3H-(6, 10, 15); H-5H-(3w, 6, 9w); H-6H-(3, 5); H-9H-(3, 5, 
10); H-10H-(3, 9); H-13H-(15) 
(5S)-Amphyd H-3H-(5, 10); H-5H-(3, 6); H-6H-(5, 13w); H-9H-(3, 10, 15); H-
10H-(3, 9); H-13H-(6w, 15) 
 
Crystal structures of BapA inhibitor complexes 
 179 
 
Figure S3: Numbering of carbon atoms used for the NMR signal assignment of 
ampicillin and its derivatives (5R)-Amphyd and (5S)-Amphyd (as employed by Kiener and 
Waley, 1978) 
 
 
Scheme S1: Proposed reaction mechanism of the epimerization at C-5 of Amphyd 
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INTRODUCTION 
 
 
The NLRP1- and NLRP3 inflammasomes1 the apoptosome, the NOD-signalosome2 and the 
PIDDosome3 are intracellular pathogen sensing complexes. The membrane bound DISC4, 
TRAIL5 and Toll-like receptors are complexes that sense extracellularly occurring 
bacterially derived components [1], [2], [3], [4]. All these molecules share several 
common structural features. They possess a microbial ligand-sensing domain, which is 
often made up of a series of leucine rich repeats, a protein-protein interaction domain 
that is used for the recruitment and activation of signal transducers such as caspases and 
kinases [5], [6] as well as relatively small domains, called death domains, which are 
postulated to be involved in homotypic interactions with partner molecules. They 
represent the “glue” of these multimeric protein complexes. According to their similar 
functional characteristics and the structural domain arrangement, the molecules are 
combined into the group of pathogen associated molecular pattern6 recognition molecules 
[4]. The detection of bacterially derived components in the extracellular or intracellular 
environment stimulates these PAMP molecules to assemble into large multimeric 
complexes, often termed activation platforms. They are responsible for the regulation of 
downstream signalling processes. The detection of microorganisms is highly efficient 
because structural components like lipopolysaccharides, muramyl peptides and other 
bacterial cell wall components remained conserved during evolution [7]. 
 Molecules that recognize pathogen associated patterns are rather large and 
flexible and possess unfavourable biophysical properties to be structurally investigated. 
Consequently, the focus in structural research is predominantly based on the functional 
units, which comprise the four different types of death domains as well as the caspase 
entity, the helicase entity, the ligand sensing leucine rich repeat and the oligomerization 
inducing nucleotide binding domain, which also exhibits essential inflammatory and 
apoptotic functions. This chapter focuses on the pyrin7 death domain interactions of 
NLRP1 and the adaptor protein apoptosis associated speck-like protein containing a 
CARD8, which both are components of the multi-protein complex termed inflammasome. 
 
                                                 
1
 Nucleotide binding and leucine rich repeat containing protein; NLRP 
2
 Nucleotide binding and oligomerization domain; NOD 
3
 P53 induced protein with a death domain; PIDD 
4
 Death inducing signalling complex; DISC 
5
 Tumour necrosis factor-related apoposis-inducing ligand receptor; TRAIL 
6
 Pathogen associated molecular pattern; PAMP 
7
 Pyrin; PYD 
8
 Apoptosis associated speck-like protein containing a CARD; ASC 
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1. Superfamily of death domain fold9 containing proteins 
The superfamily of death domain fold containing proteins comprises four families 
according to the SCOP database: 
 
DD: death domain family 
DED: death effector domain family 
CARD: caspase activation and recruitment domain family 
PYD: pyrin family 
 
 
The common motif of all four DDF families is an antiparallel six helix bundle of 
amphipathic helices with an approximate size of 85-100 amino acids (Figure 1_4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1_4) 
Cartoon representation of a representative DDF structure (the CARD domain of Apaf-1; 
protein database code 2P1H). The helices are numbered from 1 to 6, N and C denote the 
amino- and carboxy-termini, respectively. 
 
The individual lengths and orientations of the six α-helices vary within and between each 
family. The sequence identity of all proteins among the four families is low (between 10% 
and 25%). Due to relatively high diversity of the domains, experimental structure 
determination as well as protein-protein interaction studies of different members of the 
families are a prerequisite for a detailed understanding of the structural and functional 
relationships of these domains. 
 
A selection of the most important DDF containing proteins, used in the following sections, 
is shown in Figure 2_4). 
                                                 
9
 Death domain fold; DDF 
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Figure 2_4) 
Domain organizations of a selected set of proteins containing the DDF superfamily 
domains. (Abbreviations in alphabetical order: CARD, caspase activation and recruitment 
domain; CRD, cysteine-rich domain; DD, death domain; DED, death effector domain; 
LRR, leucine-rich repeat; NOD, nucleotide-binding oligomerization domain; PYD, pyrin 
domain; TM, transmembrane; TIR, Toll/interleukin-1 receptor; WD, Trp-Asp repeat, Zu5, 
ZO-1 and C.elegans uncoordinated protein 5. Figure adapted and modified from [8]. 
 
 
Currently, the crystal structures of the homotypic DD interactions of PELLE and TUBE [9] 
(protein database code 1D2Z), a Drosophila kinase with its adaptor protein, the DD-DD 
interaction between the PIDD and RAIDD death domains [8] (protein database code 
2OF5) a CARD-CARD interaction between Apaf-1 CARD and caspase-9 CARD [10] 
(protein database code 3YGS) and the DED1:DED2 interaction in the tandem DED of MC 
DEATH DOMAIN INTERACTIONS 
 185 
159 a viral FLIP protein from poxvirus [11] (protein database code 2BBR) are known. 
However, to date, there is no structural data for a homotypic PYD-interaction available. 
Two cases of non-homotypic interactions of DDF-superfamily members are known: 
PEA-15 (phosphoprotein enriched in astrocytes 15) a DED containing protein 
heterotypically interacts with the structurally unrelated MAP kinase ERK [12]. The second 
published example is ARC, a CARD containing protein that interacts heterotypically with 
the death domains of FAS and FADD thereby inhibiting FAS-FADD binding and the 
assembly formation of the DISC. The same study also shows a non-homotypic interaction 
between the CARD domain of ARC and the carboxy-terminal regulatory domain of BAX a 
non-death-fold Bcl-2 family protein [13]. 
 
 
1.1 Intracellular pattern recognition molecules 
One important family of proteins containing death domains is the NLR family. This family 
of intracellular pattern recognition molecules comprises 5 groups, called NLRA, NLRB, 
NLRC, NLRP and IPAF. The NLRP is the largest group and contains 14 members. 
 
 
Table 1_4) The human NLR family 
NLR Name Other names 
NLRP NLRP1 
NLRP2 
NLRP3 
NLRP4 
NLRP5 
NLRP6 
NLRP7 
NLRP8 
NLRP9 
NLRP10 
NLRP11 
NLRP12 
NLRP13 
NLRP14 
NALP1, DEFCAP, NAC, CARD7, CLR17.1  
NALP2, PYPAF2, NBS1, PAN1, CLR19.9  
NALP3, CRYOPYRIN, PYPAF1, CIAS1, CLR1.1 
NALP4, PYPAF4, PAN2, RNH2, CLR19.5 
NALP5, PYPAF8, MATER, PAN11, CLR19.8 
NALP6, PYPAF5, PAN3, CLR11.4 
NALP7, PYPAF3, NOD12, PAN7, CLR19.4 
NALP8, PAN4, NOD16, CLR19.2 
NALP9, NOD6, PAN12, CLR19.1 
NALP10, PAN5, NOD8, PYNOD, CLR11.1 
NALP11, PYPAF6, NOD17, PAN10, CLR19.6 
NALP12, PYPAF7, Monarch1, RNO2, PAN6, CLR19.3 
NALP13, NOD14, PAN13, CLR19.7 
NALP14, NOD5, PAN8, CLR11.2 
NLRC NOD1 
NOD2 
NOD3 
NOD4 
NOD5 
CARD4, CLR7.1 
CARD15, IBD1, PSORAS, CLR16.3 
CLR16.2 
NOD27, CLR16.1 
NOD9, CLR11.3 
NLRA CIITA MHC2TA, C2TA 
IPAF IPAF CARD12, CLAN, CLR2.1 
NLRB NAIP BIRC1, CLR5.1 
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Historically, the family of intracellular pattern recognition molecules was divided into two 
families, the NALP proteins (NALP1-14) and the NOD proteins (NOD1-5). CIITA, IPAF and 
NAIP were classified as standalone proteins with similar functions and domains like the 
NALP and NOD proteins. Recently, this classification scheme has changed. CIITA, IPAF 
and NAIP proteins now belong to the NLR family, which currently comprises 22 members 
(Table 1_4) [14]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3_4) 
Domain organization of representative NLR. NLR contain three distinct domains: the 
ligand sensing domain LRR (orange), the oligomerization domain NACHT (green), and the 
effector domains PYD and CARD (dark green and blue, respectively). CIITA, IPAF and 
NAIP form the remaining NLR members. Abbreviations: AD: activator domain; BIR: 
baculovirus inhibitor of apoptosis protein repeat; CIITA: class II transcriptional activator; 
IPAF: ICE (interleukin-1 converting enzyme) peptidase activating factor; FIIND: function 
to find; NACHT: NAIP (neuronal apoptosis inhibitor protein), CIITA, HET-E and TP1; NAD: 
NACHT associated domain; NAIP: neuronal apoptosis inhibitor protein; NOD: nucleotide 
binding and oligomerization domain. Figure adapted and modified from [15]. 
 
 
Proteins of the NLRP and NLRC group contain at least three distinct domains: An amino-
terminal CARD or PYD domain, a nucleotide binding and oligomerization domain (NOD) or 
NACHT and a carboxy-terminal leucine rich repeat [4]. Furthermore NLRB and NAIP 
members possess a NACHT associated domain, with so far unknown function. NLRP1 is 
the only protein of the NLR family with an additional carboxy-terminal CARD domain that 
is responsible for the recruitment of caspase-5. No functionality has been assigned to the 
domain named FIIND (Figure 3_4). 
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The NOD1osome and the NOD2osome are the first reported signalling platforms that 
detect bacterially derived peptidoglycans [16], [17]. They activate mitogen activated 
protein kinases (MAPK) via RIP2 and lead to nuclear factor kappa B (NF-κB) release 
through the recruitment of the IKK complex to the central domain of RIP2 [18], [19], 
[20] (Figure 4_4). Further studies identify the chemical nature of the compounds and 
provide evidence that not only the NOD proteins but also NLRP3 are able to sense 
peptidoglycans [21], [22], [23]. 
 
 
1.2 General overview of inflammasomes 
14 different NLRP proteins are known in the human genome (Table 1_4). They contain an 
amino-terminal PYD domain, a nucleotide binding and oligomerization domain (NACHT) 
and a carboxy-terminal leucine rich repeat [15]. The only structural information available 
on NLRP proteins is the nuclear magnetic resonance (NMR) structure of NLRP1-PYD 
(protein database code 1PN5) [24]. Although structural information is missing, NLRP1, 
and -3 have been biochemically characterized regarding their state of assembly and their 
proposed mode of action. 
 
1.2.1 The NLRP1 inflammasome 
Acute inflammatory responses are mediated through IL-1β and IL-18 release. Both 
cytokines are produced as inactive cytoplasmic precursors which are processed into their 
active forms by caspase-1 [25], [26]. The molecular mechanisms that control the 
caspase-1 activity rely on a multiprotein complex composed of NLRP1, the protein ASC, 
caspase-1 and caspase-5 (Figure 4_4) [15], [27], [28]. 
Mechanistic details have not been published so far, but models describe the signal 
processing as follows. Upon ligand binding to the LRR of NLRP1, the oligomerization 
interfaces of the NACHT domain become accessible and NLRP1 oligomerizes. This process 
is accompanied by large conformational changes and leads to a cluster formation of 
interaction domains on both termini. The amino-terminal PYD domains of NLRP1 
subsequently recruit the adaptor protein ASC through a homotypic PYD-interaction. ASC 
is a bipartite molecule and comprises a PYD and a CARD domain. ASC, in turn, recruits 
caspase-1 through a homotypic CARD-interaction. The accessible CARD domain cluster at 
the carboxy-terminal end of NLRP1 similarly is able to recruit caspase-5 via a homotypic 
CARD-interaction. The inactive pro-caspase-1 and pro-caspase-5 are transiently brought 
together, process and activate each other. The exact stoichiometry of this about 700 kD 
multimeric protein complex is not known. Because this complex regulates pro-
inflammatory cytokine activation that cause inflammation symptoms, it was termed “the 
inflammasome” [29], [30]. 
The activation of caspase-1 is essential to process inactive IL-1β and IL-18 into 
their active forms. (Caspase-1 is historically known as Interleukin-1 converting enzyme 
(ICE)). Once active, IL-1β and IL-18 are secreted and bind to their corresponding IL-1 
(IL-1R) and IL-18 receptors (IL-18R) on neighbouring cells [31]. Similarly to Toll-like 
receptors (TLR), IL-1R and IL-18R possess extracellular LRR and intracellular TIR 
domains. Since TIR domains are known to recruit adaptor proteins such as MyD88, 
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which, in turn, activates NF-κB and other signalling cascades, the NLRP activation can be 
considered a direct link of intracellular pathogen sensing to NF-κB signalling pathways 
[15]. 
The ligands that trigger NLRP1 inflammasome activation are unknown. However, 
extracellular adenosine tri-phosphate, sensed by P2X7 receptors from lipopolysaccaride-
primed macrophages, leads to IL-1 cytokine release [32]. In addition, hypotonic stress 
has been shown to activate NLRP1 by the release of not further specified “host danger 
signals” [29]. 
 
1.2.2 The NLRP3 inflammasome 
Similarly to the NLRP1 inflammasome, the NLRP3 inflammasome is a multi-protein 
complex assembly that controls the processing and activation of IL-1β and IL-18 [33]. In 
contrast to the NLRP1 inflammasome, the NLRP3 inflammasome comprises ASC, a 
bipartite molecule termed CARDINAL, which substitutes the two carboxy-terminal FIIND 
and CARD domains of NLRP1 (absent in NLRP3) and two caspase-1 molecules instead of 
caspase-1 and caspase-5 (Figure 4_4). 
Muramyl-dipeptides, low concentrations of intracellular potassium and potassium 
channel forming bacterial toxins from Staphylococcus aureus or gramicidin from Bacillus 
bravis can trigger NLRP3 inflammasome activation [29], [34], [35]. Uric acid present in 
tissues as degradation product of purines and calcium pyrophosphate crystals also seem 
to activate the NLRP3 inflammasome [36], [37]. Moreover, bacterial ribonucleic acid and 
antiviral compounds are proposed to activate the NLRP3 inflammasome [38]. 
 
The stoichiometric composition and the oligomeric state of the ligand sensor are not 
known for most complexes. The trigger molecule inducing oligomerization for NLRP1 and 
PIDD is unknown. NLRP3 detects peptidoglycans, NOD detect muramyl-dipeptides and 
peptidoglycans, TLR sense lipopolysaccharides, viral ribonucleic acid, CpG rich DNA 
strands and bacterial flagellin each with their leucine rich repeats. The helicase domain of 
RIG-I detects double stranded ribonucleic acid (Figure 4_4). Upon binding of pathogen 
associated molecular patterns to their corresponding receptor units, conformational 
changes expose DD-interaction sites and induce oligomerization analogously to the 
process as previously described for NLRP1. Adaptor and effector proteins are supposed to 
be recruited strictly via homotypic DD-interactions. 
 
DEATH DOMAIN INTERACTIONS 
 189 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4_4) 
Schematic overview of multiprotein complexes in the innate immune system of A, B) the 
NLRP1 and NLRP3 inflammasome [30], C) the RIG-I platform [39], D) Toll-like receptors 
(TLR) [40], E) NODosome [41], and F) the PIDDosome [42]. Abbreviations: dsRNA, 
double stranded ribonucleic acid; vRNA, viral ribonucleic acid; LPS, lipopolysaccaride; 
CpG, cytosine-phosphate-guanosine; DNA, desoxyribonucleic acid; PG, peptidoglycan; 
MDP, muramyl-dipeptide; 
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1.3 TMS1/ASC 
Processes, which maintain the delicate balance between survival and death by death 
domain containing proteins, can result in diseases when they are imbalanced or even 
disrupted. In particular the discovery of TMS1 implicated in auto-inflammatory disorders 
raised interests. Importantly, the loss of expression of TMS1/ASC in breast tumours and 
other cancers strongly implies its involvement in tumorigenesis. 
TMS1/ASC was originally identified by monoclonal antibodies against proteins in 
an insoluble cytoskeletal fraction of differentiating HL-60 cells [43]. Upon treatment with 
retinoic acid perinuclear aggregates “specks” were observed giving the protein its name: 
apoptosis associated speck-like protein containing a CARD domain (ASC). An independent 
study identified “ASC” in a screen for downstream targets of methylation associated gene 
silencing. This gene was named TMS1 for Target of Methylation-Induced Silencing-1 
(TMS1) and was later found to be identical to ASC [44]. In following sections TMS1/ASC 
will be named ASC. 
 
1.3.1 ASC in the inflammasome 
The bipartite structure of ASC is ideally suited to act as an adaptor molecule by linking 
some of the NLRP proteins to caspase-1. The amino-terminal PYD domain of NLRP1 and 
ASC and the carboxy-terminal CARD domain of ASC the CARD domain of caspase-1 can 
homotypically interact with each other. This adaptor function for ASC has been shown for 
NLRP1, NLRP3 and NLRP12 [29], [45], [46]. Interestingly, not all NLRP proteins, although 
very similar in their domain arrangement, require ASC as an adaptor molecule. Dowds et 
al. show that the PYD domains of NLRP2 and ASC do not interact [47]. 
 
 
1.4 Structural and biochemical investigations of the PYD superfamily 
The model of the inflammasomes and interaction modes of the multi-protein assemblies 
are based on a variety of biochemical studies obtained by immuno-precipitations, yeast 
two hybrid screens, cellular co-localizations and pull-down experiments. The structures of 
the NLRP1-PYD and the ASC-PYD domains have been solved by nuclear magnetic 
resonance (NMR) spectroscopy (protein database codes 1PN5 and 1UCP, respectively) 
[24], [48]. Interestingly, the helix 3 in both structures is disordered or only partially 
ordered (Figure 5_4), although the sequences are predicted to assume a six helix bundle. 
Kaufmann et al. suggested that the helices might play an important role in protein-
protein interaction and might represent a significantly different interaction mode 
compared to other DDF-members [49], [50]. 
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Figure 5_4) 
Cartoon representation of PYD domains. A) PYD domain of human NLRP1, protein 
database code 1PN5; B) PYD domain of ASC, protein database code 1UCP. Helix 
numbering is indicated; N-terminal helix is coloured in blue, C-terminal helix is coloured 
in red. 
 
 
2. Rationale and aim of the project 
The aim of this study is to show a direct homotypic interaction between the PYD domains 
of NLRP1 and ASC by NMR spectroscopy and to elucidate whether the unstructured loops 
3 of both PYD domains might become structured into helices or undergo at least 
significant structural changes upon dimer formation. 
CHAPTER 4 
 192 
RESULTS 
 
 
[15N,1H] hetero spin single quantum correlation spectroscopy10 is a mild procedure that is 
used elucidate protein-protein interactions. The fundamental requirement for that 
experiment is a protein that is completely 15N-labelled (15N = heavy nitrogen nuclide). 
Recording data of the labelled protein in the absence of its interaction partner results in 
spectrum “A”. Recording data of the labelled protein in the presence of its interaction 
partner results in spectrum “B”. Peak shifts might occur in spectrum “B” upon complex 
formation due to alterations in the local environment of residues that are localized in the 
interaction interface. The subtraction of “A” from “B” results in a difference spectrum, 
showing interacting residues (if the peak assignment is known), but the peak assignment 
is not a prerequisite. 
To study the possible complex formation by nuclear magnetic resonance11 
spectroscopy, both domains had to be brought to a condition where they remained 
monomeric in solution. Extensive solubility tests showed that neither the GB112_NLRP1-
PYD nor the ASC-PYD construct stayed in solution at pH values below 6.5 or above pH 4, 
respectively. Thus, both domains featured incompatible pH conditions to be able to co-
exist in solution. Therefore, the ASC-PYD domain was produced in a soluble form as GB1-
fusion protein to overcome the insolubility. This construct proved to be soluble and 
monomeric at low concentrations in the physiological pH range. 
 
 
3. Protein production and purification 
The PYD domain of NLRP1 and the PYD domain of TMS1/ASC were cloned into a modified 
pET20b+ vector from Novagen, producing a fusion protein with an N-terminal GB1-
solubility-enhancer tag and a C-terminal hexa-histidine sequence (see appendix section). 
The PYD domain of ASC was cloned into a pET20 vector (Novagen) which 
produced the recombinant protein with an N-terminal hexa-histidine sequence. Almost 
uniformly 15N-labelled GB1_NLRP1-PYD was obtained by expressing the protein in E. coli 
BL21 pLysS cells grown in 100 ml minimal medium (M9) supplied with 15NH4Cl as the sole 
heavy nitrogen source, vitamin mix, solution Q (see Appendix), antibiotics (100 µg/ml 
ampicillin, 25 µg/ml chloramphenicol), 0.5 % glucose and 1 mM MgSO4. Cells were grown 
at 37°C to an optical density of OD600 = 1.5 – 2 cooled down to 18°C and then induced 
with 1 mM IPTG (isopropyl-β-D-thiogalacto-pyranoside) for 14 hours. The cells were 
resuspended in 50 mM Tris, 100 mM NaCl, 3 mM β-mercaptoethanol, 2 mM PMSF 
(phenylmethylsulphonylfluoride), 1 mM CHAPS (3-[(3-Cholamidopropyl)-
dimethylammonio]-1 propanesulfonate, 1 mM imidazole (pH 8.0 at RT), lyzed with a 
French press. The protein was purified by IMAC (immobilized metal affinity 
chromatography) on Ni2+-loaded nitrilo-triacetic acid (NTA) matrix from Qiagen and by 
                                                 
10
 [15N,1H] hetero spin single quantum correlation spectroscopy; HSQC 
11
 Nuclear magnetic resonance; NMR 
12
 B1-domain of protein G; GB1 
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size exclusion chromatography on a S75 26/60 column (Amersham, Pharmacia Biotech) 
thereby getting rebuffered into 20 mM Tris (2-amino-2-hydroxymethyl-propane-1,3-diol, 
100 mM NaCl (sodium chloride), 0.2 mM CHAPS, 0.1 mM EDTA (ethylenediamine 
tetraacetic acid), 10 mM DTT (dithiothreitol) pH 7.5 at 4°C. This buffer was used for 
circular dichroism spectroscopy13 and dynamic light scattering experiments. 
Unlabelled GB1_ASC-PYD was obtained by expressing the protein in E. coli BL21 
pLysS cells grown in 500 ml Luria Bertani cultures using the same conditions as described 
above. 
 
     1     2     3      4       5       6    7 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6_4) 
15% SDS-PAGE of IMAC purified GB1-ASC-PYD; lane 1: supernatant; lane 2: flow 
through; lane 3: wash; lanes 4-6: elution fractions; lane 7: marker, molecular weights 
indicated. 
 
The protein was purified by IMAC and by size exclusion chromatography on a S75 26/60 
column (Amersham, Pharmacia Biotech) thereby getting rebuffered in 20 mM Tris, 500 
mM NaCl, 0.2 mM CHAPS, 0.1 mM EDTA, 10 mM DTT pH 7.5 at 4°C (Figure 6_4). This 
buffer was used for CD-spectroscopy and dynamic light scattering experiments. Prior to 
NMR measurements the proteins were dialyzed for 24 hours against 50 mM 
Na2HPO4/NaH2PO4, pH 7.0, 5% D2O. 
 
 
 
3.1 Mass analysis and protein purity 
The calculated relative molecular masses of GB1_ASC-PYD and uniformly labelled 15N 
GB1_NLRP1-PYD are 17493.8 Da and 20784.8 Da, respectively (www.expasy.org; 
protparam). The quadrupole time of flight mass spectra electron spray ionization14 
confirmed the calculated molecular masses (Figure 8_4). The labelling degree of 
GB1_NLRP1-PYD was estimated to be greater than 95%, sufficient for adequate NMR 
                                                 
13
 Circular dichroism spectroscopy; CD spectroscopy 
14
 Quadrupole time of light mass spectra electron spray ionization; QTOF MS ESI 
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measurements (Hiller S., personal comment). Since ESI spectra display the relevant 
mass peaks only within a mass window, GB1_ASC-PYD was also analyzed on a C8 column 
by high pressure liquid chromatography15 to confirm its purity (Figure 7_4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7_4) 
HPLC chromatogram of purified GB1_ASC-PYD. Purified on a C8 column using a gradient 
of 0-40% acetonitrile and 0.1% TFA (trifluoro-acetic acid) 
 
 
Previous studies have shown that the NLRP1-PYD construct is not soluble without the 
GB1-solubility-enhancer tag in a variety of buffer conditions (including 10% glycerol and 
sucrose, high and low salt concentrations) from pH 3 to pH 9 (Kohl, A., personal 
comment). The GB1_NLRP1-PYD construct had improved solubility behaviour and 
remained in solution above pH 6.5 without stabilizing additives such as glycerol and 
sucrose or divalent salt ions. 
The NMR structure of ASC-PYD with an N-terminal hexa-histidine sequence was 
recorded at pH 3.7, where it is stable and monomeric in solution [48]. However, the 
domain aggregated and precipitated in buffered systems above pH 4. Because ASC-PYD 
is not soluble above pH 4 and GB1_NLRP-PYD is not soluble below pH 6.5 it was 
impossible to analyze the protein-protein interaction by NMR spectroscopy or any other 
method. Therefore ASC-PYD was produced with a GB1-solubility-enhancer tag. This 
successfully prevented aggregation at a neutral pH. However, GB1_ASC-PYD had the 
tendency to precipitate over time (days), at concentrations above 1 – 2 mg/ml at neutral 
pH, and readily precipitated within minutes when precipitated protein was already 
present. Both GB1-tagged domains proved to be monomeric in solution at concentrations 
around 1 mg/ml. This state was stable and the concentrations were sufficient for 
overnight [15N,1H] HSQC measurements. 
                                                 
15
 High pressure liquid chromatography; HPLC 
HPLC chromatogram of GB1_ASC-PYD
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Figure 8_4) 
Quadrupole time of flight mass spectrum and electrospray ionization of the unlabelled 
GB1_ASC-PYD domain (upper panel) and 15N labelled GB1_NLRP1-PYD domain (lower 
panel). The experimentally determined masses of 17493.6 Da and 20775.0 Da are in 
agreement with the calculated masses of 17493.8 Da and 20784.8 Da. The x-axis 
indicates the mass, the y-axis the percentage of intensity, respectively. The 
measurements were performed at the Functional Genomics Centre Zurich (FGCZ). 
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3.2 CD spectroscopy 
The GB1_NLRP1-PYD protein is correctly folded in a buffer containing 20 mM Tris, 100 
mM NaCl, 10 mM DTT, 1 mM CHAPS, 0.1 mM EDTA pH 7.5 (at room temperature) (Kohl, 
A., personal comment). The CD spectrum of ASC-PYD was recorded at pH 4 in 20 mM 
NaH2PO4 showing two absorption minima at 223 nm and 208 nm reminiscent of a protein 
with a high α-helical content. The CD spectrum of GB1_ASC-PYD was recorded at pH 7.5 
in 20 mM Tris 100 mM NaCl and similarly showed a α-helical curve, with absorption 
minima at 223 nm and 208 nm (Figure 9_4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9_4) 
Overlaid circular dichroism spectra of the ASC-PYD domain () recorded at pH 4.0 left 
scale (y-axis) and the GB1_ASC-PYD domain () recorded at pH 7.5 right scale (y-axis) 
 
 
3.3 NMR measurement 
To structurally determine the proposed homotypic PYD-interaction between GB1_ASC-
PYD and GB1_NLRP1-PYD, the [15N,1H]-HSQC run was kindly performed by Sebastian 
Hiller (group of Prof. Dr. K. Wüthrich, ETH, Zürich). 
A solution containing 200 µM GB1_NLRP1-PYD was mixed with a solution 
containing 80 µM GB1_ASC-PYD. The two samples had been dialyzed for 24 hours in the 
same buffer (50 mM NaH2PO4/Na2HPO4, buffered at pH 7.0). The GB1_NLRP1-PYD fusion 
protein was uniformly 15N-labelled; the GB1_ASC-PYD fusion protein was unlabelled. One 
dimensional 1H-NMR spectra verified that both proteins were still in solution and had not 
aggregated in the mixed sample. The [15N,1H]-HSQC spectra of GB1_NLRP1-PYD and 
together with its putative binding partner GB1_ASC-PYD were identical (Figure 10_4). 
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Figure 10_4) 
[15N,1H] HSQC spectra; left: spectrum with uniformly labelled 15N-GB1_NLRP1-PYD; 
middle: spectrum of a mixture of uniformly labelled 15N-GB1_NLRP1-PYD and unlabelled 
GB1_ASC-PYD; right: difference spectrum of 15N-GB1_NLRP1-PYD minus 15N-
GB1_NLRP1-PYD mixed with unlabelled GB1_ASC-PYD. The difference spectrum does not 
show significant peak shifts, which would occur upon complex formation. 
 
 
Based on the known protein concentrations at the beginning of the experiment, and the 
calculated signal intensity of the NMR spectra, the calculated concentration of a complex 
between the two PYD domains was below 5% (based on the concentration of 
uncomplexed GB1_NLRP1-PYD). This allows the calculation of a dissociation constant 
(KD), which, taking the known parameters into account is 1.3 mM (see equation I). The 
concentration of 1.3 mM is above physiological relevance. From this result, it can be 
concluded, that the two PYD domains, both in construct with a GB1 fusion protein, do not 
interact under the buffer conditions used for this experimental setup. 
 
 
 
         equation I 
 
 
 
[ ] [ ]
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1 190 70 1.3
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NLRP ASC
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DISCUSSION 
 
 
Despite the importance of death domains in inflammatory signalling and regulatory 
mechanisms of the innate immune system, only few structures (X-ray and NMR) have 
been solved in recent years. The overall low number of structures of DDF proteins can 
reasonably be explained with solubility difficulties. As shown in previous sections, the 
ASC-PYD and the NLRP1-PYD domain could only be kept in solution at either non-
physiological pH values or with solubility enhancing fusion proteins. As a consequence of 
lacking structural data, information about death domain interactions is limited to few 
representatives of each DDF domain. 
Generally, death domains are small in size and well-expressed in bacterial 
expression systems, but are prone to aggregation, and mainly found in either insoluble 
inclusion bodies, globular aggregates (specks) or filamentous structures [43], [50]. As 
described before, the NLRP1-PYD domain could not be stabilized and kept in solution in a 
variety of buffers over a broad pH range. The ASC-PYD domain was only soluble in a non-
physiological acidic buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11_4) 
GB1_NLRP1-PYD fusion protein; The GB1-domain depicted in red (protein database code 
2J52) was positioned close to the “amino-terminus” of the NLRP1-PYD structure (10 
average structures shown in black) (protein database code 1PN5). Two linker residues 
between the domains are depicted as dotted line. The estimated length of the GB1-
domain is drawn as a circle indicating the blocked area on the NLRP1-PYD domain. 
 
The crucial point of the experimental setup was the amino-terminal modification with a 
solubility enhancing GB1-tag. This modification allowed the two fusion proteins to co-
exist in a monomeric state in a physiological buffer. Construct truncations or elongations 
such as solubility tags (GB1 domain or even fusion proteins), detection tags or 
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purification tags, always bear the risk to completely abrogate possible interactions. Figure 
11_4 shows for this experimental setup, where the N-terminal GB1-fusion protein would 
be located with respect to the disordered helix 3 of the NLRP1-PYD domain. 
 
It has been shown that short detection tags such as vesicular stomatitis virus (VSV-tag), 
Flag-tag, myelocytomatosis virus (Myc-tag) or hexa-histidine-tag do not affect domain-
domain interactions. For example: VSV-tagged full length ASC, co-expressed with FLAG-
tag PYD of ASC (without CARD) was immuno-precipitated. Moreover, the same study 
showed that full length VSV-tagged ASC interacts with the FLAG-tagged NLRP1-PYD 
domain [51]. A summary of published results about death domain interactions is depicted 
in Figure 12_4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12_4) 
Schematic drawing of investigated protein-protein interactions. Abbreviations used: IP: 
immuno-precipitation, DLS: dynamic light scattering, SEC: size exclusion 
chromatography, NMR: nuclear magnetic resonance. Constructs (with N-terminal waved 
tags): VSV-ASC / FLAG-PYD (lit.1); Myc-ASC or Myc-ASC-PYD / FLAG-NLRP1-PYD / VSV-
pyrin (lit. 1 and 2); Myc-ASC-PYD (lit. 3 and 4). Indicated literature references: 1) 
Martinon et al., 2001; 2) Papin et al., 2007; 3) Srinivasula et al., 2002 4) Richards et al., 
2001. 
 
 
However, the [15N,1H] HSQC experiment showed that the GB1-tagged NLRP1-PYD domain 
and the GB1-tagged ASC-PYD domain did not interact under given conditions. Several 
reasons might account for this experimental finding. 
It cannot be excluded that the GB1 domain in contrast to the VSV-tag, Flag-tag or 
Myc-tag does not negatively influence domain-domain interactions. Whereas the 
detection tags are highly flexible and short amino acid sequences, the GB1 domain is a 
stable entity comprising 56 amino acids. Thus, steric hindrance might be a major 
criterion preventing interactions. Furthermore, due to important regulatory mechanisms 
and consequences of the release of IL-1β, the protein interactions in the native 
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inflammasome must be tightly controllable by the cell. The inflammasome complex must 
remain transient, built upon weak interactions, during its processing state, maybe too 
weak to be measured as single domain constructs. Intracellular conditions are of utmost 
importance regulating the complex assembly and disassembly in vivo. The NMR 
experiment was performed in low salt conditions (50 mM NaH2PO4/Na2HPO4, at pH 7.0) 
without further additives, a condition that is far from a cytosolic milieu. 
Nevertheless, this study showed the necessary measures to bring the two PYD 
domains together in solution. Martinon et al., 2001, shows in a different experiment that 
the PYD domains of NLRP1 and ASC interact [51]. Thus, only minor changes in the 
experimental setup might be required to be able to show the NLRP1-PYD – ASC-PYD 
interaction by NMR and to elucidate their interaction mode. 
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RIBOSOME DISPLAY AGAINST SELECTED CASPASES 
 
 
Caspase-1, -2, -3, -5 and -8 were used as target proteins for the initial ribosome display1 
selection with a N2C messenger RNA library (provided by Molecular Partners). The 
selection of caspase-1 binders was not successful, because the protein was unstable in 
any chosen buffer. A pool of caspase-2 binders (N3C) is currently investigated. Several 
binders against caspase-3 have been selected and characterized regarding the formation 
of protein-protein complexes and their inhibitory activity. However, further biophysical 
characterization is still ongoing. Due to the limited stability of caspase-5 further RD 
selection rounds are necessary. Nevertheless, a first selection trial yielded a few positive 
clones, including several caspase-8 binders, which also need further characterization. 
Preliminary binding experiments were not conclusive so far. Reasonable binding results 
were only obtained with caspase-3 binders, and data will be presented in the following 
sections. 
 
 
Enzyme linked immuno sorbent assay2 
The detailed ELISA and RD protocols are given in the protocol section of the appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1_A) 
ELISA readout from two 96well plates coated with caspase-3 and MBP: Blue bars 
represent binding of N2C ankyrin binders against caspase-3 adjacent dark pink bars 
represent the background signal of that particular binder against MBP. This data has been 
acquired three days after the start of the colour development, indicating that selected 
binders do not give background signals for MBP. 
 
After four RD rounds, the DNA fragments encoding N2C library members for putative 
caspase-3 binders were cloned into expression vectors (pQE-30), transformed into E. coli 
XL-1 blue cells and streaked out onto LB agar plates supplied with appropriate antibiotics 
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(ampicillin and tetracycline). Single colonies were picked and separately expressed in 96-
well plates. After cell lysis, the crude extracts containing N2C binders were transferred 
onto caspase-3 / maltose binding protein (MBP) coated plates. MBP was used as target 
protein for pre-panning selections during RD rounds. For every well coated with caspase-
3, a second well was coated with MBP serving as negative control for caspase-3 binders, 
and as positive control for a previously selected MBP binder. All binders were expressed 
with an amino-terminal hexa-histidine tag, which was recognized by the primary 
antibody. The signal readout originated from an alkaline phosphatase coupled secondary 
antibody that turned 4-nitrophenyl phosphate into a yellow coloured product (4-
nitrophenolate; detected at 405 nm wavelength). The signal followed over time (30 min 
intervals, and 1-2 days), indicated the quality of the background binding (Figure 1_A). 
 
 
Size exclusion chromatography (SEC) 
Caspase-3 and the selected binders against caspase-3, chosen from the previous ELISA 
experiment, were separately analyzed by size exclusion chromatography on a S200 
(Sephadex, 10/300) column (Pharmacia) to obtain the retention times each in the 
unbound form. The binders and caspase-3 were subsequently allowed to form a complex 
by mixing each individual binder with caspase-3 in a 2.2:1 molar excess in 150 µl 
volume. This mixture incubated on ice for 2 hours, was centrifuged for 5 min and then 
injected. Calculated theoretical molecular masses of selected N2C binders against 
caspase-3 are given in Table 1_A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2_A) 
Overlaid chromatograms of the N2C binder (A12) against caspase-3 (pink profile), 
caspase-3 (red profile) and caspase-3 in complex with A12 (blue profile). The peaks 
(retention time) correspond to molecular masses of 15 kD for a single N2C ankyrin, 60 
kD for the caspase-3 and 93 kD for the complex. The loading volume was 100 µl; flow 
rate: 0.5 ml/min; buffer: 20 mM Tris pH 8.0, 150 mM NaCl; temperature 4°C, S200 
(10/300) Sephadex column (Pharmacia). 
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Caspase-3 is a stable dimer in solution and displays a molecular mass of 60 kD according 
to its retention time in size exclusion chromatography experiments. Its exact molecular 
mass is 61.08 Da. The selected N2C binders against caspase-3 have an average 
molecular mass of 14.8 kD and elute with an apparent molecular mass of 15 kD. The 
expected theoretical mass of the 2:1 complexes would be 90 kD or slightly higher. 
Caspase-3 is globular and heterodimeric, the overall shape of the complexes will be 
elongated, and consequently elute at a slightly shorter retention time. Therefore, the 
selected binders A2, A4, A12, C7, G5 and H2 in complex with caspase-3, displaying 
apparent molecular masses above 90 kD, are expected to be strong binders, whereas A7 
and C8 with apparent molecular masses around 80 kD are expected to be weaker 
binders. The peak corresponding to the N2C ankyrin disappears upon complex formation 
(Figure 2_A), which is a good visual indicator for strong binders. 
Two binders precipitated during incubation and could not be used for further 
studies (Table 1_A). An example of the elution profile of caspase-3 in complex with the 
selected N2C ankyrin binder A12, and the elution profiles of caspase-3 and A12 is shown 
in Figure 2_A. 
 
 
 
Table 1_A: Selected N2C binders in complex with caspase-3, analyzed on a S200 
analytical size exclusion column 
Selected N2C binder in 
complex with caspase-3 
Theoretical mol. mass comment 
A2_complex 101 kD Strong 2:1 complex 
A4_complex 96 kD Strong 2:1 complex 
A7_complex 81 kD Weak complex 
A12_complex 93 kD Strong 2:1 complex 
C7_complex 101 kD Strong 2:1 complex 
C8_complex 79 kD Weak complex 
D7_complex X Precipitation 
G2_complex X Precipitation 
G5_complex 97 kD Strong 2:1 complex 
H2_complex 95 kD Strong 2:1 complex 
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SDS-PAGE analysis3 
Fractions from analytical size exclusion experiments were analyzed on SDS-PAGE. Figure 
3_A shows the selected binders A4 (1) and H2 (2) in complex with caspase-3 separated 
on a 15% SDS-PAGE gel. The three bands correspond to the α- and β-subunit of caspase-
3 (18.6 kD and 11.8 kD, respectively) as well as the N2C binder (14.8 kD). 
 
      1     2     3     4     5     6     7     8     9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3_A) 
A4_N2C (1) and H2_N2C (2) co-eluted with caspase-3, separated on a SDS-PAGE. Lanes 
1-5: fractions (0.5 ml) of the complex peak of A4 and caspase-3; lane 6: marker; lanes 
7-9 fractions (0.5 ml) of the complex peak of H2 and caspase-3. 20 µl of each fraction 
were applied per slot. Marker bands are indicated. 
 
                                                 
3
 Sodium dodecyl sulfate polyacryl gel electrophoresis; SDS-PAGE 
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50% Inhibitory concentration (IC50) 
The IC50 value indicates the concentration, which is required to limit the enzymatic 
activity to the half-maximal turnover rate. It does not represent a kinetic parameter and 
is not comparable to the dissociation constant (KD). Increasing amounts of inhibitor were 
mixed in caspase assay buffer (see appendix) with a constant amount of caspase-3 (1 
nM) and incubated at 4°C for 2 hours. After substrate addition (Ac-DEVD-AMC; acetyl- 
aspartyl- glutamyl- valinyl- aspartyl-amino-methyl-coumarin) AMC was detected at 405 
nm wavelength (Figure 4_A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4_A) 
Plot of inhibitor concentrations of selected N2C binders versus relative caspase-3 activity 
determined with the fluorogenic substrate Ac-DEVD-AMC at 405 nm wavelength on a 
plate reader (Genion, Tecan). The solid white line delineates the half-maximal turnover 
rate (50%). 
 
The binders A2 and C7 show 50% inhibition of caspase-3 activity at a concentration of 20 
nM, and the binder G5 decreases caspase-3 activity to 50% at 100 nM concentration. 
Other N2C binders identified by RD against caspase-3 were also tested. However, they 
showed either no, or rather weak (80%) inhibition at a 100 fold concentration excess 
(100 nM), and hence were not used for further studies. 
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APPENDIX PART II 
Chapter 4 
Construct sequence of NALP1 PYD with N-terminal GB1 tag, and C-terminal 
6xHis tag: 
MQYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDATKTFTVTEGSMAGGAWG
RLACYLEFLKKEELKEFQLLLANKAHSRSSSGETPAQPEKTSGMEVASYLVAQYGEQRAWDLALHTW
EQMGLRSLCAQAQEGAGHHHHHHH 
 
Construct sequence of TMS1/ASC PYD with N-terminal GB1 tag, and C-terminal 
6xHis tag: 
MQYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDATKTFTVTEGSMGRARDAI
LDALENLTAEELKKFKLKLLSVPLREGYGRIPRGALLSMDALDLTDKLVSFYLETYGAELTANVLRDMG
LQEMAGQLQAATHQLEHHHHHH 
 
(The first 56 aa represent the N-terminal GB1-tag followed by a GS linker, and the 
domain sequence) The constructs were provided by A. Kohl 
 
Expression media for 15N-labelled NALP1 PYD: 
Vitamin mix (for 100ml) 
- Thiamine    50 mg 
- d-Biotin    10 mg 
- Choline chloride   10 mg 
- Folic acid     10 mg 
- Niacin amide   10 mg 
- D-Panthothenic acid  10 mg 
- Pyridoxal    10 mg 
- Riboflavin    1 mg  (10 ml Vitamin mix / l M9) 
 
M9 Medium /L culture 
- ddH2O     865 ml 
- M9 salts 10x   100 ml to be autoclaved 
- MgSO4 1M stock   2 ml 
- NH4Cl
#    1 g 
- Vitamine mix   10 ml 
- Solution Q    2 ml 
- Glucose 20%   20 ml 
- Ampicillin 100 mg/ml  1 ml (0.5, when in D2O) 
- Chloramphenicol 25 mg/ml 1 ml (0.5, when in D2O) 
 
# 15NH4Cl for 
15N-labelled protein 
all solutions above have to be sterile filtered before addition to M9 medium 
(15NH4Cl can be added to M9 salts 10x) 
 
M9 salts 10x (for 1 l culture) 
- Na2HPO4*2H2O   85.1 g 
- KH2PO4    30 g 
- NaCl     5 g 
Alternatively 15NH4Cl added here! 
pH adjusted to 7.2 (can be higher e.g. 7.4) 
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Solution Q (for 1 l culture; 1-2 ml / l M9) 
- Conc. Hydrochloric acid (5M) 8 ml 
- FeCl2*4H2O    5 g 
- CaCl2*2H2O    184 mg 
- H3BO3     64 mg 
- CoCl2*6H2O    18 mg 
- CuCl2*2H2O    4 mg 
- ZnCl2    340 mg 
- Na2MoO4*2H2O
#   605 mg 
- MnCl2*4H2O    40 mg 
# can be left away 
 
Expression procedure for proteins in M9 minimal medium 
Cells: BL21 pLys // Construct: GB1Nalppyd long form c6xHis in pET20 
 
5 ml LB medium supplied with appropriate amounts of ampicillin and chloramphenicol 
were inoculated with single colonies from a freshly transformed LB (better 2YT) agar 
plate and grown O/N at 37°C under vigorous shaking (250 rpm). These O/N cultures 
were centrifuged for 5` at 3000 g and resuspended in 2 ml LB. Intermediate cultures (50 
ml LB, amp / cam) were inoculated with 1 ml resuspended cells, growth for 3h until OD600 
~ 0.7 is reached. In order to inoculate 250 ml LB (2 L flasks) with equal amounts of cells, 
ratios were calculated according to cell densities in the intermediate cultures. Further 
growth at 37°C until OD600 ~ 0.7 is reached. In the meantime, M9 media (100 ml 
aliquots, 250 ml flasks) was prewarmed. The cells were centrifuged and washed in M9 
(without NH4Cl). Finally, the cells were resuspended in M9 supplied with vitamin mix, 
antibiotics, glucose and magnesium sulphate. Protein expression was induced with 1 mM 
IPTG for 14 h at 18°C with moderate shaking. 
 
Protein expression and purification 
The PYD domain of NALP1 and the PYD domain of TMS1/ASC were cloned into a modified 
pET20 vector (Novagen), which produced the recombinant protein with an N-terminal 
GB1 solubility enhancer tag (B1 domain of Protein G) and a C-terminal hexa-histidine 
(His6) sequence. The PYD domain of ASC was also cloned into a standard pET20 vector 
(Novagen) which produced the recombinant protein with an N-terminal hexa-histidine 
(His6) sequence. Almost uniformly 
15N-labelled GB1_NALP1-PYD was obtained 
overexpressing the protein in BL21 pLys cells grown in 100 ml minimal medium (M9) 
containing 15NH4Cl as the sole heavy nitrogen source, vitamin mix, solution Q (see 
Appendix I), antibiotics (100 µg/ml ampicillin, 25 µg/ml chloramphenicol), 0.5% glucose 
and 1 mM MgSO4. Cells were grown at 37°C to an optical density of OD600 = 1.5 – 2 
cooled down to 18°C and then induced with 1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG) for 14 hours O/N. The cells were resuspended in 50 mM Tris, 100 mM NaCl, 3 mM 
β-mercaptoethanol, 2 mM PMSF, 1 mM CHAPS, 1 mM imidazole (pH 8.0 at RT), lysed 
with a French press and centrifuged. The protein was isolated by Ni2+ affinity 
chromatography and subsequently purified by size exclusion chromatography on a S75 
26/60 column (Amersham, Pharmacia Biotech) thereby rebuffering in 20 mM Tris, 100 
mM NaCl, 0.2 mM CHAPS, 0.1 mM EDTA, 10 mM DTT pH 7.5 at 4°C. This buffer was used 
to measure interactions using NMR spectroscopy. 
Unlabelled GB1_TMS1/ASC-PYD and ASC-PYD was obtained overexpressing the 
protein in BL21 pLys cells grown in 500 ml LB cultures supplied with ampicillin (100 
µg/ml) and chloramphenicol (25 µg/ml). Cells were grown at 37°C to an optical density 
of OD600 = 0.6 – 0.8 cooled down to 18°C and then induced with 1 mM IPTG for 14 hours 
O/N). The cells were resuspended in 50 mM Tris, 100 mM NaCl, 2 mM PMSF, 0.5 mM 
CHAPS, 1 mM imidazole (pH 8.0 at RT), lysed with a French press and centrifuged. The 
protein was isolated by Ni2+ affinity chromatography and subsequently purified by size 
exclusion chromatography on a S75 26/60 column (Amersham, Pharmacia Biotech) 
thereby rebuffering in 20 mM Tris, 500 mM NaCl, 0.2 mM CHAPS, 0.1 mM EDTA, 10 mM 
DTT pH 7.5 at 4°C. This buffer was used to measure interactions using NMR 
spectroscopy. 
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Mass determination 
The QTOF MS ESI was performed at the Functional Genomics Centre Zürich (FGCZ) 
 
Dynamic light scattering 
Dynamic light scattering experiments of both GB1 tagged domains were performed on a 
DynaPro Titan spectrometer (Wyatt technology corp., Charlottesville, USA) (data not 
shown) in a buffer containing 20 mM Tris, 100 mM NaCl, 0.2 mM CHAPS, 0.1 mM EDTA, 
and 10 mM DTT pH 7.5 at 4°C. The protein concentration was 1 – 2 mg/ml. 
 
Circular dichroism 
Circular dichroism spectra were recorded on a Jasco J-715 instrument (Jasco, Japan) at 
20°C with a wavelength scan from 250 nm to 180 nm, data pitch of 1 nm, 4 seconds 
response time and a band width of 1 nm. The buffer contained 20 mM NaH2PO4, pH 4 
(RT) with a protein concentration of 0.3 mg/ml or 20 mM Tris, 100 mM NaCl, 0.2 mM 
CHAPS pH 7.5 (RT) with a protein concentration of around 1.2 mg/ml. 
 
 
APPENDIX PART III 
Ribosome display and crude extract ELISA protocols 
Constructs of caspase-3 
Plasmid – caspase-3 active wild type // vector: pet11d // no tag // NcoI, BamHI sites 
 
Caspase-3 Protein seq : C3P17-RG 
MSGISLDNSYKMDYPEMGLCIIINNKNFHKSTGMTSRSGTDVDAANLRETFRNLKYEVRNKNDLTRE
EIVELMRDVSKEDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQAC
RGTELDCGIETD 
 
Caspase-3 Protein seq : C3P12-RG 
MASGVDDDMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQSLCAMLKQYADKLEFMHILTRV
NRKVATEFESFSFDATFHAKKQIPCIVSMLTKELYFYH 
 
Caspase-3 DNA seq : C3P17-RG 
ATG AGC GGT ATC TCC CTG GAC AAC AGT TAT AAA ATG GAT TAT CCT GAG ATG GGT 
TTA TGT ATA ATA ATT AAT AAT AAG AAT TTT CAT AAA AGC ACT GGA ATG ACA TCT CGG 
TCT GGT ACA GAT GTC GAT GCA GCA AAC CTC AGG GAA ACA TTC AGA AAC TTG AAA 
TAT GAA GTC AGG AAT AAA AAT GAT CTT ACA CGT GAA GAA ATT GTG GAA TTG ATG 
CGT GAT GTT TCT AAA GAA GAT CAC AGC AAA AGG AGC AGT TTT GTT TGT GTG CTT 
CTG AGC CAT GGT GAA GAA GGA ATA ATT TTT GGA ACA AAT GGA CCT GTT GAC CTG 
AAA AAA ATA ACA AAC TTT TTC AGA GGG GAT CGT TGT AGA AGT CTA ACT GGA AAA 
CCC AAA CTT TTC ATT ATT CAG GCC TGC CGT GGT ACA GAA CTG GAC TGT GGC ATT 
GAG ACA GAC TAA 
 
Caspase-3 DNA seq : C3P12-RG 
ATG GCT AGT GGT GTT GAT GAT GAC ATG GCG TGT CAT AAA ATA CCA GTG GAG GCC 
GAC TTC TTG TAT GCA TAC TCC ACA GCA CCT GGT TAT TAT TCT TGG CGA AAT TCA AAG 
GAT GGC TCC TGG TTC ATC CAG TCG CTT TGT GCC ATG CTG AAA CAG TAT GCC GAC 
AAG CTT GAA TTT ATG CAC ATT CTT ACC CGG GTT AAC CGA AAG GTG GCA ACA GAA 
TTT GAG TCC TTT TCC TTT GAC GCT ACT TTT CAT GCA AAG AAA CAG ATT CCA TGT ATT 
GTT TCC ATG CTC ACA AAA GAA CTC TAT TTT TAT CAC TAA 
 
(the vectors containing the p12 and p17 fragments of caspase-3 were obtained form R. 
Ganesan) 
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Caspase-3 purification protocol 
The protocol is modified for the purification of caspase-3 based on this primary 
literature: 
- Garcia-Calvo et al, Purification and catalytic properties of human caspase family 
members, 1999, 6(4), 362-9 
- Stennicke, HR and Salvesen, GS (2000) Caspase assays. Methods Enzymol 322, 91–
100 
Human recombinant caspase-3 was produced in E. coli as inclusion bodies, 
refolded and purified according to the following protocol, obtained from R. Ganesan: Both 
subunits were separately expressed in BL21 CodonPlus (DE3) RIL cells. The cultures were 
grown to a density of A600 = 0.5 at 37°C in 0.5 L
 LB-medium (2 L flasks, vigorous shaking 
~110 rpm) and expression was induced by the addition of IPTG (1 mM). The culture was 
shaken at 37°C for 4 hours post induction. The cells were harvested by centrifugation at 
3000 g for 15 min, resuspended in 25 mL PBS buffer (8 g NaCl, 0.2 g KCl, 1.45 g 
Na2HPO4, 0.15 g KH2PO4 pH 7.4 in 100 mL) and lysed using a French Pressure cell. Since 
protein is predominantly present in inclusion body (IB) portion, the sample after cell lysis 
was centrifuged for 60 min at 20,000 g and the supernatant was discarded. The pellets 
were re-suspended in IB-wash-buffer A (25 mM HEPES pH 7.5, 1% CHAPS, 1 mM EDTA) 
using a homogenizer. After centrifugation for 30 min at 20,000 g the pellets were 
resuspended in IB-wash-buffer B (25 mM HEPES pH 7.5, 1 M urea) using a homogenizer. 
At least 3 cycles of washing with IB-wash-buffer-A & B were performed. The IB obtained 
after 3 washing steps were dissolved overnight at room temperature by slow rotation, in 
a buffer containing 6.5 M guanidine hydrochloride, 25 mM Tris pH 7.5, 5 mM EDTA, 100 
mM DTT (Volume app. 10 mL per L culture).  
Next day, the samples were centrifuged for 30 min at 20,000 g to remove any 
undissolved substances. This denatured protein sample can be aliquoted and stored at -
80°C. Refolding was achieved at room temperature by rapid dilution to a final 
concentration of about 100 ug of subunit/L in refolding buffer (100 mM HEPES, pH 7.5, 
10% sucrose, 1% CHAPS, 100 mM NaCl and 10 mM DTT). The p12 subunit was premixed 
with the p17 subunit in a 2:1 ratio. The solution was then transferred into an AMICON 
concentrating cell with a membrane cut-off of 10 kDa at 4°C. In order to reduce the salt 
concentration and to facilitate binding to an anion exchange column, the refolded protein 
was up-concentrated to 10-20 ml, diluted the first time with 20 mM Tris, 10 mM DTT, and 
the second time with anion exchange buffer A (20 mM Tris, pH 8.0, 20 mM NaCl and 10 
mM DTT). 50 ml were loaded using a sample pump onto a 1 ml ResQ column (Pharmacia 
Biotech). The protein was eluted in a continuous gradient with anion exchange buffer B 
(20 mM Tris, 500 mM NaCl, 10 mM DTT, pH 8.0). The peak fractions were collected, 
concentrated with centricon, and loaded (500 uL) on a S200 (23 ml) size exclusion 
chromatography column equilibrated with 20 mM Tris, 150 mM NaCl pH 8.0. Fractions 
containing pure and active caspase were pooled and concentrated by ultra filtration 
(centricons-10,000 Da cut-off) to a final concentration of 10 mg/mL and the final yield 
was about 3- 4 mg/L culture. 
 
Caspase assay 
The caspase activity was determined from the initial rate of hydrolysis of substrate by 
measuring the accumulation of the fluorogenic product 7-amino-4-methylcoumarin. The 
increase in sample fluorescence was measured at an excitation wavelength of 360 nm 
and an emission wavelength of 465 nm for 5 min at room temperature (22-25°C) using 
an HTS 7000 Plus Bio Assay plate reader (Perkin Elmer). Both, the enzymes and the 
substrates were diluted in the assay buffer consisting of 20 mM piperazine-N,N`-bis (2-
ethanesulfonic acid) (PIPES) pH 7.2, 100 mM NaCl, 10 mM 1,4-dithiothreitol (DTT), 1 mM 
EDTA, 0.1% (w/v) 3-((3-cholamidopropyl)-dimethyl-ammonio)-1-propane sulfonate 
(CHAPS) and 10% (w/v) sucrose. The typical assay volume was 150 ul in a Greiner 96-
well black, flat bottom microtitre plate. 
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Ribosome display Selection Protocol 
1. Coating plates 
1.1 Neutravidin plate coating (done the day before the RD round) 
- Neutravidin stock: 1.2 mg/ml in TBS; 20 uM (dilution 1:300 in TBS final conc. 66 nM) 
- Pipet 100 ul of a 66 nM Neutravidin-TBS solution into the wells (duplicates) 
- Seal with sticky plastic tape 
- Store overnight at 4°C (no shaking required) 
 
1.2 BSA-blocking of neutravidin coated plates 
- Wash overnight incubated plate 2x   with 1xTBS (flask), beat dry on paper 
- Add 300 ul 0.5% BSA in 1xTBS to the wells (or WBT-BSA) 
- Seal with sticky plastic tape 
- Incubate on Shaker for 1 h at RT (7-800 rpm) 
 
1.3 Immobilization with antigen 
- Wash plate 3x with 1xTBS (flask), beat dry 
- Add 200 ul 0.5% BSA in WBT (WBT-BSA) to each well (depends on target) 
- Add 10 ul Antigen of approx. 10 uM conc. to the respective wells. Use biotinylated 
Antigen (with AVI-tag) void of free biotin 
- Seal with sticky plastic tape 
- Incubate on shaker for 1 h at 4°C 
- Thaw Extract SL119(100 ul aliquots, -80°C) and Premix SL119 (-20°C) after 30` 
 
Preparation before next step: 
 30` after Antigen immobilization: 
- Thaw Extract SL119(100 ul aliquots, -80°C) and Premix SL119 (-20°C) 
 - Prepare bottle with liquid nitrogen 
 
15` before translation start 
- thaw RNA, and Heparin 
 - label tubes with “Name and stop” 
 
 10` before Translation: 
- Wash plate with 3x 200 ul WBT-BSA each, beat dry 
- Incubate wells that will not directly be used for panning with 128 ul WBT-BSA 
(Identical amount of liquid as will be used for panning) 
  
 
2. Translation 
2.1 In vitro translation 
Mix according to pipetting scheme: 
- Extract (100 ul aliquot) SL119 (contains all ribosomes from cells) 
- Premix SL119 (vortex quickly) (contains amino acids) 
-  6 setups for 5 samples (always one more) (10 wells = 6 setups) 
- This mixture can shortly be kept on ice! 
- When RNA is thawed: add the appropriate amount of H2O to RNA (2.5 ug/ul), transfer 2 
ul into new tube; immediately N2 freeze all RNA containing tubes 
- After dispensing 2 ul RNA into labelled tubes, quick freeze tube in N2 and keep on ice 
- Add the mix to 2 ul 2.5 ug/ul RNA (prepipetted and N2-frozen) and immediately start 
translation for 8 min 30 sec at 37°C on the heat block 
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to: add 53 ul Premix/Extract to RNA, dissolve RNA pellet, put tube at 37°C 
30`` add again 53 ul Premix/Extract to 2nd sample 
1`: add again 53 ul Premix/Extract to 3rd sample 
1`30``:     “ 
2`:     “ 
- During translation prepare stopping buffer (WBT-BSA plus 12.5 ul/ml Heparin à 200 
mg/ml) in previously labelled RNase free tubes, keep on ice (see pipetting scheme) 
 8`30``: remove translation mix, flick shortly and transfer to stopping buffer 
 9`:  remove 2nd sample 
 9`30``: remove 3rd sample 
 10`:  “ 
 10`30``:   “  and keep them on ice 
Centrifuge all tubes at 20000 g for 5min at 4°C, keep tubes on ice 
 
2.2 Stop reaction 
(If not done before) during centrifugation wash all wells  3x  with 300 ul WBT-BSA 
(transfer of Mg2+!) 
- Add 128 ul into “panning” or prepanning wells respectively 
- keep tubes on ice and plate always at 4°C 
 
3. RD in plates 
The translated tertiary Ribosome-RNA-Protein complex first has to incubate in the 
“prepanning” well and is further transferred into the true panning wells.  
Always perform 2 prepanning steps! (In duplicates) 
 
3.1 Panning at temperatures equal or below 4°C) 
- Pipet 128 ul stopped translation mix to the first column of prepanning wells (duplicate) 
- Seal with sticky plastic tape and incubate for 45 min at 4°C in the shaker (prepanning) 
- Remove 128 ul WBT-BSA from the 2nd prepanning wells 
- Transfer the 128 ul prepanning mix into the 2nd prepanning wells, seal and incubate for 
another 45 min at 4°C in the shaker 
- Finally transfer the supernatant into the panning wells, seal and incubate for another 45 
min at 4°C in the shaker 
 
Washing: General washing principle  
- 3x wash  -  1x incubate (30 min, 1 h, 2 h, 3 h)  -  3x wash (totally 7x) 
 In the first round: remove lid and add 3x 200 ul WBT-BSA into the wells, beat dry 
- Go ahead without long incubations 
In later rounds: As in first, but make long washing incubations (30 min, 1 h, 3 h) 
 
Preparation before RNA elution: 
10-20` before end of incubation: 
- Cool down a centrifuge to 4°C (tighten lid, select fast cool procedure) 
- Set two heating blocks to 50°C and 70°C 
- Prepare 3 series of tubes (duplicates! = 3 tubes for each well to be eluted and label 
them with sample/exp. “lysis”, “eluted RNA”, “RT”, name and round number 
- Add 400 ul lysis buffer of Roche RNA-purification kit into “lysis” tubes 
- Prepare Roche-RNA purification columns for each sample and label them 
 
Just before elution: 
- thaw the reagents for RT (WTC4, DTT and buffer) 
 
3.2 Elution (4°C room) 
- Make sure that the RNA is kept at 4°C or below! 
- Elution buffer: EB25 (+50 ug/ml S.cerevisiae RNA; 2 ul of a 25 ug/ul stock per ml) 
- Prepare 2x 1.2 ml EB25 + 2.2ul RNA (5 targets = 10 wells = min. 2 ml) 
- Add 100 ul elution buffer incubate on shaker for 5min and pipet the eluate directly into 
previously prepared chilled 400 ul Lysis buffer (Roche) and vortex quickly to mix well 
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- Repeat this elution step, again 5 min elution and vortex quickly 
- The RNA is stable in the lysis buffer and can be brought to room temperature 
 
 
4. RT-PCR  I 
4.1 RNA purification using Roche high pure RNA isolation kit 
- Just before RNA-purification thaw the reagents for RT (WTC4, DTT and buffer) 
- All centrifugation steps are performed at 4°C 
- Apply the lysis buffer/eluate mixture onto the column 
- Spin for 1 min at 8000 g, discard flow through 
- Wash with 500 ul buffer 1 (black cap), discard flow through (manual short spin 8000 g) 
- Wash with 500 ul buffer 2 (blue cap), discard flow through (manual short spin 8000 g) 
- Add 200 ul buffer 2 (blue cap) and spin down for 2 min at 13000 rpm 
- If required, wait with the RNA elution (should be stable) 
- Add 30 ul elution buffer and incubate for 1 min keep tubes on ice, elute RNA (at 8000 g 
for 1 min and directly transfer the RNA to 70°C for 10 min. 
- During RNA denaturation prepare Master mix (pipetting scheme) for RT-PCR 
(Inner primer WTC4) and spread mix into previously labelled tubes keep on ice! 
 
4.2 Reverse Transcription (RNA  DNA) 
- Immediately start RT-PCR right after 70°C incubation of the RNA 
- Flick tubes, spin down the denatured eluted RNA and keep on ice 
- Add 12.25 ul eluted RNA to RT mix and N2 freeze the rest of the RNA 
- Put at 50°C for 1h (can be less) 
- Store this RT-mixture on ice  
- Mastermix: Primer (WTC4) 
- DTT 
- Buffer 
- Enzymes 
 
4.3 PCR on RT (DNA amplification of binding region)  -  1st PCR 
- Pipetting scheme: use INNER PRIMERS (EWT5/WTC4) 
- Always take a fresh aliquot of VENT polymerase for this amplification, following PCR`s 
can be performed with the leftover; thaw it up just before PCR 
- Prepare mastermix without VENT 
- Program (to be adapted according to primers and template) name: RIBDIS (RD50) 
- Hot start: start program and press pause; the program stops, but the lid heats up 
- Prepare PCR tubes with 5ul RT-mixture and N2 freeze the rest 
- Start the program (whole block has to be at 95°C) 
- Add VENT into mastermix just before PCR start and equally dispense 45 ul 
- Include positive control with known DNA and negative control with DNA elution buffer 
 
5. RT-PCR  II 
Program: 
  5`  95°C 
  30``  95°C 
  30``  55°C     25-45 cycles depending on RD round 
  45``  72°C   45x – 1st 
       35x – 2nd 
  5`  72°C   30x – 3rd 
    4°C   25x – 4th 
 
- Verify the PCR on a 1.2% agarose Gel (2 ul PCR product + 2 ul 2x loading buffer) 
- If the agarose Gel is OK make a preparative Gel, cut the band and purify the Product 
with a QIAGEN Gel purification Kit 
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5.1 PCR on RT-PCR  -  2nd PCR 
Mix the following reaction according to pipetting scheme (Inner primers EWT5/ WTC4) 
Program to be adapted 
  5`  95°C 
  30``  95°C 
  30``  55°C     25-45 cycles depending on RD round 
  45``  72°C 
  5`  72°C 
    4°C 
- Verify the PCR on a 1.2% agarose Gel (2 ul PCR product + 2 ul 2x loading buffer) 
- If the agarose Gel is OK make a preparative Gel, cut the band and purify the Product 
with a QIAGEN Gel purification Kit 
 
 
6. Cloning into pRDV 
6.1 Digest 
DNA  5 ul (2nd PCR step from 4.4) 
NcoI  1 ul 
HindIII 1 ul 
NEB2  2 ul 
H2O  11 ul   60 min, 37°C 
 
Use MinElute PCR purification kit for the digested fragments and elute with 10ul 
(5.1.2 Digest pRDV (only done if plasmid stock is empty)) 
 
pRDV  x uL 
NcoI  3 uL   60 min, 37°C 
HindIII 2 uL   + 3 uL CIP 
NEB2  5 ul   60 min, 37°C 
H2O  xx to 50 ul 
 
6.2 Ligation 
pRDV   2 ul (check concentration) can be less e.g. 1.5 ul 
PCR product  9 ul whole MinElute eluate 
T4 DNA Ligase 1 ul 
10x LB  1.5 ul 
H2O   xx ul 
Leave ligation mix for 60 min at RT on bench, then put ligation mix at 70°C for 10 min 
 
 
7. PCR of pRDV  -  3rd PCR 
Mix the following reaction according to pipetting scheme (OUTER PRIMERS T7B/TolAk) 
Adapt program 
 
  5`  95°C 
  30``  95°C 
  30``  55°C  30-35 cycles depending on RD round 
  1`  72°C 
  5`  72°C  keep for infinite time at 4°C 
 
- Verify on small 1.2% agarose Gel 
- Purify product via preparative 1.2% agarose gel (better than PCR purification Kit) 
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8. PCR for Transcription  -  4th PCR 
Mix the following reaction according to pipetting scheme (OUTER PRIMERS T7B/TolAk) 
Same program as before: 
  5`  95°C 
  30``  95°C 
  30``  55°C  30-35 cycles depending on RD round 
  1`  72°C 
  5`  72°C  keep for infinite time at 4°C 
- Verify on a small 1.2% agarose Gel 
- Do not purify this product!!! 
 
 
9. Transcription of PCR products into mRNA 
9.1 Transcription (50%) 
- Mix the reaction according to protocol 
- Transcription for 2-3 h at 37-38°C (better 3 h) 
- Strange smell, like a freshly opened can of corn 
 
9.2 RNA isolation 
- Add 100 ul ice-cold UHP 
- Add 200 ul 6 M LiCl 
- Keep on ice for 30 min 
- Spin 20`000 g, 4°C, 30 min 
- Remove supernatant carefully add 70% EtOH and remove it right afterwards 
- Short spin 
- Remove supernatant with small tips (200 ul pipette) 
- Leave the pellet for 5`at RT (tubes remain open) 
- Dissolve pellet in 200 ul ice-cold UHP (takes some time) vortex shortly 
- Spin suspension 20`000 g 4°C, 5 min 
- Transfer 180 ul supernatant into tubes containing 20 ul 3 M NaOAc 
- Add 500 ul ice cold 100% EtOH, vortex 
- Put at -20°C for 30`(or leave O/N at -20°C) 
- Spin 20`000 g, 4°C, 30 min 
- Discard supernatant 
- Wash with 500 ul ice-cold 70% EtOH 
- Short spin 
- Discard supernatant 
- Dry pellet in a speedvac apparatus 
 
9.3 RNA aliquotation 
- Take up the pellet in 30 ul ice cold UHP 
- Immediately transfer 2 ul to 500 ul ice cold UHP for OD260 quantif. and N2 freeze rest 
- Measure OD260 
- For RNA, 1OD corresponds to a concentration of 40 ug/ml. At the here used dilution 1 
OD corresponds to 10 ug/ul of stock RNA. Thus OD*10 = concentration in ug/ul 
- Add UHP to the RNA before next RD round in order to reach an equal RNA concentration 
of all samples. 
 
 
Crude Extract ELISA (Enzyme linked immunosorbent 
Assay with DARPins) 
(Adapted protocol from Molecular Partners PL00003_CrudeExtract_ELISA.doc Version 
20070213) 
Protocol modified by Tobias Merz July 2007-07-06 
(Minor modifications include indications of required amounts per plate and cancellations 
of unused material and procedures) 
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Protocol 01: Immobilization (Coating of plates) 
Equipment and Reagents: 
- Nunc MaxiSorp 96-well plate (Nunc, no. 442404) 
- 25% Tween 20 
- TBS (50 mM TrisHCl pH 7.4, 150 mM NaCl) 
- 300 x Neutravidin (Neu) stock (Pierce, no. 31000) (1.2 mg/ml 20uM) Neutravidin 
dissolved in UHP, filter through 0.22 um filter, store at -80°C) 
- TBS-T (TBS containing 0.1% (v/v) Tween20 (4 ml/l of 24% Tween20)) 
- TBS-TB (TBS-T containing 0.5% (w/v) BSA) 
- Shaker for Nunc MaxiSorp 96-well plates 
 
Method 
Day1 
- Coat a Nunc MaxiSorp 96-well plate with 100 ul per well of 66 nM Neutravidin (4 ug/ml, 
1:300 dilution of stock solution) in TBS overnight at 4°C.  
>> Required amount (96 samples) 2 x 96-well = 20 ml TBS, 66 ul Neutravidin stock 
- Start with the expression of DARPins in the 96-well format 
 
Day2 (in parallel with the expression of DARPins in the 96-well format) 
Beat dry the plate on stacked paper towels. Add 300 ul/well of TBS-B blocking buffer and 
incubate the plate at room temperature (RT) with orbital shaking (900 rpm) for 1 hour. 
>> Required amount (96 samples) 2 x 30ml TBS, 2 x 150 mg BSA 
Beat dry the plate on stacked paper towels, add 300 ul/well TBS wash buffer. Repeat 
wash cycle 3 times. 
Beat dry the plate on stacked paper towels. Add 100 ul/well TBS-B with 10-500 nM 
antigen (the higher the better) and incubate the plate at 4°C for 1 hour. 
>> Required amount (96 samples) 1 x 96-well = 10 ml TBS-B + antigen 
Wash the plate as in step 2. 
Proceed to the ELISA: Protocol 03, Step 1 
 
Every target needs a direct MBP background sample, thus 2 plates with 2 x 96-wells! 
 
 
Protocol 02: Expression of DARPins in the 96-well format 
Equipment and Reagents 
- 96-deep well plates for bacterial cell cultures (e.g. AbGene, no. AB-0932) 
- Isopropyl-β-D-thiogalactoside (IPTG) stock (1 M IPTG 238 mg/ml) 
- Ampicillin (1000x stock) (50 mg/ml ampicillin 0.22 um filtered) 
- 2YT media (1% bacto-yeast extract (10g/l), 1.6% bacto-tryptone (16 g/l), 0.5% NaCl 
(5 g/l) 
LB media (premix, 25 g/l) or (0.5% bacto-yeast extract (5 g/l), 1% bacto-tryptone (10 
g/l), 1% NaCl (10 g/l) 
- 20% glucose (200 g/l) in UHP, autoclave and cool) 
 
Method (performed with 8 fold multichannel pipette) 
Day 1 
- Aliquot 1.2 ml LB/Glu/Amp into each well of a 96-deep well plate (master plate). 2YT 
gives higher densities than LB and higher plasmid DNA yields. 
>> required amount (96 samples) 123.5 ml LB, 6.5 ml 20% Glc, 130 ul Amp (1000x) 
- Pick individual colonies into each well and seal the plate by applying an air permeable 
membrane. A simple method that avoids cross contamination and double inoculation is to 
seal the plate with a piece of parafilm during inoculation. Just stab the picked colonies 
through the parafilm into the medium. As negative control, leave at least one well 
without inoculation. 
- Incubate sealed plate in an orbital shaker (450 rpm) and grow O/N at 37°C 
 
Day 2 (Parallel continue preparation of Nunc MaxiSorp 96-well plates for the ELISA) 
- Aliquot 0.9 ml of LB/Amp into each well of a 96-deep well plate (expression plate). 
>> required amount (96 samples) 130 ml LB, 130 ul Amp (1000x) 
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- Transfer 0.3 ml from each well of the master plate into the corresponding well of the 
expression plate. (Estimated OD600 = 0.3, if properly grown) 
- Incubate the sealed plate in an orbital shaker (450 rpm) for 1 hour, at 37°C 
- Facultative: Spin master plate at 3000 g for 10 min, empty plate, blot dry store at -20° 
for later plasmid DNA preparations 
- Add 50 ul LB/Amp/IPTG (0.5 mM) and incubate sealed plate at 37°C for 3-4 h at 450 
rpm. 
>> required amount (96 samples) 14 ml LB, 14 ul Amp, 175 ul IPTG (= 12.5 mM) 
- Spin expression plate at 3000 g for 6 min, blot dry on paper towels 
- Add 50 ul B-Per II to each well and resuspend pellet by vortexing 2 min, 10 – 15 min 
shaking 
- Add 950 ul TBS 400 and spin plate at 3000 g for 10 min to remove cell debris. 
- Proceed with the screening of DARPins as described in Protocol 03, Step 1 
- For further experiments store the plate at -20°C 
 
 
Protocol 03: Screening DARPins by ELISA 
Comment 
Include appropriate positive controls (MBP) and negative controls for ELISA 
 
Equipment and reagents 
- Antigen coated plate and with control lanes for background binding (Protocol 01) 
- Anti-RGS(His)4 mAb (mouse anti RGS(His)4 IgG1 (Qiagen, no. 34650) 
- Anti-mouse mAb AP conjugate (goat anti-mouse IgG (Sigma, no. A3562) 
- pNPP substrate (3 mM (di-sodium 4-nitrophenyl phosphate (pNPP) (1.1 mg/ml), 50 mM 
NaHCO3 (4.2 mg/ml), 50 mM MgCl2 6H2O (10.2 mg/ml), store at -20°C) 23.1 mg pNPP, 
88.2 mg NaHCO3, 214.2 mg MgCl2 6H2O in H2O (for 96 samples) 
- 96-well plate containing crude extracts (Protocol 02) and a shaker for Nunc MaxiSorp 
96-well plates 
 
Method 
- Transfer 100 ul of the supernatant form Protocol 02 onto the ELISA plate form Protocol 
01 Step 05. Supernatants can be diluted up to 200 fold for further competition ELISAS. 
- Incubate for 30-40 min at 4°C on orbital shaker (900 rpm). 
- Empty plate and blot dry, wash 3 times all wells with TBS-T (300 ul/well approx.). 
- add 100 ul 1:2000 Anti-RGS(His)4 mAb (1st Ab) in TBS-TB and incubate for 30-45 min 
at RT. 
>> required amount (96 samples) 21 ml TBS-T, 105 mg BSA, 10.5 ul Anti-RGS(His)4 
- Wash plate as in step 3 (3 wash cycles). 
- Add 100 ul 1:10000 Anti-mouse AP conjugate (2nd Ab) in TBS-TB, incubate for 30-45 
min at RT. 
>>  required amount (96 samples) 21 ml TBS-T, 105 mg BSA, 2.1 ul Anti- mAb-
APconj. 
Wash plate as in step 3 (4 wash cycles). 
- Add 100 ul pNPP substrate solution for the detection; prepare 21 ml (for 96 samples). 
- The reaction can be stopped by adding 3 M NaOH. 
- Measure OD405 – OD450 in 15 min intervals depending on the color development. 
- Perform further SDS-PAGE analysis of single clones if additional information is needed. 
- Take 10 ul from Protocol 02 step 11, add 3 ul SDS gel loading buffer and heat the 
samples. Load 5-10 ul on SDS-PAGE 
- Prepare plasmid DNA from positive clones using a standard kit (Qiagen) by directly 
adding resuspension buffer to the respective well of the master plate (thaw plate) by 
shaking (900 rpm) for 1 min. 
- Strike out (still frozen) cells from the wells with a toothpick on a new plate, grow O/N, 
cultivate 3 ml O/N culture and prepare Mini/Midiprep to get higher plasmid DNA yields. 
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Paradoxerweis ist der der fragt, 
und selbst Nichts lernt im täglich Tun, 
nur scheinbar klüger, wenn er sagt:“ 
genau so hätt’ ichs auch gemacht“. 
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